0000912061-17-000022.txt : 20170802 0000912061-17-000022.hdr.sgml : 20170802 20170802091304 ACCESSION NUMBER: 0000912061-17-000022 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170802 DATE AS OF CHANGE: 20170802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATURAL HEALTH TRENDS CORP CENTRAL INDEX KEY: 0000912061 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190] IRS NUMBER: 592705336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36849 FILM NUMBER: 17998551 BUSINESS ADDRESS: STREET 1: 609 DEEP VALLEY DRIVE STREET 2: SUITE 395 (EAST BUILDING) CITY: ROLLING HILLS ESTATES STATE: CA ZIP: 90274 BUSINESS PHONE: 310-541-0888 MAIL ADDRESS: STREET 1: 609 DEEP VALLEY DRIVE STREET 2: SUITE 395 (EAST BUILDING) CITY: ROLLING HILLS ESTATES STATE: CA ZIP: 90274 10-Q 1 nhtc20170802_10q.htm 10-Q Document
false--12-31Q220170000912061YesAccelerated Filer0.0010.001500000005000000012979414129794140.0010.001500000050000000000P3Y16922181637524 0000912061 2017-01-01 2017-06-30 0000912061 2017-07-28 0000912061 2016-12-31 0000912061 2017-06-30 0000912061 2016-01-01 2016-06-30 0000912061 2016-04-01 2016-06-30 0000912061 2017-04-01 2017-06-30 0000912061 2016-06-30 0000912061 2015-12-31 0000912061 us-gaap:CashEquivalentsMember 2016-12-31 0000912061 us-gaap:CashMember 2016-12-31 0000912061 us-gaap:CashMember 2017-06-30 0000912061 us-gaap:CashEquivalentsMember 2017-06-30 0000912061 nhtc:MunicipalBondsAndNotesMember 2017-06-30 0000912061 us-gaap:CorporateDebtSecuritiesMember 2017-06-30 0000912061 nhtc:MunicipalBondsAndNotesMember 2016-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2017-06-30 0000912061 us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2016-12-31 0000912061 2017-01-01 2017-03-31 0000912061 2017-03-31 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 us-gaap:RestrictedStockMember 2016-04-08 2016-04-08 0000912061 2015-07-28 0000912061 us-gaap:RestrictedStockMember 2017-06-30 0000912061 us-gaap:RestrictedStockMember 2017-01-01 2017-06-30 0000912061 2017-01-24 2017-01-24 0000912061 2016-01-12 0000912061 us-gaap:RestrictedStockMember 2016-12-31 0000912061 2017-04-24 2017-04-24 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-01-01 2017-06-30 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-06-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-06-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-06-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2017-06-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000912061 2016-01-01 2016-03-31 0000912061 nhtc:SecuritiesClassActionMember 2016-01-01 2016-01-31 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-06-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2017-01-01 2017-06-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-06-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2016-04-01 2016-06-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2016-04-01 2016-06-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2013-02-01 2013-02-28 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2017-04-01 2017-06-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2017-04-01 2017-06-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-04-29 2015-04-29 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2017-01-01 2017-06-30 0000912061 us-gaap:SubsequentEventMember 2017-07-31 2017-07-31 xbrli:pure xbrli:shares iso4217:USD iso4217:USD xbrli:shares nhtc:complaint


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q 
(Mark One)
þ
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended June 30, 2017
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from ______ to _______
 
Commission File Number: 001-36849
NATURAL HEALTH TRENDS CORP.
(Exact name of registrant as specified in its charter)
Delaware
59-2705336
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)
609 Deep Valley Drive
Suite 395
Rolling Hills Estates, California 90274
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (310) 541-0888
 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for shorter period that the registrant was required to submit and post such files). Yes þ No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one): 
Large accelerated filer o
Accelerated filer þ
Non-accelerated filer   o
Smaller reporting company o
 
Emerging growth company o
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No þ
 
At July 28, 2017, the number of shares outstanding of the registrant’s common stock was 11,341,890 shares.




NATURAL HEALTH TRENDS CORP.
Quarterly Report on Form 10-Q
June 30, 2017
 
INDEX 
 




FORWARD-LOOKING STATEMENTS
 
This Quarterly Report on Form 10-Q, in particular “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this report, the words or phrases “will likely result,” “expect,” “intend,” “will continue,” “anticipate,” “estimate,” “project,” “believe” and similar expressions are intended to identify “forward-looking statements” within the meaning of the Exchange Act. These statements represent our expectations or beliefs concerning, among other things, future revenue, earnings, growth strategies, new products and initiatives, future operations and operating results, and future business and market opportunities.
 
Forward-looking statements in this report speak only as of the date hereof, and forward-looking statements in documents incorporated by reference speak only as of the date of those documents. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on certain assumptions that may not be realized and involve risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein.
 
For a summary of certain risks related to our business, see “Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K, which includes the following:
We could be adversely affected by management changes or an inability to attract and retain key management, directors and consultants;
Because our Hong Kong operations account for a substantial portion of our overall business, and substantially all of our Hong Kong business is derived from the sale of products to members in China, any material adverse change in our business relating to either Hong Kong or China would likely have a material adverse impact on our overall business;
Our operations in China are subject to compliance with a myriad of applicable laws and regulations, and any actual or alleged violations of those laws or government actions otherwise directed at us could have a material adverse impact on our business and the value of our company;
Our failure to maintain and expand our member relationships could adversely affect our business;
We are currently being sued in three lawsuits alleging, among other things, that we made materially false and misleading statements regarding the legality of our business operations in China;
We are currently involved in, and may in the future face, litigation claims and governmental proceedings and inquiries that could harm our business;
Although our members are independent contractors, improper member actions that violate laws or regulations could harm our business;
Direct-selling laws and regulations may prohibit or severely restrict our direct sales efforts and cause our revenue and profitability to decline, and regulators could adopt new regulations that harm our business;
The high level of competition in our industry could adversely affect our business;
Challenges by third parties to the legality of our business operations could harm our business;
An increase in the amount of compensation paid to members would reduce profitability;
Currency exchange rate fluctuations could lower our revenue and net income;
Changes in tax or duty laws, and unanticipated tax or duty liabilities, could adversely affect our net income;
Transfer pricing regulations affect our business and results of operations;
Our products and related activities are subject to extensive government regulation, which could delay, limit or prevent the sale of some of our products in some markets;
Failure of new products to gain member and market acceptance could harm our business;
New regulations governing the marketing and sale of nutritional supplements could harm our business;
Regulations governing the production and marketing of our personal care products could harm our business;
If we are found not to be in compliance with good manufacturing practices our operations could be harmed;




Failure to comply with domestic and foreign laws and regulations governing product claims and advertising could harm our business;
Adverse publicity associated with our products, ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results;
We are subject to risks relating to product concentration and lack of revenue diversification;
We rely on a limited number of independent third parties to manufacture and supply our products;
Growth may be impeded by the political and economic risks of entering and operating foreign markets;
We may be held responsible for certain taxes or assessments relating to the activities of our members, which could harm our financial condition and operating results;
We may be unable to protect or use our intellectual property rights;
We do not have a comprehensive product liability insurance program and product liability claims could hurt our business;
Our internal controls and accounting methods may require modification;
If we fail to achieve and maintain an effective system of internal controls in the future, we may not be able to accurately report our financial results or prevent fraud. As a result, investors may lose confidence in our financial reporting;
We rely on and are subject to risks associated with our reliance upon information technology systems;
System failures and attacks could harm our business;
Terrorist attacks, cyber-attacks, acts of war, epidemics or other communicable diseases or any other natural disasters may seriously harm our business;
Because our systems, software and data reside on third-party servers, our access could be temporarily or permanently interrupted;
We may experience substantial negative cash flows, which may have a significant adverse effect on our business and could threaten our solvency;
If we experience negative cash flows, we may need to seek additional debt or equity financing, which may not be available on acceptable terms or at all. If available, it could have a highly dilutive effect on the holdings of existing stockholders;
Disappointing quarterly revenue or operating results could cause the price of our common stock to fall;
Our common stock is particularly subject to volatility because of the industry in which we operate;
Our common stock continues to experience wide fluctuations in trading volumes and prices. This may make it more difficult for holders of our common stock to sell shares when they want and at prices they find attractive; and
Future sales by us or our existing stockholders could depress the market price of our common stock.

Additional factors that could cause actual results to differ materially from our forward-looking statements are set forth in this report, including under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our financial statements and the related notes.




PART I - FINANCIAL INFORMATION
 
Item 1. FINANCIAL STATEMENTS
  
NATURAL HEALTH TRENDS CORP.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
 
 
June 30, 2017
 
December 31, 2016
 
(Unaudited)
 
 
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
136,261

 
$
125,921

Inventories
9,804

 
11,257

Other current assets
3,638

 
4,066

Total current assets
149,703

 
141,244

Property and equipment, net
1,292

 
1,388

Goodwill
1,764

 
1,764

Restricted cash
3,039

 
2,963

Other assets
768

 
692

Total assets
$
156,566

 
$
148,051

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
2,371

 
$
2,145

Income taxes payable
4,971

 
663

Accrued commissions
12,666

 
13,611

Other accrued expenses
10,366

 
14,989

Deferred revenue
3,994

 
4,948

Amounts held in eWallets
18,713

 
19,165

Other current liabilities
1,622

 
1,633

Total current liabilities
54,703

 
57,154

Deferred tax liability
285

 
268

Long-term incentive
7,179

 
8,190

Total liabilities
62,167

 
65,612

Commitments and contingencies (Note 8)

 

Stockholders’ equity:
 
 
 
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding

 

Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at June 30, 2017 and December 31, 2016
13

 
13

Additional paid-in capital
86,665

 
86,574

Retained earnings
49,198

 
38,548

Accumulated other comprehensive loss
(907
)
 
(807
)
Treasury stock, at cost; 1,637,524 and 1,692,218 shares at June 30, 2017 and December 31, 2016, respectively
(40,570
)
 
(41,889
)
Total stockholders’ equity
94,399

 
82,439

Total liabilities and stockholders’ equity
$
156,566

 
$
148,051

 
See accompanying notes to consolidated financial statements.

1



NATURAL HEALTH TRENDS CORP. 
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except per share data)
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
Net sales
$
51,465

 
$
80,391

 
$
111,339

 
$
154,737

Cost of sales
9,793

 
15,059

 
21,038

 
29,339

Gross profit
41,672

 
65,332

 
90,301

 
125,398

Operating expenses:
 
 
 
 
 
 
 
Commissions expense
22,075

 
37,883

 
48,040

 
72,969

Selling, general and administrative expenses
6,590

 
12,431

 
16,126

 
23,335

Depreciation and amortization
140

 
91

 
276

 
180

Total operating expenses
28,805

 
50,405

 
64,442

 
96,484

Income from operations
12,867

 
14,927

 
25,859

 
28,914

Other income (expense), net
80

 
16

 
236

 
(8
)
Income before income taxes
12,947

 
14,943

 
26,095

 
28,906

Income tax provision
2,644

 
2,742

 
5,367

 
5,425

Net income
$
10,303

 
$
12,201

 
$
20,728

 
$
23,481

Net income per common share:
 
 
 
 
 
 
 
Basic
$
0.92

 
$
1.08

 
$
1.84

 
$
2.03

Diluted
$
0.91

 
$
1.07

 
$
1.84

 
$
2.03

Weighted-average number of common shares outstanding:
 
 
 
 
 
 
 
Basic
11,243

 
11,333

 
11,236

 
11,553

Diluted
11,274

 
11,359

 
11,264

 
11,579

Cash dividends declared per common share
$
0.45

 
$
0.06

 
$
0.89

 
$
0.11

 
See accompanying notes to consolidated financial statements.
 

2



NATURAL HEALTH TRENDS CORP.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)
(In thousands)
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
Net income
$
10,303

 
$
12,201

 
$
20,728

 
$
23,481

Other comprehensive income (loss), net of tax:
 
 
 
 
 
 
 
Foreign currency translation adjustment
87

 
(327
)
 
163

 
(275
)
Release of cumulative translation adjustment

 
132

 
(258
)
 
132

Net change in foreign currency translation adjustment
87

 
(195
)
 
(95
)
 
(143
)
Unrealized gains (losses) on available-for-sale securities
2

 
(1
)
 
(5
)
 
7

Comprehensive income
$
10,392

 
$
12,005

 
$
20,628

 
$
23,345

 
See accompanying notes to consolidated financial statements.
 

3



NATURAL HEALTH TRENDS CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands)
 
 
Six Months Ended June 30,
 
2017
 
2016
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net income
$
20,728

 
$
23,481

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
276

 
180

Stock-based compensation
17

 
84

Cumulative translation adjustment realized in net income
(258
)
 
132

Changes in assets and liabilities:
 
 
 
Inventories
1,388

 
(1,865
)
Other current assets
489

 
(612
)
Other assets
(58
)
 
2

Accounts payable
226

 
665

Income taxes payable
4,304

 
487

Accrued commissions
(915
)
 
(989
)
Other accrued expenses
(3,229
)
 
2,597

Deferred revenue
(939
)
 
4,816

Amounts held in eWallets
(327
)
 
1,759

Other current liabilities
(24
)
 
203

Long-term incentive
(1,049
)
 
(506
)
Net cash provided by operating activities
20,629

 
30,434

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(170
)
 
(524
)
Net cash used in investing activities
(170
)
 
(524
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Repurchase of common stock

 
(23,704
)
Dividends paid
(10,078
)
 
(1,262
)
Net cash used in financing activities
(10,078
)
 
(24,966
)
Effect of exchange rates on cash and cash equivalents
(41
)
 
(209
)
Net increase in cash and cash equivalents
10,340

 
4,735

CASH AND CASH EQUIVALENTS, beginning of period
125,921

 
104,914

CASH AND CASH EQUIVALENTS, end of period
$
136,261

 
$
109,649

SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:
 
 
 
Issuance of treasury stock for employee awards, net
$
1,393

 
$
1,741

 
See accompanying notes to consolidated financial statements.

4



NATURAL HEALTH TRENDS CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION

Nature of Operations 
 
Natural Health Trends Corp. (the “Company”), a Delaware corporation, is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.
 
The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

Basis of Presentation 
 
The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2016 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 10, 2017.

Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

2. ACCOUNTING PRONOUNCEMENTS
 
In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows - Restricted Cash, that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption was permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
 

5



In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. Under this guidance, entities are required to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance was effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities were permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016.

In July 2015, the FASB issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory. Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method are to be measured at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation.  The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. Early adoption is permitted to the original effective date of December 15, 2016, including interim reporting periods. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

3. NET INCOME PER COMMON SHARE

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.

The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data): 
 
Three Months Ended June 30,
 
2017
 
2016
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
10,303

 
11,243

 
$
0.92

 
$
12,201

 
11,333

 
$
1.08

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
31

 
 

 

 
26

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
10,303

 
11,274

 
$
0.91

 
$
12,201

 
11,359

 
$
1.07


6




 
Six Months Ended June 30,
 
2017
 
2016
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
20,728

 
11,236

 
$
1.84

 
$
23,481

 
11,553

 
$
2.03

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
28

 
 

 

 
26

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
20,728

 
11,264

 
$
1.84

 
$
23,481

 
11,579

 
$
2.03



4. BALANCE SHEET COMPONENTS

The components of certain balance sheet amounts are as follows (in thousands):
 
June 30, 2017
 
December 31, 2016
Cash and cash equivalents:
 
 
 
Cash
$
63,036

 
$
52,453

Cash equivalents
73,225

 
73,468

 
$
136,261

 
$
125,921

Other accrued expenses:
 
 
 
Sales returns
$
2,301

 
$
1,632

Employee-related
6,087

 
10,541

Warehousing, inventory-related and other
1,978

 
2,816

 
$
10,366

 
$
14,989



5. FAIR VALUE MEASUREMENTS

As of June 30, 2017, cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at June 30, 2017 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.

The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.


7



Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
June 30, 2017
 
December 31, 2016
 
Adjusted Cost
 
Gross Unrealized Gains
(Losses)
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
Municipal bonds and notes
$
11,895

 
$
2

 
$
11,897

 
$
43,490

 
$

 
$
43,490

Corporate debt securities
16,312

 
(9
)
 
16,303

 
1,673

 
(2
)
 
1,671

Financial institution instruments
45,025

 

 
45,025

 
28,307

 

 
28,307

Total available-for-sale investments
$
73,232

 
$
(7
)
 
$
73,225

 
$
73,470

 
$
(2
)
 
$
73,468


 
Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.

6. STOCKHOLDERS’ EQUITY
 
Dividends
 
The following table summarizes the Company’s cash dividend activity for the six months ended June 30, 2017 (in thousands, except per share data):
Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
April 24, 2017 (special)
 
$
0.35

 
$
3,964

 
May 9, 2017
 
May 19, 2017
April 24, 2017
 
0.10

 
1,133

 
May 9, 2017
 
May 19, 2017
January 24, 2017 (special)
 
0.35

 
3,962

 
February 21, 2017
 
March 3, 2017
January 24, 2017
 
0.09

 
1,019

 
February 21, 2017
 
March 3, 2017
 
 
$
0.89

 
$
10,078

 
 
 
 

Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

Stock Repurchases

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of June 30, 2017, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

Restricted Stock

Stock-based compensation expense totaled $8,600 and $10,000 for the three months ended June 30, 2017 and 2016, respectively, and $17,300 and $84,000 for the six months ended June 30, 2017 and 2016, respectively. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company’s 2016 annual meeting of stockholders. The modification of the award resulted in an additional $64,000 in stock-based compensation expense for the three months ended March 31, 2016.


8



At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At June 30, 2017, 2,393,873 shares remained available for issuance under the 2016 Plan.

On January 24, 2017, the Company granted 56,260 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2016 performance incentives totaling $1.4 million. The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2016
38,256

 
$
34.13

Granted
56,260

 
25.44

Vested
(17,668
)
 
29.58

Forfeited
(1,148
)
 
28.55

Nonvested at June 30, 2017
75,700

 
28.90



The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2016
22,348

 
$
12.15

Granted

 

Vested
(10,970
)
 
12.15

Forfeited
(418
)
 
12.28

Nonvested at June 30, 2017
10,960

 
12.15


 
As of June 30, 2017, total unrecognized stock-based compensation expense related to non-vested restricted stock was $18,500, which is expected to be recognized over a weighted-average period of 0.5 years.

Accumulated Other Comprehensive Loss
 
The changes in accumulated other comprehensive loss by component for the first six months of 2017 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Losses on Available-For-Sale Investments
 
Total
Balance, December 31, 2016
$
(805
)
 
$
(2
)
 
$
(807
)
Other comprehensive income (loss)
163

 
(5
)
 
158

Amounts reclassified out of accumulated other comprehensive loss
(258
)
 

 
(258
)
Balance, June 30, 2017
$
(900
)
 
$
(7
)
 
$
(907
)



9



7. INCOME TAXES

As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the year ended December 31, 2016 was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate. As of June 30, 2017, the Company has accrued tax liabilities for earnings that the Company plans to repatriate out of accumulated earnings in future periods. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of June 30, 2017.

The Company and its subsidiaries file tax returns in the United States, California and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2015 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries.

8. COMMITMENTS AND CONTINGENCIES

Securities Class Action

In January 2016, two putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the Court consolidated these actions under the caption Ford v. Natural Health Trends Corp., Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng, Timothy S. Davidson and George K. Broady (together, the “Individual Defendants”), and (ii) Section 20(a) of the Securities Exchange Act of 1934 against the Individual Defendants. The consolidated complaint alleges, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. The Company moved to dismiss the consolidated complaint on June 15, 2016. After full briefing and a hearing, the Court denied defendants’ motion to dismiss on December 5, 2016. On February 17, 2017, the Company filed an answer to the consolidated complaint. On April 14, 2017, the Court entered an order setting case management deadlines for the case, which include the conclusion of fact discovery in May 2018 and a final pretrial conference in August 2018. On July 10, 2017, the Court entered a stipulation between the parties, postponing all deadlines and staying the case for thirty days to allow the parties to engage in settlement discussions. On July 17, 2017, the parties reached an agreement in principle to settle the action. On July 18, 2017, the parties jointly filed a stipulation and proposed order with the Court, seeking to extend the stay for approximately sixty days to allow them an opportunity to negotiate the terms of a written settlement agreement and prepare and file the documentation necessary to obtain Court approval of the settlement. The Court entered the requested order on July 25, 2017, effecting a further stay of the case until September 25, 2017.  If approved, the proposed settlement will be fully funded by the Company’s insurers.  Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if a settlement is not finalized and approved by the Court.


10



Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the Zhou action pending conclusion of the related federal class action in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. and Li v. Natural Health Trends Corp. A nearly identical stipulated stay was entered in the Kleinfeldt case on February 8, 2017. The Company believes that these claims are without merit and intends to vigorously defend against them.

The consolidated class action, if a settlement is not finalized and approved by the Court, and the Derivative Complaints, or others filed alleging similar facts, could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition.

9. RELATED PARTY TRANSACTIONS

On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called Soothe™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS. Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide. Royalties recognized for the three months ended June 30, 2017 and 2016 were $500 and $800, respectively, and $1,200 and $2,000 for the six months ended June 30, 2017 and 2016, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice. Otherwise, the agreement terminates March 31, 2020.

In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called ReStor™.  Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. Such provision was effective retroactively to January 1, 2015. Such royalties were $86,000 and $141,000 for the three months ended June 30, 2017 and 2016, respectively, and $177,000 and $280,000 for the six months ended June 30, 2017 and 2016, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.

10. SUBSEQUENT EVENT
 
On July 31, 2017, the Board of Directors declared a quarterly cash dividend of $0.11 and a special cash dividend of $0.25 on each share of common stock outstanding. Such dividends are payable on August 31, 2017 to stockholders of record on August 21, 2017. Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.


11



Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
Business Overview
 
We are an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. We also operate through an engagement of a third-party service provider in Russia and Kazakhstan.
 
Our member network operates in a seamless manner from market to market, except for our China market where we sell to consumers through an e-commerce platform, and our Russia and Kazakhstan market where our engagement of a third-party service provider results in a different economic structure than in our other markets. Otherwise, we believe that all of our other operating segments are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. There is no separate segment manager who is held accountable by our chief operating decision-makers, or anyone else, for operations, operating results and planning for neither the China market nor the Russia and Kazakhstan market on a stand-alone basis, and neither market is material for the periods presented. As such, we consider ourselves to be in a single reporting segment and operating unit structure. 
 
As of June 30, 2017, we were conducting business through 107,290 active members, compared to 113,710 three months ago and 126,440 a year ago. We consider a member “active” if they have placed at least one product order with us during the preceding year. Our priority is to focus our resources in our most promising markets, which we consider to be Greater China and countries where our existing members have the connections to recruit prospects and sell our products, such as Southeast Asia. We have also begun to invest some resources in Mexico and Peru.
 
We generate approximately 97% of our net sales from subsidiaries located outside the Americas, with sales of our Hong Kong subsidiary representing 89% of net sales in the latest fiscal quarter. Because of the size of our foreign operations, operating results can be impacted negatively or positively by factors such as foreign currency fluctuations, and economic, political and business conditions around the world. In addition, our business is subject to various laws and regulations, in particular regulations related to direct selling activities that create uncertain risks for our business, including improper claims or activities by our members and potential inability to obtain necessary product registrations. For further information regarding some of the risks associated with the conduct of our business in China, see generally in “Part I, Item 1A, Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, and more specifically under the captions “Risk Factors - Because our Hong Kong operations account for a substantial portion of our overall business...” and “Risk Factors - Our operations in China are subject to compliance with a myriad of applicable laws and regulations...”.
 
China has been and continues to be our most important business development project. We operate an e-commerce direct selling model in Hong Kong that generates revenue derived from the sale of products to members in Hong Kong and elsewhere, including China. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. Through a separate Chinese entity, we operate an e-commerce retail platform in China. We believe that neither of these activities requires a direct selling license in China, which we do not currently hold. We have previously sought to obtain a direct selling license, and in August 2015 initiated the process for submitting a new preliminary application for a direct selling license in China. If we are able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. We do not expect that any increased sales in China derived from obtaining a direct selling license would initially be material and, in any event may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers, branch offices, manufacturing facilities, certification programs and other legal requirements. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.


12



Income Statement Presentation
 
We mainly derive revenue from sales of products. Substantially all of our product sales are to independent members at published wholesale prices. Product sales are recorded when the products are shipped and title passes to independent members, which generally is upon our delivery to the carrier that completes delivery to the members. We estimate and accrue a reserve for product returns based on our return policies and historical experience. Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. We bill members for shipping charges and recognize the freight revenue in net sales. Event and training revenue is deferred and recognized as the event or training occurs.
 
Cost of sales consists primarily of products purchased from third-party manufacturers, freight cost for transporting products to our foreign subsidiaries and shipping products to members, import duties, packing materials, product royalties, costs of promotional materials sold to our members at or near cost, and provisions for slow moving or obsolete inventories. Cost of sales also includes purchasing costs, receiving costs, inspection costs and warehousing costs.
 
Member commissions are our most significant expense and are classified as an operating expense. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled, generally in their home country currency, for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay any commissions. This “seamless” compensation plan enables a member located in one country to enroll other members located in other countries where we are authorized to conduct our business. Currently, there are basically two ways in which our members can earn income:
through commissions paid on product purchases made by their down-line members; and
through retail markups on sales of products purchased by members at wholesale prices (in the majority of our markets, sales are for personal consumption only and income may not be earned through retail mark-ups on sales in that market).
 
Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands from successfully enrolling other members who in turn expand their own businesses by selling product to other members, the member receives higher commissions from purchases made by an expanding down-line network. In some of our markets, to be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases.

Under our current compensation plan, certain of our commission payouts may be limited to a hard cap dollar amount per week or a specific percentage of total product sales. In some markets, commissions may be further limited. In some markets, we also pay certain bonuses on purchases by up to three generations of personally enrolled members, as well as bonuses on commissions earned by up to three generations of personally enrolled members. Members can also earn income, trips and other prizes in specific time-limited promotions and contests we hold from time to time. Member commissions are dependent on the sales mix and, for the first six months of 2017 and 2016, represented 43% and 47%, respectively, of net sales. Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions.We may also enter into agreements for business or market development, which could result in additional compensation to specific members.
 
Selling, general and administrative expenses consist of administrative compensation and benefits (including stock-based compensation), travel, credit card fees and assessments, professional fees, certain occupancy costs, and other corporate administrative expenses. In addition, this category includes selling, marketing, and promotion expenses (including the costs of member training events and conventions). Because our various member conventions are not always held at the same time each year, interim period comparisons will be impacted accordingly.

The functional currency of our international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.
 

13



Sales by our foreign subsidiaries are generally transacted in the respective local currencies and are translated into U.S. dollars using average rates of exchange for each monthly accounting period to which they relate.  Most of our product purchases from third-party manufacturers are transacted in U.S. dollars.  Consequently, our sales and net earnings are affected by changes in currency exchange rates, with sales and earnings generally increasing with a weakening U.S. dollar and decreasing with a strengthening U.S. dollar, see “Item 3. Quantitative and Qualitative Disclosures About Market Risk” and more specifically under the caption “Foreign Currency Exchange Risk” for further information. 

Results of Operations 
 
The following table sets forth our operating results as a percentage of net sales for the periods indicated.
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
Net sales
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
Cost of sales
19.0

 
18.7

 
18.9

 
19.0

Gross profit
81.0

 
81.3

 
81.1

 
81.0

Operating expenses:
 
 
 
 
 
 
 
Commissions expense
42.9

 
47.1

 
43.2

 
47.1

Selling, general and administrative expenses
12.8

 
15.5

 
14.5

 
15.1

Depreciation and amortization
0.3

 
0.1

 
0.2

 
0.1

Total operating expenses
56.0

 
62.7

 
57.9

 
62.3

Income from operations
25.0

 
18.6

 
23.2

 
18.7

Other income (expense), net
0.1

 

 
0.2

 

Income before income taxes
25.1

 
18.6

 
23.4

 
18.7

Income tax provision
5.1

 
3.4

 
4.8

 
3.5

Net income
20.0
%
 
15.2
%
 
18.6
%
 
15.2
%

Net Sales
 
The following table sets forth revenue by market for the periods indicated (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
Americas
$
1,641

 
3.2
%
 
$
1,995

 
2.5
%
 
$
3,101

 
2.8
%
 
$
3,058

 
2.0
%
Hong Kong
45,688

 
88.8

 
73,347

 
91.2

 
100,255

 
90.0

 
141,506

 
91.4

China
1,247

 
2.4

 
2,500

 
3.1

 
3,001

 
2.7

 
5,815

 
3.8

Taiwan
1,729

 
3.4

 
1,899

 
2.4

 
2,887

 
2.6

 
3,124

 
2.0

South Korea
129

 
0.2

 
191

 
0.2

 
251

 
0.2

 
392

 
0.3

Japan
33

 
0.1

 
16

 

 
60

 
0.1

 
36

 

Singapore
39

 
0.1

 
16

 

 
84

 
0.1

 
42

 

Russia and Kazakhstan
229

 
0.4

 
222

 
0.3

 
446

 
0.4

 
427

 
0.3

Europe
730

 
1.4

 
205

 
0.3

 
1,254

 
1.1

 
337

 
0.2

Total
$
51,465

 
100.0
%
 
$
80,391

 
100.0
%
 
$
111,339

 
100.0
%
 
$
154,737

 
100.0
%
 
Net sales were $51.5 million for the three months ended June 30, 2017 compared with $80.4 million for the comparable period a year ago, a decrease of $28.9 million, or 36%.  Hong Kong net sales, substantially all of which were shipped to members residing in China, decreased $27.7 million, or 38%, over the comparable period a year ago. The sales decrease was primarily attributable to the slowdown we have been experiencing in our Asian markets since the third quarter of 2016. In addition, Hong Kong experienced a decrease of 21,800 active members, or 19%, from June 30, 2016 to June 30, 2017, which contributed to the decrease in product sales volume.


14



Outside of our Hong Kong business, net sales decreased $1.3 million, or 18%, over the comparable three month period a year ago, driven by a 50% decrease in our China e-commerce business and a 18% decrease in the Americas, offset by a 256% increase in Europe. The $1.3 million net sales decrease in our China e-commerce business was primarily the result of decreased sales of our Home and Wellness product lines.
 
Net sales were $111.3 million for the six months ended June 30, 2017 compared with $154.7 million for the comparable period a year ago, a decrease of $43.4 million, or 28%.  Hong Kong net sales, substantially all of which were shipped to members residing in China, decreased $41.3 million, or 29%, over the comparable period a year ago. Hong Kong experienced a decrease of 21,800 active members, or 19%, from June 30, 2016 to June 30, 2017, which contributed to the decrease in product sales volume.
 
Outside of our Hong Kong business, net sales for the six months ended June 30, 2017 decreased $2.1 million, or 16%, over the comparable six month period a year ago, driven by a 48% decrease in our China e-commerce business, offset by a 272% increase in net sales in Europe. The $2.8 million net sales decrease in our China e-commerce business was primarily the result of decreased sales of our Home product line.

As of June 30, 2017, deferred revenue was $4.0 million, which primarily consisted of $1.7 million pertaining to unshipped product orders, $1.9 million pertaining to auto ship advances and $440,000 pertaining to unamortized enrollment package revenue.
 
Gross Profit
 
Gross profit was 81.0% of net sales for the three months ended June 30, 2017 compared with 81.3% of net sales for the three months ended June 30, 2016. The gross profit margin percentage decrease was primarily due to lower event revenue, offset by lower logistics costs.

Gross profit was 81.1% of net sales for the six months ended June 30, 2017 compared with 81.0% of net sales for the six months ended June 30, 2016. The gross profit margin percentage increase was primarily due to lower logistics costs, offset by lower event revenue.

Commissions
 
Commissions were 42.9% of net sales for the three months ended June 30, 2017, compared with 47.1% of net sales for the three months ended June 30, 2016, and 43.2% of net sales for the six months ended June 30, 2017, compared with 47.1% for the comparable period a year ago. The decrease as a percentage of net sales for the three and six month periods ended June 30, 2017 primarily resulted from lower estimated costs for on-going cash and other incentive programs.
 
Selling, General and Administrative Expenses
 
Selling, general and administrative expenses were $6.6 million for the three months ended June 30, 2017 compared with $12.4 million in the same period a year ago. For the six months ended June 30, 2017, selling, general and administrative expenses were $16.1 million compared with $23.3 million for the comparable period a year ago. Selling, general and administrative expenses decreased by 47% and 31%, respectively, during the three and six month periods mainly due to decreases in employee-related costs and event costs, as well as a decrease in credit card fees and assessments due to lower net sales, offset by an increase in professional fees as compared to the same period in the prior year.

Income Taxes
 
An income tax provision of $2.6 million and $2.7 million was recognized during the three month periods ended June 30, 2017 and 2016, respectively, and $5.4 million was recognized during each of the six month periods ended June 30, 2017 and 2016. As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, we determined that a portion of our undistributed foreign earnings were no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. We repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to existing U.S. net operating losses was reduced. We will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. corporate tax rate.


15



Liquidity and Capital Resources
 
At June 30, 2017, our cash and cash equivalents totaled $136.3 million. Total cash and cash equivalents increased by $10.3 million from December 31, 2016 to June 30, 2017. We consider all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. As of June 30, 2017, we had $73.2 million in available-for-sale investments classified as cash equivalents. In addition, cash and cash equivalents included $130.4 million held in bank accounts overseas, which included $6.1 million held in banks located within China subject to foreign currency controls.

As of June 30, 2017, the ratio of current assets to current liabilities was 2.74 to 1.00 and we had $95.0 million of working capital. Working capital as of June 30, 2017 increased $10.9 million compared to our working capital as of December 31, 2016, due primarily to an increase in cash from operations during the six months ended June 30, 2017.
 
Cash provided by operations was $20.6 million for the first six months of 2017 compared with $30.4 million in the comparable period of 2016. The decrease in operating cash flows resulted primarily from the decrease in product orders, offset by a reduction in inventories and inventory-related deposits.
 
Cash flows used in investing activities totaled $170,000 during the first six months of 2017 and consisted primarily of software development costs and buildout costs for our expansion into Peru and Vietnam. Cash flows used in investing activities totaled $524,000 during the first six months of 2016 and consisted primarily of software development costs of $426,000 for our Oracle ERP upgrade and enhancement of our back office software platform.
 
Cash flows used in financing activities during the first six months of 2017 consisted solely of the following dividend payments (in thousands, except per share amounts):
Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
April 24, 2017 (special)
 
$
0.35

 
$
3,964

 
May 9, 2017
 
May 19, 2017
April 24, 2017
 
0.10

 
1,133

 
May 9, 2017
 
May 19, 2017
January 24, 2017 (special)
 
0.35

 
3,962

 
February 21, 2017
 
March 3, 2017
January 24, 2017
 
0.09

 
1,019

 
February 21, 2017
 
March 3, 2017
 
 
$
0.89

 
$
10,078

 
 
 
 

On July 31, 2017, the Board of Directors declared a quarterly cash dividend of $0.11 and a special cash dividend of $0.25 on each share of common stock outstanding. Such dividends are payable on August 31, 2017 to stockholders of record on August 21, 2017. Payment of any future dividends on shares of common stock will be at the discretion of our Board of Directors.

Cash flows used in financing activities during the first six months of 2016 totaled $25.0 million, and consisted primarily of $23.7 million in stock repurchases.

We believe that our existing internal liquidity, supported by cash on hand and cash flows from operations should be adequate to fund normal business operations and address our financial commitments for the foreseeable future.
 
We do not have any significant unused sources of liquid assets. If necessary, we may attempt to generate more funding from the capital markets, but currently we do not believe that will be necessary.

Our priority is to focus our resources on investing in our most important markets, which we consider to be Greater China and countries where our existing members may have the connections to recruit prospects and sell our products, such as Southeast Asia. We will continue to invest in our Mainland China entity for such purposes as establishing China-based manufacturing capabilities, increasing public awareness of our brand and our products, sourcing more Chinese-made products, building a chain of service stations, opening additional Healthy Lifestyle Centers or branch offices, adding local staffing and other requirements for a China direct selling license application. We also have invested some resources in Mexico and Peru.
 

16



Critical Accounting Policies and Estimates 
 
A summary of our significant accounting policies is provided in Note 1 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 10, 2017. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.
 
Critical accounting policies and estimates are defined as both those that are material to the portrayal of our financial condition and results of operations and as those that require management’s most subjective judgments.  Management believes our critical accounting policies and estimates are those related to revenue recognition, as well as those used in the determination of liabilities related to sales returns, member commissions and income taxes.
 
Revenue Recognition.  Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon our delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” We primarily receive payment by credit card at the time members place orders. Our sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. Amounts received for unshipped product are recorded as deferred revenue. Such amounts totaled $1.7 million and $2.2 million at June 30, 2017 and December 31, 2016, respectively. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs.

Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal. At June 30, 2017 and December 31, 2016, enrollment package revenue totaling $440,000 and $430,000 was deferred, respectively. Although we have no immediate plans to significantly change the terms or conditions of enrollment packages, any changes in the future could result in additional revenue deferrals or could cause us to recognize the deferred revenue over a longer period of time. Additionally, deferred revenue includes advances for auto ship orders. In certain markets, when a member’s cumulative commission income reaches a certain threshold, a percentage of the member’s weekly commission is held back as an advance and applied to an auto ship order once the accumulated amount of the advances is sufficient to pay for the pre-selected auto ship package of the member.  Such advances were $1.9 million and $2.3 million at June 30, 2017 and December 31, 2016, respectively.

Allowance for Sales Returns. An allowance for sales returns is provided during the period the product is shipped.  The allowance is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 7% of sales.  Sales returns were 1% of sales for the six month periods ended June 30, 2017 and 2016.  The allowance for sales returns was $2.3 million and $1.6 million at June 30, 2017 and December 31, 2016, respectively.  No material changes in estimates have been recognized during the periods presented.
 
Commissions. Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of our products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  We accrue commissions when earned and as the related revenue is recognized and pay commissions on product sales generally two weeks following the end of the weekly sales period.
 
Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  These incentives may be both monetary and non-monetary in nature.  For each individual incentive, we estimate the total number of qualifiers as well as the expected per qualifier cost and accrue all costs associated with incentives throughout the qualification period. We regularly review and update, if necessary, the estimates of both qualifiers and cost as more information is obtained during the qualification period. Any resulting change in total cost is recognized over the remaining qualification period. Accrued commissions, including the estimated cost of our international recognition incentive program and other supplemental programs, totaled $12.7 million and $13.6 million at June 30, 2017 and December 31, 2016, respectively.
 

17



Income Taxes.  Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory rates for the years in which the temporary differences are expected to be recovered or settled. We evaluate the probability of realizing the future benefits of any of our deferred tax assets and record a valuation allowance when we believe a portion or all of our deferred tax assets may not be realized. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Based on the technical merits of our tax position, tax benefits may be recognized if we determine it is more likely than not that our position will be sustained on examination by tax authorities. The complex nature of these estimates requires us to anticipate the likely application of tax law and make judgments on the largest benefit that has a greater than fifty percent likelihood of being realized prior to the completion and filing of tax returns for such periods. As of June 30, 2017, we no longer have a valuation allowance against our U.S. deferred tax assets. We maintain a valuation allowance in certain foreign jurisdictions with an overall tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

Provision for income taxes depends on the statutory tax rates in each of the jurisdictions in which we operate. An income tax provision of $2.6 million and $2.7 million was recognized during the three month periods ended June 30, 2017 and 2016, respectively, and $5.4 million was recognized during each of the six month periods ended June 30, 2017 and 2016. As a result of capital return activities, we determined that a portion of our current undistributed foreign earnings are no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. We will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. corporate tax rate. As of June 30, 2017, we have accrued tax liabilities for earnings that we plan to repatriate out of accumulated earnings in future periods. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of June 30, 2017.

We estimate what our effective tax rate will be for the full fiscal year at each interim reporting period and record a quarterly tax provision based on that estimated effective tax rate. Throughout the year that estimated rate may change based on variations in our business, changes in our corporate structure, changes in the geographic mix and amount of income, applicable tax laws and regulations, communications with tax authorities, as well as our estimated and actual level of annual pre-tax income. We adjust our income tax provision in the reporting period in which the change in our estimated rate occurs so that the year-to-date provision is consistent with the anticipated annual tax rate. 
 
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
We have operations both internationally and within the United States, and we are exposed to market risks in the ordinary course of our business. These risks include primarily interest rate, foreign exchange and inflation risks.

Interest Rate Fluctuation Risk

Our cash and cash equivalents consist of cash, available-for-sale securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The primary objective of our investment in available-for-sale securities is to preserve principal while maximizing income without significantly increasing risk. Because our cash and cash equivalents have a relatively short maturity, our portfolio's fair value is relatively insensitive to interest rate changes. In future periods, we will continue to evaluate our investment policy relative to our overall objectives.

Foreign Currency Exchange Risk

We have foreign currency risks related to our revenue and expenses denominated in currencies other than the U.S. dollar. Our most significant foreign exchange exposure, the Hong Kong dollar, is for now pegged to the U.S. dollar. Our foreign currency exchange rate exposure to South Korean won, Taiwan dollar, Japanese yen, Chinese yuan, Russian ruble, Kazakhstani tenge, Singaporean dollar, Malaysian ringgit, Canadian dollar, and European euro represented approximately 8% and 7% of our revenue during each of the six month periods ended June 30, 2017 and 2016, respectively. We have experienced and will continue to experience fluctuations in our net income as a result of transaction gains and losses related to translating certain balances denominated in currencies other than the U.S. dollar.


18



Our foreign currency exchange rate exposure may increase in the near future as we develop opportunities in Southeast Asia, Canada, Central America, South America and Europe. Additionally, our foreign currency exchange rate exposure would significantly increase if the Hong Kong dollar were no longer pegged to the U.S. dollar. We also experience indirect exchange rate exposure to the Chinese yuan, which affects our Chinese members’ purchasing power. Given our inability to predict the degree of exchange rate fluctuations, we cannot estimate the effect these fluctuations may have upon future reported results, product pricing or our overall financial condition. Further, to date we have not attempted to reduce our exposure to short-term exchange rate fluctuations by using foreign currency exchange contracts.

Inflation Risk

We do not believe that inflation has had a material effect on our business, financial condition or results of operations. If our costs were to become subject to significant inflationary pressures, we might not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition and results of operations.

Item 4. CONTROLS AND PROCEDURES
 
Disclosure Controls and Procedures
 
Management, with the participation of the Company’s principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of June 30, 2017. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including the Company’s principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, the principal executive officer and principal financial officer concluded that, as of June 30, 2017, the Company’s disclosure controls and procedures were effective.
 
Changes in Internal Control over Financial Reporting
 
There were no changes in internal control over financial reporting that occurred during the fiscal quarter ended June 30, 2017 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

19



PART II — OTHER INFORMATION
 
Item 1. LEGAL PROCEEDINGS

Securities Class Action
 
In January 2016, two putative securities class action complaints were filed against us and our top executives in the United States District Court for the Central District of California. On March 29, 2016, the Court consolidated these actions under the caption Ford v. Natural Health Trends Corp., Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against Natural Health Trends Corp., and Chris T. Sharng, Timothy S. Davidson and George K. Broady (together, the “Individual Defendants”), and (ii) Section 20(a) of the Securities Exchange Act of 1934 against the Individual Defendants. The consolidated complaint alleges, inter alia, that we made materially false and misleading statements regarding the legality of our business operations in China, including running an allegedly illegal multilevel marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. We moved to dismiss the consolidated complaint on June 15, 2016. After full briefing and a hearing, the Court denied defendants’ motion to dismiss on December 5, 2016. On February 17, 2017, we filed an answer to the consolidated complaint. On April 14, 2017, the Court entered an order setting case management deadlines for the case, which include the conclusion of fact discovery in May 2018 and a final pretrial conference in August 2018. On July 10, 2017, the Court entered a stipulation between the parties, postponing all deadlines and staying the case for thirty days to allow the parties to engage in settlement discussions. On July 17, 2017, the parties reached an agreement in principle to settle the action. On July 18, 2017, the parties jointly filed a stipulation and proposed order with the Court, seeking to extend the stay for approximately sixty days to allow them an opportunity to negotiate the terms of a written settlement agreement and prepare and file the documentation necessary to obtain Court approval of the settlement. The Court entered the requested order on July 25, 2017, effecting a further stay of the case until September 25, 2017.  If approved, the proposed settlement will be fully funded by our insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if a settlement is not finalized and approved by the Court.

Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of our officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed us and our assets. The Derivative Complaints allege, inter alia, that we made materially false and misleading statements regarding the legality of our business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the Zhou action pending conclusion of the related federal class action in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. and Li v. Natural Health Trends Corp. A nearly identical stipulated stay was entered in the Kleinfeldt case on February 28, 2017. We believe that these claims are without merit and intend to vigorously defend against them.

Item 1A. RISK FACTORS
 
Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock. There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2016.
 
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

20




Item 3. DEFAULTS UPON SENIOR SECURITIES
 
None.
 
Item 4. MINE SAFETY DISCLOSURES
 
Not applicable.
 
Item 5. OTHER INFORMATION
 
None.
 
Item 6. EXHIBITS
 
Exhibit
Number
 
 
Exhibit Description
 
 
 
31.1
 
Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
 
Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
 
Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS
 
Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH
 
XBRL Taxonomy Extension Schema
101.CAL
 
XBRL Taxonomy Extension Calculation
101.DEF
 
XBRL Taxonomy Extension Definition
101.LAB
 
XBRL Taxonomy Extension Labels
101.PRE
 
XBRL Taxonomy Extension Presentation

21



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
NATURAL HEALTH TRENDS CORP.
 
 
 
 
Date: August 2, 2017
/s/ Timothy S. Davidson
 
 
Timothy S. Davidson
 
 
Senior Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
 

22



EXHIBIT INDEX
 
Exhibit
Number
 
Exhibit Description
 
 
 
31.1
 
Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
 
Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
 
Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS
 
Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH
 
XBRL Taxonomy Extension Schema
101.CAL
 
XBRL Taxonomy Extension Calculation
101.DEF
 
XBRL Taxonomy Extension Definition
101.LAB
 
XBRL Taxonomy Extension Labels
101.PRE
 
XBRL Taxonomy Extension Presentation

23
EX-31.1 2 ex31-1.htm EXHIBIT 31.1 Exhibit


EXHIBIT 31.1
 
CERTIFICATION
 
I, Chris T. Sharng, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: August 2, 2017
/s/ Chris T. Sharng
 
 
Chris T. Sharng
 
 
President
 
 
(Principal Executive Officer)
 


EX-31.2 3 ex31-2.htm EXHIBIT 31.2 Exhibit


EXHIBIT 31.2
 
CERTIFICATION
 
I, Timothy S. Davidson, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: August 2, 2017
/s/ Timothy S. Davidson
 
 
Timothy S. Davidson
 
 
Senior Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
 


EX-32.1 4 ex32-1.htm EXHIBIT 32.1 Exhibit


EXHIBIT 32.1
 

CERTIFICATIONS PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Natural Health Trends Corp. (the “Company”) on Form 10-Q for the period ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Chris T. Sharng, the Principal Executive Officer, and Timothy S. Davidson, the Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
 
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: August 2, 2017
/s/ Chris T. Sharng
 
 
Chris T. Sharng
 
 
President
 
 
(Principal Executive Officer)
 
 
 
 
 
 
 
Date: August 2, 2017
/s/ Timothy S. Davidson
 
 
Timothy S. Davidson
 
 
Senior Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
 
 
The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


EX-101.SCH 5 nhtc-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2207200 - Disclosure - ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - COMMITMENTS AND CONTINGENCIES NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - FAIR VALUE MEASUREMENTS (Notes) link:presentationLink link:calculationLink link:definitionLink 2211201 - Disclosure - FAIR VALUE MEASUREMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - INCOME TAXES INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - INCOME TAXES NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2206201 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2208201 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies) link:presentationLink link:calculationLink link:definitionLink 2308302 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - RELATED PARTY TRANSACTIONS NARRATIVE (Detail) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) link:presentationLink link:calculationLink link:definitionLink 2312302 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) link:presentationLink link:calculationLink link:definitionLink 2312303 - Disclosure - STOCKHOLDERS' EQUITY Dividends (Tables) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - STOCKHOLDERS' EQUITY NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - SUBSEQUENT EVENT link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - SUBSEQUENT EVENT - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 nhtc-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 nhtc-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 nhtc-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Fair Value Disclosures [Abstract] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Accounting Policies [Abstract] Recently Issued and Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statement of Comprehensive Income [Abstract] Net income Net Income (Loss) Attributable to Parent Other comprehensive income (loss), net of tax: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Unrealized (losses) gains on available-for-sale securities Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Principles of Consolidation Consolidation, Policy [Policy Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Accumulated Other Comprehensive Loss [Abstract] Accumulated Other Comprehensive Loss [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Available-for-sale Securities [Table Text Block] Available-for-sale Securities [Table Text Block] Earnings Per Share [Abstract] Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic Earnings Per Share, Basic Earnings Per Share, Basic Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Net Income (Loss) Available to Common Stockholders, Diluted Net Income (Loss) Available to Common Stockholders, Diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted Earnings Per Share, Diluted Earnings Per Share, Diluted Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] AOCI Attributable to Parent [Member] AOCI Attributable to Parent [Member] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Balance, December 31, 2016 Accumulated Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Balance, March 31, 2017 Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Inventories Inventory, Net Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Goodwill Goodwill Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Liabilities Liabilities [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Income taxes payable Accrued Income Taxes, Current Accrued commissions Accrued Liabilities, Current Other accrued expenses Other Accrued Liabilities, Current Deferred revenue Deferred Revenue, Current Amounts held in eWallets Other Deferred Credits, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Deferred Tax Liabilities, Net, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Long-term incentive Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 8) Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at June 30, 2017 and December 31, 2016 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Treasury stock, at cost; 1,637,524 and 1,692,218 shares at June 30, 2017 and December 31, 2016, respectively Treasury Stock, Value Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Earnings Per Share, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Municipal Bonds and Notes [Member] Municipal Bonds and Notes [Member] Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments. Corporate Debt Securities [Member] Corporate Debt Securities [Member] Financial Institution Instruments [Member] Financial Institution Instruments [Member] Information pertaining to financial institution instruments. Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax Available-for-sale Securities Available-for-sale Securities NATURE OF OPERATIONS AND BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Securities Class Action Securities Class Action [Member] Securities Class Action [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Number of complaints Loss Contingency, New Claims Filed, Number INCOME TAXES [Abstract] INCOME TAXES [Abstract] Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Document And Entity Information Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Current Reporting Status Entity Current Reporting Status Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Earnings Per Share [Text Block] Earnings Per Share [Text Block] Balance Sheet Components [Abstract] Balance Sheet Components [Abstract] Schedule of Additional Balance Sheet Components [Table Text Block] Schedule of Additional Balance Sheet Components [Table Text Block] Schedule of Additional Balance Sheet Components [Table Text Block] Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Summary of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation Stock-based compensation Share-based Compensation Cumulative Translation Adjustment Realized In Net Income Cumulative Translation Adjustment Realized In Net Income Represents cumulative translation adjustment realized in net income. Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Inventories Increase (Decrease) in Inventories Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable Income taxes payable Increase (Decrease) in Income Taxes Payable Accrued commissions Increase (Decrease) in Accrued Liabilities Other accrued expenses Increase (Decrease) in Other Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Amounts held in eWallets Increase (Decrease) in Customer Advances and Deposits Other current liabilities Increase (Decrease) in Other Current Liabilities Long-term incentive Increase (Decrease) in Deferred Compensation Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Repurchase of common stock Payments for Repurchase of Common Stock Dividends paid Payments of Dividends Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Effect of exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION: Noncash Investing and Financing Items [Abstract] Issuance of treasury stock for employee awards, net Stock Issued Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted Stock Restricted Stock [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Equity Incentive Plan 2016 Equity Incentive 2016 Plan [Member] Equity Incentive 2016 Plan Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Nonvested, beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Nonvested, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Nonvested, beginning balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Nonvested, ending balance (in dollars per share) Stock Issued During Period, Value, Restricted Stock Award, Gross Stock Issued During Period, Value, Restricted Stock Award, Gross Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Common Stock, Dividends, Per Share, Declared Common Stock, Dividends, Per Share, Declared CommonStockSpecialDividendsPerShareDeclared CommonStockSpecialDividendsPerShareDeclared Special dividends declared during the period for each share of common stock outstanding. Income Tax, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Common Stock Common Stock [Member] Dividends, Common Stock, Cash Dividends, Common Stock, Cash Dividends, Cash Dividends, Cash Share-based compensation expense Allocated Share-based Compensation Expense Additional stock-based compensation expense Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost Shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Award vesting period (in years) Share-based compensation expense not yet recognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Recognition period for compensation costs not yet recognized (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Stock repurchase program, amount authorized Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Common Stock, Dividends, Per Share, Cash Paid Common Stock, Dividends, Per Share, Cash Paid Condensed Balance Sheet Statement [Table] Condensed Balance Sheet Statement [Table] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Cash Equivalents [Member] Cash Equivalents [Member] Cash [Member] Cash [Member] Condensed Balance Sheet Statements, Captions [Line Items] Condensed Balance Sheet Statements, Captions [Line Items] Cash and Cash Equivalents, at Carrying Value Accrued Sales Returns Accrued Sales Returns Accrued Sales Returns Accrued Employee Benefits, Current Accrued Employee Benefits, Current Accrued Warehousing And Inventory Related Expense Accrued Warehousing And Inventory Related Expense Accrued Warehousing And Inventory Related Expense Other Accrued Liabilities, Current SUBSEQUENT EVENT Subsequent Events [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Broady Health Sciences Broady Health Sciences [Member] Represents Broady Health Sciences. Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Soothe Soothe [Member] Represents Soothe. ReStore ReStore [Member] Represents a product called ReStore™. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Royalty rate Royalty Rate Represents the royalty rate. Royalty expense Royalty Expense Number of days for termination notice Number Of Days Termination Notice Represents number of days termination notice. Dividends [Abstract] Dividends Declared [Table Text Block] Dividends Declared [Table Text Block] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Treasury stock, shares Treasury Stock, Shares Income Statement [Abstract] Net sales Sales Revenue, Goods, Net Cost of sales Cost of Goods Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Commissions expense Sales Commissions and Fees Selling, general and administrative expenses Selling, General and Administrative Expense Depreciation and amortization Depreciation, Depletion and Amortization Total operating expenses Operating Expenses Income from operations Operating Income (Loss) Other income (expense), net Other Nonoperating Income (Expense) Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax provision Income Tax Expense (Benefit) Net income per common share: Basic (in dollars per share) Weighted-average number of common shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Basic (in shares) Diluted (in shares) Cash dividends declared per share: Common (in dollars per share) EX-101.PRE 9 nhtc-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 nhtc20170802_10q_htm.xml IDEA: XBRL DOCUMENT 0000912061 2017-01-01 2017-06-30 0000912061 us-gaap:CashEquivalentsMember 2016-12-31 0000912061 us-gaap:CashMember 2016-12-31 0000912061 us-gaap:CashMember 2017-06-30 0000912061 us-gaap:CashEquivalentsMember 2017-06-30 0000912061 nhtc:MunicipalBondsAndNotesMember 2017-06-30 0000912061 us-gaap:CorporateDebtSecuritiesMember 2017-06-30 0000912061 nhtc:MunicipalBondsAndNotesMember 2016-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2017-06-30 0000912061 us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2016-12-31 0000912061 2017-07-28 0000912061 2017-01-01 2017-03-31 0000912061 2017-03-31 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 us-gaap:RestrictedStockMember 2016-04-08 2016-04-08 0000912061 2015-07-28 0000912061 us-gaap:RestrictedStockMember 2017-06-30 0000912061 us-gaap:RestrictedStockMember 2017-01-01 2017-06-30 0000912061 2017-01-24 2017-01-24 0000912061 2016-01-12 0000912061 us-gaap:RestrictedStockMember 2016-12-31 0000912061 2016-12-31 0000912061 2017-04-24 2017-04-24 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-01-01 2017-06-30 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2017-06-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-06-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-06-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2017-06-30 0000912061 2017-06-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000912061 2016-01-01 2016-03-31 0000912061 nhtc:SecuritiesClassActionMember 2016-01-01 2016-01-31 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-06-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2017-01-01 2017-06-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-06-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2016-04-01 2016-06-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2016-04-01 2016-06-30 0000912061 2016-01-01 2016-06-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2013-02-01 2013-02-28 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2017-04-01 2017-06-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2017-04-01 2017-06-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-04-29 2015-04-29 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2017-01-01 2017-06-30 0000912061 us-gaap:SubsequentEventMember 2017-07-31 2017-07-31 0000912061 2016-04-01 2016-06-30 0000912061 2017-04-01 2017-06-30 0000912061 2016-06-30 0000912061 2015-12-31 pure shares iso4217:USD iso4217:USD shares nhtc:complaint false --12-31 Q2 2017 0000912061 Yes Accelerated Filer 0.001 0.001 50000000 50000000 12979414 12979414 0.001 0.001 5000000 5000000 0 0 0 0 P3Y 1692218 1637524 10-Q 2017-06-30 NATURAL HEALTH TRENDS CORP. 11341890 136261000 125921000 9804000 11257000 3638000 4066000 149703000 141244000 1292000 1388000 1764000 1764000 3039000 2963000 768000 692000 156566000 148051000 2371000 2145000 4971000 663000 12666000 13611000 10366000 14989000 3994000 4948000 18713000 19165000 1622000 1633000 54703000 57154000 285000 268000 7179000 8190000 62167000 65612000 0 0 13000 13000 86665000 86574000 49198000 38548000 -907000 -807000 40570000 41889000 94399000 82439000 156566000 148051000 51465000 80391000 111339000 154737000 9793000 15059000 21038000 29339000 41672000 65332000 90301000 125398000 22075000 37883000 48040000 72969000 6590000 12431000 16126000 23335000 140000 91000 276000 180000 28805000 50405000 64442000 96484000 12867000 14927000 25859000 28914000 80000 16000 236000 -8000 12947000 14943000 26095000 28906000 2644000 2742000 5367000 5425000 10303000 12201000 20728000 23481000 0.92 1.08 1.84 2.03 0.91 1.07 1.84 2.03 11243000 11333000 11236000 11553000 11274000 11359000 11264000 11579000 0.45 0.06 0.89 0.11 10303000 12201000 20728000 23481000 87000 -327000 163000 -275000 0 -132000 258000 -132000 87000 -195000 -95000 -143000 2000 -1000 -5000 7000 10392000 12005000 20628000 23345000 20728000 23481000 276000 180000 17000 84000 258000 -132000 -1388000 1865000 -489000 612000 58000 -2000 226000 665000 4304000 487000 -915000 -989000 -3229000 2597000 -939000 4816000 -327000 1759000 -24000 203000 -1049000 -506000 20629000 30434000 170000 524000 -170000 -524000 0 23704000 10078000 1262000 -10078000 -24966000 -41000 -209000 10340000 4735000 125921000 104914000 136261000 109649000 1393000 1741000 NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Nature of Operations</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Natural Health Trends Corp. (the “Company”), a Delaware corporation, is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2016 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 10, 2017.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Principles of Consolidation<div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. ACCOUNTING PRONOUNCEMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows - Restricted Cash</span><span style="font-family:inherit;font-size:10pt;">, that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting</span><span style="font-family:inherit;font-size:10pt;">, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption was permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes</span><span style="font-family:inherit;font-size:10pt;">. Under this guidance, entities are required to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance was effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities were permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Inventory: Simplifying the Measurement of Inventory.</span><span style="font-family:inherit;font-size:10pt;"> Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method are to be measured at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation.  The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue From Contracts With Customers</span><span style="font-family:inherit;font-size:10pt;">, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. Early adoption is permitted to the original effective date of December 15, 2016, including interim reporting periods. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements. NET INCOME PER COMMON SHARE<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.92</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,333</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.08</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,303</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,274</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.91</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,359</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,728</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,236</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,481</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,553</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.03</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,481</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.03</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares. 10303000 11243000 0.92 12201000 11333000 1.08 31000 26000 10303000 11274000 0.91 12201000 11359000 1.07 20728000 11236000 1.84 23481000 11553000 2.03 28000 26000 20728000 11264000 1.84 23481000 11579000 2.03 The components of certain balance sheet amounts are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,036</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,453</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,261</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,301</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,632</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,087</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,541</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,978</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,816</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,366</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,989</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 63036000 52453000 73225000 73468000 136261000 125921000 2301000 1632000 6087000 10541000 1978000 2816000 10366000 14989000 FAIR VALUE MEASUREMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;"> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,897</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,312</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,671</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits. As of <span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices. The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets. Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,897</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,312</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,671</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 11895000 2000 11897000 43490000 0 43490000 16312000 -9000 16303000 1673000 -2000 1671000 45025000 0 45025000 28307000 0 28307000 73232000 -7000 73225000 73470000 -2000 73468000 . STOCKHOLDERS’ EQUITY<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s cash dividend activity for the </span><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Record Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 9, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 19, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 9, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 19, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 21, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 3, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,019</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 21, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 3, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.89</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Repurchases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$32.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$8,600</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$10,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$17,300</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$84,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the six months ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company’s 2016 annual meeting of stockholders. The modification of the award resulted in an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$64,000</span></span><span style="font-family:inherit;font-size:10pt;"> in stock-based compensation expense for the three months ended March 31, 2016.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>2,393,873</span></span><span style="font-family:inherit;font-size:10pt;"> shares remained available for issuance under the 2016 Plan. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 24, 2017, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>56,260</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2016 performance incentives totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. The shares vest on a quarterly basis over </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s restricted stock activity under the 2016 Plan:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,148</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s other restricted stock activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,348</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,970</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(418</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,960</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;">, total unrecognized stock-based compensation expense related to non-vested restricted stock was </span><span style="font-family:inherit;font-size:10pt;"><span>$18,500</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>0.5 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated Other Comprehensive Loss</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The changes in accumulated other comprehensive loss by component for the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of 2017 were as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized Losses on Available-For-Sale Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified out of accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(258</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(258</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(907</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div> The following table summarizes the Company’s cash dividend activity for the <span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Record Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 9, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 19, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 9, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 19, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 21, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 3, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,019</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 21, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 3, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.89</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors. 0.35 3964000 0.10 1133000 0.35 3962000 0.09 1019000 0.89 10078000 15000000.0 70000000.0 32000000.0 70000000.0 8600 10000 17300 84000 64000 2500000 2393873 56260 1400000 38256 34.13 56260 25.44 17668 29.58 1148 28.55 75700 28.90 The following table summarizes the Company’s other restricted stock activity:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,348</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,970</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(418</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,960</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div>The following table summarizes the Company’s restricted stock activity under the 2016 Plan:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,148</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 22348 12.15 0 0 10970 12.15 418 12.28 10960 12.15 18500 P0Y6M0D The changes in accumulated other comprehensive loss by component for the first <span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of 2017 were as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized Losses on Available-For-Sale Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified out of accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(258</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(258</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(907</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div> -805000 -2000 -807000 163000 -5000 158000 -258000 0 -258000 -900000 -7000 -907000 INCOME TAXES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated </span><span style="font-family:inherit;font-size:10pt;"><span>$19.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the year ended December 31, 2016 was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company has accrued tax liabilities for earnings that the Company plans to repatriate out of accumulated earnings in future periods. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company and its subsidiaries file tax returns in the United States, California and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2015 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries. 19800000 COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Class Action</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the Court consolidated these actions under the caption </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Ford v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;">, Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi &amp; Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng, Timothy S. Davidson and George K. Broady (together, the “Individual Defendants”), and (ii) Section 20(a) of the Securities Exchange Act of 1934 against the Individual Defendants. The consolidated complaint alleges, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. The Company moved to dismiss the consolidated complaint on June 15, 2016. After full briefing and a hearing, the Court denied defendants’ motion to dismiss on December 5, 2016. On February 17, 2017, the Company filed an answer to the consolidated complaint. On April 14, 2017, the Court entered an order setting case management deadlines for the case, which include the conclusion of fact discovery in May 2018 and a final pretrial conference in August 2018. On July 10, 2017, the Court entered a stipulation between the parties, postponing all deadlines and staying the case for thirty days to allow the parties to engage in settlement discussions. On July 17, 2017, the parties reached an agreement in principle to settle the action. On July 18, 2017, the parties jointly filed a stipulation and proposed order with the Court, seeking to extend the stay for approximately sixty days to allow them an opportunity to negotiate the terms of a written settlement agreement and prepare and file the documentation necessary to obtain Court approval of the settlement. The Court entered the requested order on July 25, 2017, effecting a further stay of the case until September 25, 2017.  If approved, the proposed settlement will be fully funded by the Company’s insurers.  Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if a settlement is not finalized and approved by the Court.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Derivative Claims</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou v. Sharng</span><span style="font-family:inherit;font-size:10pt;">. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt v. Sharng</span><span style="font-family:inherit;font-size:10pt;"> (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> action pending conclusion of the related federal class action in the United States District Court for the Central District of California:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Ford v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Li v. Natural Health Trends Corp</span><span style="font-family:inherit;font-size:10pt;">. A nearly identical stipulated stay was entered in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> case on February 8, 2017. The Company believes that these claims are without merit and intends to vigorously defend against them.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The consolidated class action, if a settlement is not finalized and approved by the Court, and the Derivative Complaints, or others filed alleging similar facts, could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition. 2 RELATED PARTY TRANSACTIONS<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Soothe</span><span style="font-family:inherit;font-size:10pt;">™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS. Under the agreement, the Company agreed to pay BHS a royalty of </span><span style="font-family:inherit;font-size:10pt;"><span>2.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide. Royalties recognized for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$500</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$800</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1,200</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;"><span>120 days</span></span><span style="font-family:inherit;font-size:10pt;">’ notice. Otherwise, the agreement terminates March 31, 2020.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ReStor™.</span><span style="font-family:inherit;font-size:10pt;">  Under the agreement, the Company agreed to pay BHS a royalty of </span><span style="font-family:inherit;font-size:10pt;"><span>2.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. Such provision was effective retroactively to January 1, 2015. Such royalties were </span><span style="font-family:inherit;font-size:10pt;"><span>$86,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$141,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$177,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$280,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;"><span>120 days</span></span><span style="font-family:inherit;font-size:10pt;">’ notice or, under certain circumstances, with </span><span style="font-family:inherit;font-size:10pt;">no</span> notice. Otherwise, the agreement terminates March 31, 2020. 0.025 500 800 1200 2000 P120DT0H 0.025 86000 141000 177000 280000 P120DT0H SUBSEQUENT EVENT<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">July 31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Board of Directors declared a quarterly cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.11</span></span><span style="font-family:inherit;font-size:10pt;"> and a special cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.25</span></span><span style="font-family:inherit;font-size:10pt;"> on each share of common stock outstanding. Such dividends are payable on </span><span style="font-family:inherit;font-size:10pt;">August 31, 2017</span><span style="font-family:inherit;font-size:10pt;"> to stockholders of record on </span><span style="font-family:inherit;font-size:10pt;">August 21, 2017</span>. Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors. 0.11 0.25 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1
Document And Entity Information - shares
6 Months Ended
Jun. 30, 2017
Jul. 28, 2017
Document And Entity Information    
Document Type 10-Q  
Document Period End Date Jun. 30, 2017  
Entity Registrant Name NATURAL HEALTH TRENDS CORP.  
Entity Central Index Key 0000912061  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Current Reporting Status Yes  
Entity Common Stock, Shares Outstanding (in shares)   11,341,890
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q2  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 136,261 $ 125,921
Inventories 9,804 11,257
Other current assets 3,638 4,066
Total current assets 149,703 141,244
Property and equipment, net 1,292 1,388
Goodwill 1,764 1,764
Restricted cash 3,039 2,963
Other assets 768 692
Total assets 156,566 148,051
Current liabilities:    
Accounts payable 2,371 2,145
Income taxes payable 4,971 663
Accrued commissions 12,666 13,611
Other accrued expenses 10,366 14,989
Deferred revenue 3,994 4,948
Amounts held in eWallets 18,713 19,165
Other current liabilities 1,622 1,633
Total current liabilities 54,703 57,154
Deferred Tax Liabilities, Net, Noncurrent 285 268
Long-term incentive 7,179 8,190
Total liabilities 62,167 65,612
Commitments and contingencies (Note 8)
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at June 30, 2017 and December 31, 2016 13 13
Additional paid-in capital 86,665 86,574
Retained earnings 49,198 38,548
Accumulated other comprehensive loss (907) (807)
Treasury stock, at cost; 1,637,524 and 1,692,218 shares at June 30, 2017 and December 31, 2016, respectively (40,570) (41,889)
Total stockholders’ equity 94,399 82,439
Total liabilities and stockholders’ equity $ 156,566 $ 148,051
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2017
Dec. 31, 2016
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 12,979,414 12,979,414
Treasury stock, shares 1,637,524 1,692,218
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Income Statement [Abstract]        
Net sales $ 51,465 $ 80,391 $ 111,339 $ 154,737
Cost of sales 9,793 15,059 21,038 29,339
Gross profit 41,672 65,332 90,301 125,398
Operating expenses:        
Commissions expense 22,075 37,883 48,040 72,969
Selling, general and administrative expenses 6,590 12,431 16,126 23,335
Depreciation and amortization 140 91 276 180
Total operating expenses 28,805 50,405 64,442 96,484
Income from operations 12,867 14,927 25,859 28,914
Other income (expense), net 80 16 236 (8)
Income before income taxes 12,947 14,943 26,095 28,906
Income tax provision 2,644 2,742 5,367 5,425
Net income $ 10,303 $ 12,201 $ 20,728 $ 23,481
Net income per common share:        
Basic (in dollars per share) $ 0.92 $ 1.08 $ 1.84 $ 2.03
Earnings Per Share, Diluted $ 0.91 $ 1.07 $ 1.84 $ 2.03
Weighted-average number of common shares outstanding:        
Basic (in shares) 11,243 11,333 11,236 11,553
Diluted (in shares) 11,274 11,359 11,264 11,579
Cash dividends declared per share:        
Common (in dollars per share) $ 0.45 $ 0.06 $ 0.89 $ 0.11
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Statement of Comprehensive Income [Abstract]        
Net income $ 10,303 $ 12,201 $ 20,728 $ 23,481
Other comprehensive income (loss), net of tax:        
Foreign currency translation adjustment 87 (327) 163 (275)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax 0 (132) 258 (132)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax 87 (195) (95) (143)
Unrealized (losses) gains on available-for-sale securities 2 (1) (5) 7
Comprehensive income $ 10,392 $ 12,005 $ 20,628 $ 23,345
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 20,728 $ 23,481
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 276 180
Stock-based compensation 17 84
Cumulative Translation Adjustment Realized In Net Income (258) 132
Changes in assets and liabilities:    
Inventories 1,388 (1,865)
Other current assets 489 (612)
Other assets (58) 2
Accounts payable 226 665
Income taxes payable 4,304 487
Accrued commissions (915) (989)
Other accrued expenses (3,229) 2,597
Deferred revenue (939) 4,816
Amounts held in eWallets (327) 1,759
Other current liabilities (24) 203
Long-term incentive (1,049) (506)
Net cash provided by operating activities 20,629 30,434
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (170) (524)
Net cash used in investing activities (170) (524)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repurchase of common stock 0 (23,704)
Dividends paid (10,078) (1,262)
Net cash used in financing activities (10,078) (24,966)
Effect of exchange rates on cash and cash equivalents (41) (209)
Net increase (decrease) in cash and cash equivalents 10,340 4,735
CASH AND CASH EQUIVALENTS, beginning of period 125,921 104,914
CASH AND CASH EQUIVALENTS, end of period 136,261 109,649
SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:    
Issuance of treasury stock for employee awards, net $ 1,393 $ 1,741
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
NATURE OF OPERATIONS AND BASIS OF PRESENTATION
6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS AND BASIS OF PRESENTATION NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION

Nature of Operations 
 
Natural Health Trends Corp. (the “Company”), a Delaware corporation, is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.
 
The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

Basis of Presentation 
 
The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2016 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 10, 2017.

Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE
6 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block] NET INCOME PER COMMON SHARE

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.

The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data): 
 
Three Months Ended June 30,
 
2017
 
2016
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
10,303

 
11,243

 
$
0.92

 
$
12,201

 
11,333

 
$
1.08

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
31

 
 

 

 
26

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
10,303

 
11,274

 
$
0.91

 
$
12,201

 
11,359

 
$
1.07


 
Six Months Ended June 30,
 
2017
 
2016
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
20,728

 
11,236

 
$
1.84

 
$
23,481

 
11,553

 
$
2.03

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
28

 
 

 

 
26

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
20,728

 
11,264

 
$
1.84

 
$
23,481

 
11,579

 
$
2.03

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
FAIR VALUE MEASUREMENTS (Notes)
6 Months Ended
Jun. 30, 2017
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS

As of June 30, 2017, cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at June 30, 2017 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.

The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
June 30, 2017
 
December 31, 2016
 
Adjusted Cost
 
Gross Unrealized Gains
(Losses)
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
Municipal bonds and notes
$
11,895

 
$
2

 
$
11,897

 
$
43,490

 
$

 
$
43,490

Corporate debt securities
16,312

 
(9
)
 
16,303

 
1,673

 
(2
)
 
1,671

Financial institution instruments
45,025

 

 
45,025

 
28,307

 

 
28,307

Total available-for-sale investments
$
73,232

 
$
(7
)
 
$
73,225

 
$
73,470

 
$
(2
)
 
$
73,468


 
Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY
6 Months Ended
Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stockholders' Equity Note Disclosure [Text Block] . STOCKHOLDERS’ EQUITY
 
Dividends
 
The following table summarizes the Company’s cash dividend activity for the six months ended June 30, 2017 (in thousands, except per share data):
Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
April 24, 2017 (special)
 
$
0.35

 
$
3,964

 
May 9, 2017
 
May 19, 2017
April 24, 2017
 
0.10

 
1,133

 
May 9, 2017
 
May 19, 2017
January 24, 2017 (special)
 
0.35

 
3,962

 
February 21, 2017
 
March 3, 2017
January 24, 2017
 
0.09

 
1,019

 
February 21, 2017
 
March 3, 2017
 
 
$
0.89

 
$
10,078

 
 
 
 

Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.

Stock Repurchases

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of June 30, 2017, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

Restricted Stock

Stock-based compensation expense totaled $8,600 and $10,000 for the three months ended June 30, 2017 and 2016, respectively, and $17,300 and $84,000 for the six months ended June 30, 2017 and 2016, respectively. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company’s 2016 annual meeting of stockholders. The modification of the award resulted in an additional $64,000 in stock-based compensation expense for the three months ended March 31, 2016.

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At June 30, 2017, 2,393,873 shares remained available for issuance under the 2016 Plan.

On January 24, 2017, the Company granted 56,260 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2016 performance incentives totaling $1.4 million. The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2016
38,256

 
$
34.13

Granted
56,260

 
25.44

Vested
(17,668
)
 
29.58

Forfeited
(1,148
)
 
28.55

Nonvested at June 30, 2017
75,700

 
28.90



The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2016
22,348

 
$
12.15

Granted

 

Vested
(10,970
)
 
12.15

Forfeited
(418
)
 
12.28

Nonvested at June 30, 2017
10,960

 
12.15


 
As of June 30, 2017, total unrecognized stock-based compensation expense related to non-vested restricted stock was $18,500, which is expected to be recognized over a weighted-average period of 0.5 years.

Accumulated Other Comprehensive Loss
 
The changes in accumulated other comprehensive loss by component for the first six months of 2017 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Losses on Available-For-Sale Investments
 
Total
Balance, December 31, 2016
$
(805
)
 
$
(2
)
 
$
(807
)
Other comprehensive income (loss)
163

 
(5
)
 
158

Amounts reclassified out of accumulated other comprehensive loss
(258
)
 

 
(258
)
Balance, June 30, 2017
$
(900
)
 
$
(7
)
 
$
(907
)
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES INCOME TAXES
6 Months Ended
Jun. 30, 2017
INCOME TAXES [Abstract]  
Income Tax, Policy [Policy Text Block] INCOME TAXES

As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the year ended December 31, 2016 was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate. As of June 30, 2017, the Company has accrued tax liabilities for earnings that the Company plans to repatriate out of accumulated earnings in future periods. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of June 30, 2017.

The Company and its subsidiaries file tax returns in the United States, California and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2015 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES

Securities Class Action

In January 2016, two putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the Court consolidated these actions under the caption Ford v. Natural Health Trends Corp., Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng, Timothy S. Davidson and George K. Broady (together, the “Individual Defendants”), and (ii) Section 20(a) of the Securities Exchange Act of 1934 against the Individual Defendants. The consolidated complaint alleges, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. The Company moved to dismiss the consolidated complaint on June 15, 2016. After full briefing and a hearing, the Court denied defendants’ motion to dismiss on December 5, 2016. On February 17, 2017, the Company filed an answer to the consolidated complaint. On April 14, 2017, the Court entered an order setting case management deadlines for the case, which include the conclusion of fact discovery in May 2018 and a final pretrial conference in August 2018. On July 10, 2017, the Court entered a stipulation between the parties, postponing all deadlines and staying the case for thirty days to allow the parties to engage in settlement discussions. On July 17, 2017, the parties reached an agreement in principle to settle the action. On July 18, 2017, the parties jointly filed a stipulation and proposed order with the Court, seeking to extend the stay for approximately sixty days to allow them an opportunity to negotiate the terms of a written settlement agreement and prepare and file the documentation necessary to obtain Court approval of the settlement. The Court entered the requested order on July 25, 2017, effecting a further stay of the case until September 25, 2017.  If approved, the proposed settlement will be fully funded by the Company’s insurers.  Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if a settlement is not finalized and approved by the Court.

Shareholder Derivative Claims

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the Zhou action pending conclusion of the related federal class action in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. and Li v. Natural Health Trends Corp. A nearly identical stipulated stay was entered in the Kleinfeldt case on February 8, 2017. The Company believes that these claims are without merit and intends to vigorously defend against them.

The consolidated class action, if a settlement is not finalized and approved by the Court, and the Derivative Complaints, or others filed alleging similar facts, could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
RELATED PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2017
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS

On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called Soothe™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS. Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide. Royalties recognized for the three months ended June 30, 2017 and 2016 were $500 and $800, respectively, and $1,200 and $2,000 for the six months ended June 30, 2017 and 2016, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice. Otherwise, the agreement terminates March 31, 2020.

In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called ReStor™.  Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. Such provision was effective retroactively to January 1, 2015. Such royalties were $86,000 and $141,000 for the three months ended June 30, 2017 and 2016, respectively, and $177,000 and $280,000 for the six months ended June 30, 2017 and 2016, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
SUBSEQUENT EVENT
6 Months Ended
Jun. 30, 2017
Subsequent Events [Abstract]  
SUBSEQUENT EVENT SUBSEQUENT EVENT
 
On July 31, 2017, the Board of Directors declared a quarterly cash dividend of $0.11 and a special cash dividend of $0.25 on each share of common stock outstanding. Such dividends are payable on August 31, 2017 to stockholders of record on August 21, 2017. Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION
6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Principles of Consolidation Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS
6 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
Recently Issued and Adopted Accounting Pronouncements ACCOUNTING PRONOUNCEMENTS
 
In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows - Restricted Cash, that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption was permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
 
In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. Under this guidance, entities are required to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance was effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities were permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016.

In July 2015, the FASB issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory. Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method are to be measured at the lower of cost and net realizable value.  Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation.  The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.  Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.  In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. Early adoption is permitted to the original effective date of December 15, 2016, including interim reporting periods. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies)
6 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Earnings Per Share, Policy [Policy Text Block] Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
FAIR VALUE MEASUREMENTS (Policies)
6 Months Ended
Jun. 30, 2017
Fair Value Disclosures [Abstract]  
Cash and Cash Equivalents, Policy [Policy Text Block] As of June 30, 2017, cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at June 30, 2017 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.
Fair Value of Financial Instruments, Policy [Policy Text Block] The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables)
6 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block] NET INCOME PER COMMON SHARE

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.

The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data): 
 
Three Months Ended June 30,
 
2017
 
2016
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
10,303

 
11,243

 
$
0.92

 
$
12,201

 
11,333

 
$
1.08

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
31

 
 

 

 
26

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
10,303

 
11,274

 
$
0.91

 
$
12,201

 
11,359

 
$
1.07


 
Six Months Ended June 30,
 
2017
 
2016
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
20,728

 
11,236

 
$
1.84

 
$
23,481

 
11,553

 
$
2.03

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
28

 
 

 

 
26

 
 

Diluted net income per common share:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
20,728

 
11,264

 
$
1.84

 
$
23,481

 
11,579

 
$
2.03

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
BALANCE SHEET COMPONENTS Balance Sheet Components (Tables)
6 Months Ended
Jun. 30, 2017
Balance Sheet Components [Abstract]  
Schedule of Additional Balance Sheet Components [Table Text Block] The components of certain balance sheet amounts are as follows (in thousands):
 
June 30, 2017
 
December 31, 2016
Cash and cash equivalents:
 
 
 
Cash
$
63,036

 
$
52,453

Cash equivalents
73,225

 
73,468

 
$
136,261

 
$
125,921

Other accrued expenses:
 
 
 
Sales returns
$
2,301

 
$
1,632

Employee-related
6,087

 
10,541

Warehousing, inventory-related and other
1,978

 
2,816

 
$
10,366

 
$
14,989

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
FAIR VALUE MEASUREMENTS (Tables)
6 Months Ended
Jun. 30, 2017
Fair Value Disclosures [Abstract]  
Available-for-sale Securities [Table Text Block] Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
June 30, 2017
 
December 31, 2016
 
Adjusted Cost
 
Gross Unrealized Gains
(Losses)
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
Municipal bonds and notes
$
11,895

 
$
2

 
$
11,897

 
$
43,490

 
$

 
$
43,490

Corporate debt securities
16,312

 
(9
)
 
16,303

 
1,673

 
(2
)
 
1,671

Financial institution instruments
45,025

 

 
45,025

 
28,307

 

 
28,307

Total available-for-sale investments
$
73,232

 
$
(7
)
 
$
73,225

 
$
73,470

 
$
(2
)
 
$
73,468

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables)
6 Months Ended
Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of Restricted Stock Activity The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2016
22,348

 
$
12.15

Granted

 

Vested
(10,970
)
 
12.15

Forfeited
(418
)
 
12.28

Nonvested at June 30, 2017
10,960

 
12.15

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2016
38,256

 
$
34.13

Granted
56,260

 
25.44

Vested
(17,668
)
 
29.58

Forfeited
(1,148
)
 
28.55

Nonvested at June 30, 2017
75,700

 
28.90

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)
6 Months Ended
Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] The changes in accumulated other comprehensive loss by component for the first six months of 2017 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Losses on Available-For-Sale Investments
 
Total
Balance, December 31, 2016
$
(805
)
 
$
(2
)
 
$
(807
)
Other comprehensive income (loss)
163

 
(5
)
 
158

Amounts reclassified out of accumulated other comprehensive loss
(258
)
 

 
(258
)
Balance, June 30, 2017
$
(900
)
 
$
(7
)
 
$
(907
)
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY Dividends (Tables)
6 Months Ended
Jun. 30, 2017
Dividends [Abstract]  
Dividends Declared [Table Text Block] The following table summarizes the Company’s cash dividend activity for the six months ended June 30, 2017 (in thousands, except per share data):
Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
April 24, 2017 (special)
 
$
0.35

 
$
3,964

 
May 9, 2017
 
May 19, 2017
April 24, 2017
 
0.10

 
1,133

 
May 9, 2017
 
May 19, 2017
January 24, 2017 (special)
 
0.35

 
3,962

 
February 21, 2017
 
March 3, 2017
January 24, 2017
 
0.09

 
1,019

 
February 21, 2017
 
March 3, 2017
 
 
$
0.89

 
$
10,078

 
 
 
 

Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
NET INCOME PER COMMON SHARE Net Income Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Earnings Per Share [Abstract]        
Net Income (Loss) Available to Common Stockholders, Basic $ 10,303 $ 12,201 $ 20,728 $ 23,481
Weighted Average Number of Shares Outstanding, Basic 11,243 11,333 11,236 11,553
Earnings Per Share, Basic $ 0.92 $ 1.08 $ 1.84 $ 2.03
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 31 26 28 26
Net Income (Loss) Available to Common Stockholders, Diluted $ 10,303 $ 12,201 $ 20,728 $ 23,481
Weighted Average Number of Shares Outstanding, Diluted 11,274 11,359 11,264 11,579
Earnings Per Share, Diluted $ 0.91 $ 1.07 $ 1.84 $ 2.03
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
BALANCE SHEET COMPONENTS Balance Sheet Components (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Jun. 30, 2016
Dec. 31, 2015
Condensed Balance Sheet Statements, Captions [Line Items]        
Cash and Cash Equivalents, at Carrying Value $ 136,261 $ 125,921 $ 109,649 $ 104,914
Accrued Sales Returns 2,301 1,632    
Accrued Employee Benefits, Current 6,087 10,541    
Accrued Warehousing And Inventory Related Expense 1,978 2,816    
Other Accrued Liabilities, Current 10,366 14,989    
Cash Equivalents [Member]        
Condensed Balance Sheet Statements, Captions [Line Items]        
Cash and Cash Equivalents, at Carrying Value 73,225 73,468    
Cash [Member]        
Condensed Balance Sheet Statements, Captions [Line Items]        
Cash and Cash Equivalents, at Carrying Value $ 63,036 $ 52,453    
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
FAIR VALUE MEASUREMENTS (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]    
Available-for-sale Securities, Amortized Cost Basis $ 73,232 $ 73,470
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax (7) (2)
Available-for-sale Securities 73,225 73,468
Municipal Bonds and Notes [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Available-for-sale Securities, Amortized Cost Basis 11,895 43,490
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax 2 0
Available-for-sale Securities 11,897 43,490
Corporate Debt Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Available-for-sale Securities, Amortized Cost Basis 16,312 1,673
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax (9) (2)
Available-for-sale Securities 16,303 1,671
Financial Institution Instruments [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Available-for-sale Securities, Amortized Cost Basis 45,025 28,307
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax 0 0
Available-for-sale Securities $ 45,025 $ 28,307
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY NARRATIVE (Details) - USD ($)
3 Months Ended 6 Months Ended
Apr. 24, 2017
Jan. 24, 2017
Apr. 08, 2016
Jun. 30, 2017
Mar. 31, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Apr. 07, 2016
Jan. 12, 2016
Jul. 28, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Common Stock, Dividends, Per Share, Declared $ 0.10 $ 0.09   $ 0.45   $ 0.06 $ 0.89 $ 0.11      
CommonStockSpecialDividendsPerShareDeclared $ 0.35 $ 0.35                  
Dividends, Common Stock, Cash $ 3,964,000 $ 3,962,000                  
Dividends, Cash $ 1,133,000 $ 1,019,000         $ 10,078,000        
Share-based compensation expense       $ 8,600   $ 10,000 $ 17,300 $ 84,000      
Additional stock-based compensation expense         $ 64,000            
Stock repurchase program, amount authorized                   $ 70,000,000.0 $ 15,000,000.0
Stock Repurchase Program, Remaining Authorized Repurchase Amount         $ 32,000,000.0            
Common Stock, Dividends, Per Share, Cash Paid             $ 0.89        
Restricted Stock                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)     56,260       0        
Award vesting period (in years)     3 years                
Share-based compensation expense not yet recognized       $ 18,500     $ 18,500        
Recognition period for compensation costs not yet recognized (in years)             6 months        
Equity Incentive Plan 2016 | Common Stock                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Shares authorized                 2,500,000    
Equity Incentive Plan 2016 | Restricted Stock                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Granted (in shares)             56,260        
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details) - USD ($)
$ / shares in Units, $ in Millions
6 Months Ended
Jan. 24, 2017
Apr. 08, 2016
Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant     2,393,873
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Stock Issued During Period, Value, Restricted Stock Award, Gross $ 1.4    
Restricted Stock      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Nonvested, beginning balance (in shares)     22,348
Granted (in shares)   56,260 0
Vested (in shares)     (10,970)
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited     (418)
Nonvested, ending balance (in shares)     10,960
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Nonvested, beginning balance (in dollars per share)     $ 12.15
Granted (in dollars per share)     0
Vested (in dollars per share)     12.15
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value     12.28
Nonvested, ending balance (in dollars per share)     $ 12.15
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period   3 years  
Restricted Stock | Equity Incentive Plan 2016      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Nonvested, beginning balance (in shares)     38,256
Granted (in shares)     56,260
Vested (in shares)     (17,668)
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited     (1,148)
Nonvested, ending balance (in shares)     75,700
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Nonvested, beginning balance (in dollars per share)     $ 34.13
Granted (in dollars per share)     25.44
Vested (in dollars per share)     29.58
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value     28.55
Nonvested, ending balance (in dollars per share)     $ 28.90
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2017
USD ($)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2016 $ (807)
Balance, March 31, 2017 (907)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2016 (805)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 163
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent (258)
Balance, March 31, 2017 (900)
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2016 (2)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (5)
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent 0
Balance, March 31, 2017 (7)
AOCI Attributable to Parent [Member]  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Balance, December 31, 2016 (807)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 158
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent (258)
Balance, March 31, 2017 $ (907)
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES NARRATIVE (Details)
$ in Millions
3 Months Ended
Mar. 31, 2016
USD ($)
INCOME TAXES [Abstract]  
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount $ 19.8
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1
COMMITMENTS AND CONTINGENCIES NARRATIVE (Details)
1 Months Ended
Jan. 31, 2016
complaint
Securities Class Action  
Loss Contingencies [Line Items]  
Number of complaints 2
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
RELATED PARTY TRANSACTIONS NARRATIVE (Detail) - Broady Health Sciences - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 29, 2015
Feb. 28, 2013
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Soothe            
Related Party Transaction [Line Items]            
Royalty rate 2.50%          
Royalty expense     $ 500 $ 800 $ 1,200 $ 2,000
Number of days for termination notice 120 days          
ReStore            
Related Party Transaction [Line Items]            
Royalty rate   2.50%        
Royalty expense     $ 86,000 $ 141,000 $ 177,000 $ 280,000
Number of days for termination notice   120 days        
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
SUBSEQUENT EVENT - NARRATIVE (Details) - $ / shares
3 Months Ended 6 Months Ended
Jul. 31, 2017
Apr. 24, 2017
Jan. 24, 2017
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Subsequent Event [Line Items]              
Common Stock, Dividends, Per Share, Declared   $ 0.10 $ 0.09 $ 0.45 $ 0.06 $ 0.89 $ 0.11
CommonStockSpecialDividendsPerShareDeclared   $ 0.35 $ 0.35        
Subsequent Event              
Subsequent Event [Line Items]              
Common Stock, Dividends, Per Share, Declared $ 0.11            
CommonStockSpecialDividendsPerShareDeclared $ 0.25            
EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 46 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 55 149 1 false 16 0 false 5 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1002000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Statements 5 false false R6.htm 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 2106100 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation NATURE OF OPERATIONS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 2108100 - Disclosure - NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE Notes 8 false false R9.htm 2111100 - Disclosure - FAIR VALUE MEASUREMENTS (Notes) Notes http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes FAIR VALUE MEASUREMENTS (Notes) Notes 9 false false R10.htm 2112100 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 10 false false R11.htm 2113100 - Disclosure - INCOME TAXES INCOME TAXES Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes INCOME TAXES INCOME TAXES Notes 11 false false R12.htm 2114100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 2115100 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 13 false false R14.htm 2116100 - Disclosure - SUBSEQUENT EVENT Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEvent SUBSEQUENT EVENT Notes 14 false false R15.htm 2206201 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION Notes 15 false false R16.htm 2207200 - Disclosure - ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS Sheet http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS Notes 16 false false R17.htm 2208201 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies) Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies) Policies 17 false false R18.htm 2211201 - Disclosure - FAIR VALUE MEASUREMENTS (Policies) Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies FAIR VALUE MEASUREMENTS (Policies) Policies 18 false false R19.htm 2308302 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables) Tables 19 false false R20.htm 2310301 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables BALANCE SHEET COMPONENTS Balance Sheet Components (Tables) Tables 20 false false R21.htm 2311302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes 21 false false R22.htm 2312301 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables) Tables 22 false false R23.htm 2312302 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Tables 23 false false R24.htm 2312303 - Disclosure - STOCKHOLDERS' EQUITY Dividends (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendsTables STOCKHOLDERS' EQUITY Dividends (Tables) Tables 24 false false R25.htm 2408403 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Details) Sheet http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails NET INCOME PER COMMON SHARE Net Income Per Common Share (Details) Details http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables 25 false false R26.htm 2410402 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Details) Sheet http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails BALANCE SHEET COMPONENTS Balance Sheet Components (Details) Details http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables 26 false false R27.htm 2411403 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) Details http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables 27 false false R28.htm 2412404 - Disclosure - STOCKHOLDERS' EQUITY NARRATIVE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails STOCKHOLDERS' EQUITY NARRATIVE (Details) Details 28 false false R29.htm 2412405 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details) Details http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables 29 false false R30.htm 2412406 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Details http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables 30 false false R31.htm 2413401 - Disclosure - INCOME TAXES NARRATIVE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails INCOME TAXES NARRATIVE (Details) Details 31 false false R32.htm 2414401 - Disclosure - COMMITMENTS AND CONTINGENCIES NARRATIVE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails COMMITMENTS AND CONTINGENCIES NARRATIVE (Details) Details 32 false false R33.htm 2415401 - Disclosure - RELATED PARTY TRANSACTIONS NARRATIVE (Detail) Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail RELATED PARTY TRANSACTIONS NARRATIVE (Detail) Details 33 false false R34.htm 2416401 - Disclosure - SUBSEQUENT EVENT - NARRATIVE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails SUBSEQUENT EVENT - NARRATIVE (Details) Details 34 false false All Reports Book All Reports nhtc20170802_10q.htm nhtc-20170630.xsd nhtc-20170630_cal.xml nhtc-20170630_def.xml nhtc-20170630_lab.xml nhtc-20170630_pre.xml true true JSON 51 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nhtc20170802_10q.htm": { "axisCustom": 0, "axisStandard": 9, "contextCount": 55, "dts": { "calculationLink": { "local": [ "nhtc-20170630_cal.xml" ] }, "definitionLink": { "local": [ "nhtc-20170630_def.xml" ] }, "inline": { "local": [ "nhtc20170802_10q.htm" ] }, "labelLink": { "local": [ "nhtc-20170630_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-doc-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml" ] }, "presentationLink": { "local": [ "nhtc-20170630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-ref-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml" ] }, "schema": { "local": [ "nhtc-20170630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-parts-codification-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd", "http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd", "http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd", "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd", "http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" ] } }, "elementCount": 234, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2016-01-31": 17, "http://xbrl.sec.gov/dei/2014-01-31": 7, "total": 24 }, "keyCustom": 7, "keyStandard": 142, "memberCustom": 7, "memberStandard": 9, "nsprefix": "nhtc", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document And Entity Information", "role": "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - INCOME TAXES INCOME TAXES", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes", "shortName": "INCOME TAXES INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - SUBSEQUENT EVENT", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEvent", "shortName": "SUBSEQUENT EVENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2206201 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation", "shortName": "NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2207200 - Disclosure - ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS", "role": "http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements", "shortName": "ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerSharePolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2208201 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies)", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies", "shortName": "NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerSharePolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2211201 - Disclosure - FAIR VALUE MEASUREMENTS (Policies)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies", "shortName": "FAIR VALUE MEASUREMENTS (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308302 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables", "shortName": "NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-3", "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables", "shortName": "BALANCE SHEET COMPONENTS Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables", "shortName": "STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312302 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables", "shortName": "STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312303 - Disclosure - STOCKHOLDERS' EQUITY Dividends (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendsTables", "shortName": "STOCKHOLDERS' EQUITY Dividends (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails", "shortName": "NET INCOME PER COMMON SHARE Net Income Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "shortName": "BALANCE SHEET COMPONENTS Balance Sheet Components (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-3", "lang": null, "name": "nhtc:AccruedSalesReturns", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - FAIR VALUE MEASUREMENTS (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails", "shortName": "FAIR VALUE MEASUREMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "D2017Q2Apr24-Apr24", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - STOCKHOLDERS' EQUITY NARRATIVE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "shortName": "STOCKHOLDERS' EQUITY NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "D2017Q2Apr24-Apr24", "decimals": "-3", "lang": null, "name": "us-gaap:DividendsCommonStockCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails", "shortName": "STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails", "shortName": "STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember", "decimals": "-3", "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q1QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413401 - Disclosure - INCOME TAXES NARRATIVE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails", "shortName": "INCOME TAXES NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q1QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2016Q1Jan01-Jan31_us-gaap_LitigationCaseAxis_nhtc_SecuritiesClassActionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "reportCount": 1, "unique": true, "unitRef": "complaint", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414401 - Disclosure - COMMITMENTS AND CONTINGENCIES NARRATIVE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails", "shortName": "COMMITMENTS AND CONTINGENCIES NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2016Q1Jan01-Jan31_us-gaap_LitigationCaseAxis_nhtc_SecuritiesClassActionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "reportCount": 1, "unique": true, "unitRef": "complaint", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2015Q2Apr29_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember", "decimals": "INF", "first": true, "lang": null, "name": "nhtc:RoyaltyRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415401 - Disclosure - RELATED PARTY TRANSACTIONS NARRATIVE (Detail)", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail", "shortName": "RELATED PARTY TRANSACTIONS NARRATIVE (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2015Q2Apr29_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember", "decimals": "INF", "first": true, "lang": null, "name": "nhtc:RoyaltyRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "D2017Q2Apr24-Apr24", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416401 - Disclosure - SUBSEQUENT EVENT - NARRATIVE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails", "shortName": "SUBSEQUENT EVENT - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "D2017Q3jul31-jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueGoodsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueGoodsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2QTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation", "shortName": "NATURE OF OPERATIONS AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE", "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare", "shortName": "NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - FAIR VALUE MEASUREMENTS (Notes)", "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes", "shortName": "FAIR VALUE MEASUREMENTS (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 16, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityFilerCategory": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "nhtc_AccruedSalesReturns": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Sales Returns", "label": "Accrued Sales Returns", "terseLabel": "Accrued Sales Returns" } } }, "localname": "AccruedSalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_AccruedWarehousingAndInventoryRelatedExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Warehousing And Inventory Related Expense", "label": "Accrued Warehousing And Inventory Related Expense", "terseLabel": "Accrued Warehousing And Inventory Related Expense" } } }, "localname": "AccruedWarehousingAndInventoryRelatedExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_AccumulatedOtherComprehensiveLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated Other Comprehensive Loss [Abstract]", "label": "Accumulated Other Comprehensive Loss [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveLossAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "xbrltype": "stringItemType" }, "nhtc_BalanceSheetComponentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Balance Sheet Components [Abstract]", "label": "Balance Sheet Components [Abstract]" } } }, "localname": "BalanceSheetComponentsAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "xbrltype": "stringItemType" }, "nhtc_BroadyHealthSciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Broady Health Sciences.", "label": "Broady Health Sciences [Member]", "terseLabel": "Broady Health Sciences" } } }, "localname": "BroadyHealthSciencesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "nhtc_CommonStockSpecialDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Special dividends declared during the period for each share of common stock outstanding.", "label": "CommonStockSpecialDividendsPerShareDeclared", "terseLabel": "CommonStockSpecialDividendsPerShareDeclared" } } }, "localname": "CommonStockSpecialDividendsPerShareDeclared", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "perShareItemType" }, "nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents cumulative translation adjustment realized in net income.", "label": "Cumulative Translation Adjustment Realized In Net Income", "negatedTerseLabel": "Cumulative Translation Adjustment Realized In Net Income" } } }, "localname": "CumulativeTranslationAdjustmentRealizedInNetIncome", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_DocumentAndEntityInformation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Document And Entity Information" } } }, "localname": "DocumentAndEntityInformation", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "xbrltype": "stringItemType" }, "nhtc_EquityIncentive2016PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Incentive 2016 Plan", "label": "Equity Incentive 2016 Plan [Member]", "terseLabel": "Equity Incentive Plan 2016" } } }, "localname": "EquityIncentive2016PlanMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "nhtc_FinancialInstitutionInstrumentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to financial institution instruments.", "label": "Financial Institution Instruments [Member]", "terseLabel": "Financial Institution Instruments [Member]" } } }, "localname": "FinancialInstitutionInstrumentsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "nhtc_INCOMETAXESAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "INCOME TAXES [Abstract]", "label": "INCOME TAXES [Abstract]" } } }, "localname": "INCOMETAXESAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "xbrltype": "stringItemType" }, "nhtc_MunicipalBondsAndNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds and Notes [Member]", "terseLabel": "Municipal Bonds and Notes [Member]" } } }, "localname": "MunicipalBondsAndNotesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "nhtc_NumberOfDaysTerminationNotice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents number of days termination notice.", "label": "Number Of Days Termination Notice", "terseLabel": "Number of days for termination notice" } } }, "localname": "NumberOfDaysTerminationNotice", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "durationItemType" }, "nhtc_ReStoreMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents a product called ReStore\u2122.", "label": "ReStore [Member]", "terseLabel": "ReStore" } } }, "localname": "ReStoreMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "nhtc_RoyaltyRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the royalty rate.", "label": "Royalty Rate", "terseLabel": "Royalty rate" } } }, "localname": "RoyaltyRate", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "percentItemType" }, "nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Additional Balance Sheet Components [Table Text Block]", "label": "Schedule of Additional Balance Sheet Components [Table Text Block]", "terseLabel": "Schedule of Additional Balance Sheet Components [Table Text Block]" } } }, "localname": "ScheduleofAdditionalBalanceSheetComponentsTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "nhtc_SecuritiesClassActionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Securities Class Action [Member]", "label": "Securities Class Action [Member]", "terseLabel": "Securities Class Action" } } }, "localname": "SecuritiesClassActionMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_SootheMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Soothe.", "label": "Soothe [Member]", "terseLabel": "Soothe" } } }, "localname": "SootheMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20170630", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r5", "r22", "r24", "r42" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued Employee Benefits, Current" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r29", "r218", "r230" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "verboseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued commissions" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r54", "r58", "r185" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from the appreciation (depreciation) in value of securities attributable to the parent.", "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r56", "r57", "r58" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Balance, March 31, 2017", "periodStartLabel": "Balance, December 31, 2016", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r55", "r58", "r185" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r51", "r58", "r185" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r32" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r154", "r165", "r168" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r217", "r229" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r19", "r20", "r49" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [ "r107", "r108", "r111" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Available-for-sale Securities" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "terseLabel": "Available-for-sale Securities, Amortized Cost Basis" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [ "r109", "r110", "r112", "r113", "r116", "r225", "r226" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Available-for-sale Securities [Table Text Block]" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r155", "r167" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r188", "r189" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "NATURE OF OPERATIONS AND BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r2", "r17", "r37", "r81" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period", "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period", "terseLabel": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [ "r75", "r200" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r1", "r2", "r26", "r82", "r86", "r104" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r2", "r26" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r1", "r26" ], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash [Member]" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r44", "r125", "r220", "r234" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r44", "r124", "r129", "r135", "r199" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Common Stock, Dividends, Per Share, Cash Paid" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common Stock, Dividends, Per Share, Declared", "verboseLabel": "Common (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r31" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at June 30, 2017 and December 31, 2016" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r4", "r10", "r11", "r61" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CondensedBalanceSheetStatementTable": { "auth_ref": [ "r16", "r91", "r180", "r224", "r228" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.", "label": "Condensed Balance Sheet Statement [Table]", "terseLabel": "Condensed Balance Sheet Statement [Table]" } } }, "localname": "CondensedBalanceSheetStatementTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Condensed Balance Sheet Statements, Captions [Line Items]", "terseLabel": "Condensed Balance Sheet Statements, Captions [Line Items]" } } }, "localname": "CondensedBalanceSheetStatementsCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r86", "r183", "r186", "r187" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsSold": { "auth_ref": [ "r68" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs related to goods produced and sold during the reporting period.", "label": "Cost of Goods Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements payable after one year (or the normal operating cycle, if longer). Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date.", "label": "Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent", "verboseLabel": "Long-term incentive" } } }, "localname": "DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r23", "r147", "r148", "r149", "r150", "r151", "r152" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.", "label": "Deferred Revenue, Current", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r171", "r172", "r173" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred Tax Liabilities, Net, Noncurrent" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r79", "r122" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r79" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dividends [Abstract]", "terseLabel": "Cash dividends declared per share:" } } }, "localname": "DividendsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r142", "r227" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "terseLabel": "Dividends, Cash" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r142" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "terseLabel": "Dividends, Common Stock, Cash" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsDeclaredTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.", "label": "Dividends Declared [Table Text Block]", "terseLabel": "Dividends Declared [Table Text Block]" } } }, "localname": "DividendsDeclaredTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r65", "r95", "r100", "r102", "r223", "r236" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Earnings Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted-average number of common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r65", "r95", "r223", "r236" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r86", "r99", "r100", "r101" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r69", "r95", "r97", "r98", "r102" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r200" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rates on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r166" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based compensation awards.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Share-based compensation expense not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Recognition period for compensation costs not yet recognized (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r190", "r194", "r195", "r196", "r197", "r198" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r86", "r192", "r193" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments, Policy [Policy Text Block]" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r119", "r120", "r121" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r67" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r63", "r216", "r221", "r237" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r7", "r90", "r178" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r86", "r169", "r170", "r176", "r177", "r179", "r241" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r174", "r175" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount", "terseLabel": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount" } } }, "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued commissions" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement, or (c) a combination of (a) and (b).", "label": "Increase (Decrease) in Customer Advances and Deposits", "terseLabel": "Amounts held in eWallets" } } }, "localname": "IncreaseDecreaseInCustomerAdvancesAndDeposits", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Long-term incentive" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Other accrued expenses" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r96", "r100" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r18", "r47", "r118" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r191", "r238", "r239", "r240" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r191", "r238", "r239", "r240" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r40" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r36", "r219", "r232" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r125", "r126", "r127", "r129", "r130", "r131", "r132", "r133", "r134" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Number of complaints" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r75", "r77" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r75", "r77" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r75", "r76", "r80" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r10", "r11", "r64", "r80", "r100", "r222", "r235" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r93", "r94" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued and Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r5", "r22", "r24", "r25", "r42" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other Accrued Liabilities, Current", "verboseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r52", "r56", "r201", "r202", "r205", "r206" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r50", "r203" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": { "auth_ref": [ "r56", "r59", "r60", "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r181", "r182", "r184" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "verboseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r53", "r56" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Unrealized (losses) gains on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDeferredCreditsCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unearned revenue or income classified as other, expected to be taken into income within one year or the normal operating cycle, if longer.", "label": "Other Deferred Credits, Current", "verboseLabel": "Amounts held in eWallets" } } }, "localname": "OtherDeferredCreditsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r21", "r22", "r42" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "verboseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r6", "r74" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r6", "r74" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r8", "r73" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r155", "r167" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r30" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductOrServiceAxis": { "auth_ref": [ "r103" ], "lang": { "en-US": { "role": { "documentation": "Information by products and services or groups of similar products and services.", "label": "Products and Services [Axis]", "terseLabel": "Products and Services [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ProductsAndServicesDomain": { "auth_ref": [ "r103" ], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Products and Services [Domain]", "terseLabel": "Products and Services [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r27", "r28", "r123", "r233" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r58", "r62" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "terseLabel": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r9", "r13", "r14", "r207", "r208", "r209" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r210", "r211", "r212", "r213", "r214" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r89", "r210", "r211", "r212", "r213", "r214" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r99" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r33", "r142", "r231" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r70" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r71" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Sales Commissions and Fees", "terseLabel": "Commissions expense" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueGoodsNet": { "auth_ref": [ "r66" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.", "label": "Sales Revenue, Goods, Net", "terseLabel": "Net sales" } } }, "localname": "SalesRevenueGoodsNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Available-for-sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r0", "r109", "r110", "r112", "r113", "r114", "r115", "r225", "r226" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r89", "r210", "r211", "r212", "r213", "r214" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r155", "r167" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r71", "r117" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Additional share-based compensation cost recognized as a result of an occurrence of an event that accelerates its recognition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost", "terseLabel": "Additional stock-based compensation expense" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period (in years)", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested, ending balance (in shares)", "periodStartLabel": "Nonvested, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested, ending balance (in dollars per share)", "periodStartLabel": "Nonvested, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r153", "r158" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r46", "r137" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables", "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r83", "r84", "r85" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Issuance of treasury stock for employee awards, net" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r30", "r31", "r137", "r142" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Stock Issued During Period, Value, Restricted Stock Award, Gross" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, amount authorized" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r31", "r34", "r35", "r105" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r12", "r31", "r34", "r35", "r87", "r88", "r106", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r145" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENT" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r45", "r144" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r45", "r144", "r146" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost; 1,637,524 and 1,692,218 shares at June 30, 2017 and December 31, 2016, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r94", "r98" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "verboseLabel": "Weighted Average Number of Shares Outstanding, Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r15", "r92", "r98" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Glossary": "Available-for-Sale Securities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6505594" }, "r1": { "Glossary": "Cash", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6506951" }, "r10": { "Glossary": "Net Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831255" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26610-111562" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r11": { "Glossary": "Other Comprehensive Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831270" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27340-111563" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266" }, "r12": { "Glossary": "Preferred Stock", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6521494" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=73718637&loc=d3e25287-109308" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349" }, "r13": { "Glossary": "Principal Owners", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6521851" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644" }, "r14": { "Glossary": "Related Parties", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=16382449" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 13.A.4(a).Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q1(c))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r15": { "Glossary": "Weighted-Average Number of Common Shares Outstanding", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6528421" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q2)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(c).Q3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-04(c)(Schedule I))", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32247-109318" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32280-109318" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31958-109318" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32809-109319" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32840-109319" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=d3e5283-111683" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4569643-111683" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=d3e5614-111684" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL6742756-110258" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13279-108611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13504-108611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621" }, "r2": { "Glossary": "Cash Equivalents", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6507016" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32022-110900" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32157-110900" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r207": { "Glossary": "Affiliate", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6504562" }, "r208": { "Glossary": "Control", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6508935" }, "r209": { "Glossary": "Immediate Family", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6515043" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-06)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6882215&loc=d3e537971-122884" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.7-05(c)(Schedule II))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879921&loc=d3e569147-122900" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r242": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12b", "Subsection": "1" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Glossary": "Common Stock", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6508022" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Glossary": "Comprehensive Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831223" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Glossary": "Current Liabilities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6509677" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e),(f),(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669686-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580" }, "r6": { "Glossary": "Financing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6513228" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e557-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004921&loc=d3e1436-108581" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(a))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.21)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r7": { "Glossary": "Income Tax Expense (or Benefit)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6515339" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r8": { "Glossary": "Investing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6516133" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r9": { "Glossary": "Management", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6517382" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1377-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1500-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" } }, "version": "2.0" } ZIP 52 0000912061-17-000022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000912061-17-000022-xbrl.zip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�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

7[ZXU](]E7K]O>/EJ5 MCNW\EF;:&E8NEO&?EVB([^OV]AI=]=".T7>X7(/W%KWNQ0.O M[M?YLJHU7[_EP8RXVL2OW7!7XPV3;Y.S7/#8<6UIH*O^'VK:5F^AJQ&\+Y>K MQ62\WF+ ?[.HFKYE7(\=3[7V>A[=L6RKU%Q+8[O\M"S_>8E6=?R&/_;V_?GB MG?3MX$E1K?I1?;]_ FFN>SLKOV0U^.OH4_EHZ7ZNWG2Q>% M'WV:?/1)Y;KS MS[76<$_17FNVLX\;;+B_:%9.YF=QUC#$SS?;2M\_K-!6:Z/W3QMNN/\?45>5 MS?;\:9--]WF^&DT;[O.3)IOK\Q'$6#WM9D467-S;2?D5/[@IG]OM)I;ANF?E M]Q4V69ZM(RLV?9O.Q\^!L ;@\VCY:8W"Y?+G+Z/1!2)(Y2_E=+7$?#G2:8V7FBQL9M#O2-^7OV]!?C^+J^N='!-]A#W[;,?Y#FRHL MMY0*XQT#!B0) T%YEW1TVJ040A54[G/3+L:OY@NTE/[\$_WI%?[+YW*QN%D6 M=X0$K:FY>J)@1HOQ$X8_K'A3XI>+]8GLS^/SR?3V$"Q'2#5/CWFGB./X-GK@ MEV<500LJXO@@GEOUT(KJJAU_4TE[/;5+\R?%\U^S0R55J%4 I2HIR9D3'L Z MQY%L46HGI#Y_,@_",[U-]&TS4@WR?+7:3:6JG MP>%H@N.>):"!NL HYT -(5YS2D^#2ZW(_3&GF@*Y*RK=;<4\W_7G/_UK^?53 MN=A!MCK-%M;+1&D0U D"FCEK?/"XY%-%M4C@3HR.#5!FWAOZ7:J\0PCX_-BB M]Z" $JZ< "&C [0:M<.A>>&(D:?%K&YH\(P&K M\EZ2JQ*0-)MQIY048-&[! M*HD&!V%!1&.C-C@Q:]"'_:!//;0[X\Q.ZP%!N5@?2J.G5K[&SW9:9 %OV9^QXO+@LSSY@ M)Y;OR]7E8O:+>X?FSY\W[*A8!$L#TT$:'2E8'#)+BD(P M3"FJDJRS+\'_@*QJ!?6Z&NM9#EV8+ZYN@OWB]XL,R1Y5 M5*F-(B1AHDV$).I1DP:CI5!. A/"Y MB+C!G<(Y(UG0-"\: ,"D]=%I+A.)UXE_3E!Q=CDMYY_MV=DDBV(T MW8']S[F-Z5 M\R9T& NTHT]ALAQ/Y_GR987PH(/:*21#&@@"('&-#XDYU+]!,F/!)V9\KZ?S M%<91)5[HL(8*HFTP2B5ET'N/PAMK7';M2126:'$B9_8ML^7)3EZ+(AB8 MD= MTGWR"L4E D&JD*26X&C0C%H3J1-:Q2@9Z4^AY)L_#WJ_+\+G^0H%MT:S(*1@ M@8 4Q%&2%'@K/?K>T5<*LCQ5!5%9^O,6H.[*&;UO!&WRS>V)Z]E6I3 :QQ8E M28DQ2%Q91K4.UEFTE(2T)[9M7U?,\U90[9,W8?YU-)D=R)SK2@5X+:E-(#15 M0$0^/;#DH_XW7MUS+8JA06A?+""2\E M4.MBY):KI+G7'J?':6F8.B+>R9:C$3WZW.9#.;Y<7.^Y3D?+I5TG8=@:1;6O M2N&9H(DHGO '2$,=S4>9"+$6TH5T8K'']84W;P77SC3(8\WY:X4XJ>V5"N\# MSACT!UP0:]B,YD",%$Z E\F0V(]*4G=@62+-"?APT5 ?9S@+1 MUIV\B06H3)='Y0LM/8Z%"1*]H%)15("W8Z-H0YT6:XX5[+/\J ?E:85-X]1B M43K+"9IAGB;&O+B=:1W;$M_*Q:=Y)T0ZF@%'147795*S@X]+4= M^MY*)R>!$64V(S7^-%>;VB9N@XAVQ9V_S.=GOT^FTQT\V10IB >:*&*1PZ_1 M132,Q,T(B'1UH\W\]EX[W)3O9$B1D\X@.<0;>1,AAC5 M!@6I;!V],L [-@UQJ#5\>S!N*Q'JV?*%Y-8%P#?P91.H-K@O/1.*(D8 Y+P<)B@=0B#B=KI$&SM-O/-"J=0H MPEWQ*=P(YGWYK9Q=5K"$GJ]0!,\#2TFBM^&5<-8C4)O1)2?K1/$=O#'X0OG3 M"+*=ZJ%-CSW^5RF7W(Y:A:>$B9PTD21)I%.@?-J,DY%8QX\_>$?QA3*H.7@[ MI='AZ]@SZM5*P@"8HYI*+R ZDC9G>Q(-OCJW8=4?B3ZUH>UO^^>@;9_"1!^M M-AH"480P*\7MAJLDKEI*K"V$T<,[P6B!+K4Q[=K&0?_P7I\KG8+NJUH$89FW MQ'$5/.5&\*#]9L1:JU.[5-W@IF'#T'9-IIS^K)PM-_=$SS^-EN6972Q&LR_7 MZ10W@[I:W_NX--$;- M3D70P[I9;<$LI$E61!6H Q6#"U'&VW'@E]0QK088O-K2P_LP%L\G7LJH&OB*V4.BIT9 =R28J8,R*0 M'!6%&%)JX&Z4LLZY[ !C7ELG5&-(=Q=;?R.A=<_WW?M[IG0A@T+-*]+Z/\VU M$R[=.K"1G5C&@"8$_"2JOBZH7:YG\UDEICPNBBNTUI%)*]'94$I9*N3M/@?Q MIHZ=,\"5JP6:U$2TLT/8VWS6[T:3L]=HVE],T*K<=03[?(U"2QL,-]H1KJT/ M0E.O-^-# [%._,< EZ86&-,,L-W=U%B-)K/R+(X6,[3"EG8\OOQZN7X_ UW& MR7BR^X;&OLH%Z&2T)=RCA^#0:Y3 V.UT01>D4T?K)=*I<8P[C O9='2]"Y]W M'A;E>3E;3KZ5U]$M.6O/FW+U]O/'T??=T2*'M%1X2PT%+9,'HFFDS(B-BE9> MT#JAV .\T=&&"FL5\*X(^'%1CI:7BZM*EM/3PH567),HF&3@E,D#"YMII2CQ MW=P',=&I%JH]J?@W^08U](#8)K3E/"7T@,5,;--5S%2:V+S0&"<->A8A/RFU&7%BKD[T[,!WI5N_ M]]$ WG<,&T!&P'=KB,_+U61\Y^:=9'I 301!?<(B!0\I"31O02C.@U8F$GO4 M.U]M[.*A1-XNUB,Z6Z]T[\K%AW.44N6-O6T-%&C8\P1,$P4Y7R^WPIA$3122 M)4UKJ85![O4U28J=NWX-(=[/KO&ZITM[N3J?+R;_6YY5YMGCBD4PR24;%&BF M@&IFD[&&$R[P?PK,B;WOWB&_:B+=)Z]>+Y>7!W/JNE(1?=+!XG\&3<"HB?4: M@H'W@]Q"[)A/1Z'<)Y?>7JZ6J]'L;#+[M59 M#P]/+',RM*H)EBV@=B=0H&:('$DF^'^&88$9#"FA%UJ#.X1=#7C9U MZL/;]S[B+3S+MY]S"'B:SG]?_FTVNCR;K.X44Y][B;>].FP/\4FU0EIK"3K9 MTAD*C E-F9>1&P=1&0:55&8[HWU3KG)WWRWFWR:(K[OZVS+G?'A[4>:GEF=? M\J-:WZKFD#J\L4(Y=!L=>HJ2<0C*:1 2C7TKJ"8I01U3=]A[BC5(,N\8]:[6 M%QS(W:'^;IK=E2MH!,.MP073:W#.ZIP+E/J$-CV3O-::T+[/\=_#W?K%""D9X$@H!)9#RH&B4 MQ 8M$QJA\<2.\_HEPY-;D$?+H;-(I.Q2N'PK\_Y5S5T&\+,5"LNM\C88194$ MR;2SECFC!% (49$Z@;<#U&Z#8EDC$MG/MRT/)?OKT,W)M_+C8C1;3J^E=XO/ M>_01\W;9Z]DM.L^0Z\B6"N*XXT0!H\D +A+H_ )(;Q,G,0K:S17MAS&3'_\8 MY.M&8EUI0>Q&Z=3U1KG[23EB;13>KF M#J//VZ#!7J8=#WB/BG!](^,FX=&^IRVJ5"^4B)Q2 $Y#@B"#$X%+[9W1@B4T MCCLQ%4^=:K5Q[YEQ=TE@CB7=XQ:*?'^62Z$\3QJ8BT89)E6T*OE$0'7S\E?7 MQF)_Y*N)?W_\>Y1/_2#F/:I;,,HL.OJ4@]2@-34Q1IZBCU0*2DFG28';-_1Z M(5L]R'NEV:/$ZT<2[OE6"H.C3E)($PT%9?,YDQ(HJU!P2C.)(M!$(H>&J_SOMT H\_ZI-WQJ/=LV]4D MW98V"FI8X!X-"\(XN"2MUI)2DSAHZV2M>TL##%CKS["K#7U_]'N4(/X@VCVJ M6Z#_;D/"@5,= )RQ,7"P/@46-7.DSOHZP""W7NA6#_+^:.8OERNT"!;V[%N^ M0INO X?R(H<$'J;I=K2#WA1QW"IK!$*A.=$V!>K0T+60C--UP@G,#_HU#/\P MMN]J+;A/VRB,L5X"B\1+ L%Q9XC2$7%)3MH@ZT2(YX.@'QQL#/O^5]R*T075 M&BB\3DY0A<-FZ$S1?*C(T-I 5\LES6J]=$('&-32Z^); _@.(THK'A]>9_^] MQ,]N_G$^VQ."6J/A0D@5@P5I(N4YX;5.*!:C?:1!&LWJQ*P>?C/YQ&)6NY-+ MSRS.AX;+IF+T=S16@+'2N\@]_LAO]6F>$DU@"&5$BU3G"'B (5Q=QN@WAWIG M]^I'5S?Q&G;\S\O)HL0AX?Q97;V;CF8K-(1S2J.+7&0'!ZLW4K D$E'$$X]C MUUY:BI8U5SZF0+"'W3Q!WN&9<)M$>7S[OBTI#$\O-K.Z5VRX,#IPRR51@HI\ MT*1E4(1HAK:X-#9T^TQ#7ZM[&XSM5"X]L_CFQF@SJ_N.Q@JMK6?.J:BT ^:) M]9Q11;0/$A*P.C?PAITEI_75O3G4NU[=TWSQOKRX7(S/T>-#I.ZNJ5=8U;=7 M+J3.F35 )XZ>8<2)QW0DZ(QJZQ#V6&MC:+"1-FVR8\N2WI@(NB;>V\]ADE&: MG>U:GY\I71 ?#,DI-)VEX*6SH%3"_P^)N)I[CH,,'NR!5?!:R*\X\(!5U(GH=#R24+*X%BJDS/LY>SWM$'-3N72%8OCY\_E& V4^!WU M]^Q+^1Z5R=OU*XGYF3+\(SMFWT;3/"=W(]^F6=1NR\65ZBT][XX5J5^H43@ MA@6P,GK@3EG$UFH7:=[@C[9.)-C!,8@7:_$@'Q:K4V%9=9'@WRUX3EF=7>S( M.SS7*23I#D[=+U88H&B!>H&Z6>/L85K)*"Q0G7A."5$G+'^ 3,M2/BY!X2. M W=0"1F?/K4VJ-2,UUU:/]O]I*.'96NLTE)A1)06&-# "20E3!#Y.2B*#AQ M%)6O)]88=Y4J%U8U)LD!ND #"BO7+0L,"((* !?RQ 9=KA0J]QJ'OFN&+?M MZ4'8Q6>(R'2X7^/-Z3S9/PHXU9"*=JW_O4F\];?+N:S#^A+OUW\.D&W^FQ=O,9LZJ&7A2+& M:!>D"3J"Y-'QP#E/UL3(%:EUK7. ZTP?LV[X4GU)L_,.D8XFVM,O+-#<8$YY M*P4XD$):X_!7R;B(.FG2[4'T'W[.U!90W_3_VVQQ,ZG_[WR:G^S:K+]O9Q_* M,2Z^ZT/^1NVVNE]9$*DM,^ 2IQS0'=,BJ<2ELJ"T=[7.&P=XTMW'%.A81 /P MG(_SF O.97*B"2%J'-&-,"PH %XR@U=M12XS]4H:/)>2II?5"<@@1J2&$.=0W&RVQ0KG3ZTM->,%NKR)K_$ M7^;SLR5R:->&\C/%"VZ$3"GG=G(BWWEPCE!.K,3QA>QPGM:^0&T9/SY)J0]I M=TO#$A7,NI,?YG<8/;L0 'Z,0V M39%Z:';%CK\LT/9YMYA_GNS2(/=*%5X0$XUDAKH$2A GT2'P$)2/0H&J$\P^ M0,.@:58=EGG2@)R?,U!JX]H9;\KI-/OBY0QQF&)?[=G7R6R2,<@/==R@ MLHM&E1HH(OI4(2!R/FHP+ME$K0[:)IRX_;(6_3\N; M34_[=;Y83?[WD/?)ME4OM(Z,Y" *92,D[XP";H4@U L6J*H3NS+ />SF"=8" MR+W938?82P4%DM!?E"*" F>- U3*.MI(@B?.U3G\.-Q.:MVJ;IXX=1'MG"65 M N.>*5W(Z$*D!F(T#/U'T)9$3HV*)@1)9)V72 9X)ZDUB_IH1#L]UWHSG\T? M]GB_+;2[8N$)0Z7)J79>(7+:!A"*XL@EEQ#@]'*=-\N?)L'M,,/EYO07 7KN MMK$K/\\7Y;TW >)WQ G%.IF-%E?KZ/,M@HNW*Y?U^]E6\M4F+* M1(3)[+.4X$R-S4* MH70(ZU=(- 5KM+$R*$FTMH(:6NM$98![WZV3YCA8>]4S^2F0ZUZOO=@P68ZG M\^7EHM(1[Y$M%C;*C(MQG"5(5CH:\J5C*YR5G/HZR9L&^NI!J^M;.[!W1S*4P[FYK:5""X.K M!<@0.84DA!'4"LF,2LHYZ^N\\/P"UN6>N-F0-#H[NM[D-JVP4#\I6WB#UHZ4 MPGH50"OB1/04QX3CHB':.EFTZ0 IUO027!?0#N^ ;#(IWW;YUEK--R 7._V& M*M4+-' )]?D>6.0@ DX5Y5Z M5LW.XFPU65V]GGV>+[X^")XYX,['['PUSGQ61'*R9G/^I*CR+?IK(/ M%?Z[3(+E\+JIE7Y4BVTH1 MI"$V =I,22?C(J2$ K!,\CHA4(<'W[U(CC0";*MDN=NMJ++W7:UB 9QYZTD" MRPV@DC0@/7+:.&8IDP",1OP_5^LA[I/?)JT#91\G$&DT6:Q?5OEK.U3F!L&.$^7(ZVIQ)/TC\S?_V%\7IY=3LNWG^TWA'?T:9J3'>?4 G>Y\C[F3W<<*U9NHZ#,@1"@ MF4K9>7;.^^2U]A"]059W\P!O-Y.X!7(\OJG?$NS=7=C)KZ!LCF_L]\FN^Q=/ M"Q<",;*0UG$;(*VR(4B&3I2WT9D83BQ$N@5I/[FX4Q/B?HASLP]SDSG@KV6. M_JE,I.)BOD $0OEI=:=J]^J9G?4*8!8UM% &W3"(BAHOG4S) M1OQ%$'IR>1<;IU,;,!^M;6[><,O'B$OTUR[SN/*OB[4;MT?M5*I<^&2B!1<8 M. T&?^#"SG7>^4-_4#-]&@$ ;>N?-K#N2A%5,0#1ZR[7-_=K>FNW[10YWC&H M9)S"F>19TLRB<2"I%B0X'4XLG5K[1G:;Z'?%Q.T]O\GA59[ES+@[.%BQA2+O M:"7/17*,@N'.>B,1;C LY&?K3\SJ:HD;\RZP'P#W[C98HHJ2"Y3G>,% "-BJ3TA]/:[;*V]8DTS^KCZ(J&D=. M\,!H\M*#U,19%J,VD2:A$^5U3DL&:"WVS;\#X1[,B?'VQCW>Q=70^B MRMS:5;_@J"XE830JPH%$ZHQFQ.OHDY..U7I+>H">2RLD:P/HP:PLZ]VOTUI7 M"&@)0BK'N85 DDW<2^NU-<2EBA?>NW8+JZPJ%6H7AND8(6K+ @4?F?:6^JBX MB0:BL"=VU-T,#2K[ADA>F" C900H-41XTZ/M=XM6=7-O6Q6D($V!A928#Q"#,12XDE$S M&X1(IQ+15%_(VS(.U\.SYVGW9K2X?F*G\4#7FG,O2$A@3&0^<;E >KU]@NM_!>[[+W3/059Z);*+]PH08-.>)A7(X7DXN;D3TCX2J&P.&-X1I)-$,K MDDL%8%VP:$ "XQZ4(I[$$XF@[XE-\X[%,PP-]V0EGOC>F W>D=U0H:T+$-"MUD:@"(LR*B M22 8![2]0=2ZI'FJ^J@R0Y[$NC8FB%XTS^;9CW?KVU#YDGN^W[[EX]ZT3),O M?_ 8%1.&2<-0)H:8Q!D#92%H+P.IM)O>S2BK*(*M=8H4C=""HQ4>/'(.G% Q M6<#EE27A](F=0]<7]YX,\,<"._Q9??S>QO FM\YIX[32DFN* DZ!$!VCXPE- M34UECT[*@P>6;O>G/\[OI18YGT]Q>BWW9>$_L*4BQ^";Z$V0E(-VH#GCUY@( MPI/]HRB"RM38]3)6XW!W=5+=SQ,0RGG-DI5$G$)4H[)6[^;H4)0;H,'(E3GO9N# M<]B^R#6Z7<#[,OB.?SJ3*Z.LE)%(5/#2!I(8V8POVFHGCL-/>-N9R7<^9Y_7@'?Y\[SGAQ, MC(#B4292*Q3I,:?LMJ[?W;JH,L,/:*70%#3+SWDII2%8ZT!13@DGP7HFH-;S MI\.;\\U18]X5Y$/2!H\"[4]2.5C%#/IL+GJ_OK\8M63:$9FXTDY!)3.WG5'? M)>O8-@AW]>!?*B>?/J"]0CE@+"<'X#YOZUIMV1JM($L[?H&"84'4>^AP@!5MF2L6%K+88 M^B!CF'\=39Y[$WE[X<+0I%1PU! 6*>=>D\@WH]) 3BP.IPUQ[V#441@?G5S6 M+>:CLZO_NS9S/HPGY6R\+Y'U]AH%R%YF!PJLC;F:)K MO4L^P'BJ;M>G!@#OF$KY'N--9Y=[%Z2M=0JJ.0(5?"126!\XTR%NQBB(.;%\ M$_7$_#QG:H-Z]$+T83Y?G9>[EY[[90J><^7P'*@ 4!+HZ7=] O]C!.[&]2 M?.;-('FTA-^7'U ">T3\H%!! J6"2A6$I9KE1]7)QG.T),03RW3;L(SK0-FS M6_QKA4SS^ZH6#/(KA-1PHB47P05G-L88ZDA^8H\:#,(%/A;\XW7*_ K-YJOW MS[]?_[A(#D!Q/JB8S7+@$J0)M[UR7/\Q=O*/$-*\$3P[4RK7/8S?+\K9$] Y*DP)$HOYD,=9\E'^!JTS@[&D'U:$UP&V,XNEI^+!=?)[.U M#-[,5[B.;M,-.RL5+""GF0T0".0)VHO0$N(.UHBR81[N.8[WZX M=$[JNKIZV*<.3_3NSDG??L[O?>+LNLEJM!9: M46H3<(@B@+/.!!H<*.\Y$$-#CQDNGPHO)Z4_+%"@D>7PFV)(XAJ%;]C[K^Y*?J19*F>0B)RYI")09JW10 M"= N2%ZI'J,&=H[A[B[-OF"!0YI91] !M8$%*<%Y81*Q22JB\J-P$N TM$5; M%'F<);<]Y+MR6FXS^5QK@CR"^6RM,G>?KNRL5Q!-\I81R2=1D"2W0DGO<+1! MY;#L$\D?V2X-GJQ S0'>V4VFAUW=>\3R;/DB!9H<^G$*K(%$HF8>E-"6A*0Y M2R>20+AA.3\.@&X V:Y8U63 ]I6O.8A[(-B;!F7VND:P/L'NBWS5PXA'>[VRB .,D= MXD#7=URB8YPI$PE7:.NF6G<#![B;V!KA&D5Y0$S+LZ7*L>>A317).B48DTGG MVUI.:VZBUU*'H!'^0$Y+T77B K0L@^X.W\?3T7(Y^3P9KR6;$,T*0_.7BRR) M=^5B,L_Z_^WGCZ/OE:Z5-/]U!5$VQFS9"%Q9!*XF2@1%I1 Q"@7\Q$).VR/> MD_/]WF4U,-V\&4U]U;QIJ? Z>#")*0&HAH317A)A+>%1A1AXIW>)+]8B0Y]W ML6KYE+%/8AVGQX\46%<$KM+U=_/%FB$/,I.]6TML!Z%KMEPH[@0U1AOBT""+ MRC$(BC ?=5P_A]VEZ=%%'J5!D;M;X?5JL\S'D^\LLH]H# M#]+W^?!O#^$.1D87 A 708"(Q'KM E-1"4E]M">2-ZDMBM0)=S@,^9<=[F#! M"2&98=X'0'2=)8)R&34/CBAS8A?3VZ'!0>$.AP'^LL(=> Y"=L ]4QH2T4Y$ M@;_R8"P!Q\5ID:DA.5<*=S@,V8%9VJT0]E?0-Y?CSF@ M=U,GC&J 2J"&S.=MXCJ,6?PH]66?TWB8-^5\,$%0H4$F3;T'I3W7-GKG CA) M*]T0:]O*N'NNZ/X [[]9Y*Z>/FGT^VAQ5CV79LWO*"2WU 9K\SW4B"N=D,;? MX*B=3R>69K\KTFVU0[H55V>IIZ:CV9O1U[W9R^X5*X@UC ?.$N40"+$B<7HS M$D-3.+4M@>X9\#@KU?'@=TVC_6G+'A3,;]<$GZ26B:J43X,2LS>C20G'=EI4 M.DZ06]AP%()')Y:XMFW0W<)AHFV3:9 [LCN-U!!PH2]%PHS310FQZ M;ITYL9OBQXIMWA*>G>TGKO4??N6>%>9!N<(GRIST3DM0CC@O()C-6&*$.KLJ M ]P)['^)J8-^9WN 1V-S-[K96>65JHVO*Y@6QN5-*46M8\&09#9F:)+)GUAN MSB-9]=@$[U\0W<7UH;LR&>?7(?.^PMY[5\^6+X0WN XP;H-77@?+HZ6W0"MV M:EGO>Z7'D_B[^@)YV<$'@C!!K*2. =JW7FHMW&:L+$(=\@TP^+/_E;M):;RL MR 3!"8O,*\ZB4\D'#^YF5D7")3FQ3?>&Y%PI,N$P9+MBC;][N7OOPOBD;&$" MA,@%$ 7)5.;*>AIESGS:(Y& ]AFPK^M4(T2_W&"TE$5*CFG8D& M35_M\UW$#6K<=QI+_H=8&[L660^J\/8(]?99\)NCU&K:<6OU(B\=GB?#I!0< M5'Y0/-V.G/I3V^7OD"K;M6M3TCAZF_=>7SY]N^WMO*'ZT/*\2LO.H2A& ZZ@=HXF ML6@KR[N91(,]L=N)/>JUAB30/<>J$BN/A4K.&+"@?-1)&*X<59NQH-]5)V1Y MB";=$-AT..R=G75-UP(NSY[':?]3#-4:* A)*@7G:!#4"N.TM[<3*"A5Y^04 M?I"N;7D,WANVXW$Y+1?7855W-7.(51O^\8ZORPG2E38Z$1_1X!4AN;399Z L MQCI,ES^8/BSI#7Y>;%[Q6/_KTEZNSN>+G/"QC4FQ[;L*#4IEXRE(QU0,WGG! M-I@2H>OL(:D?,V) HAO\=-A$(RU7B\OU)M[Z>L['\]'L[<7ZJ;6_8!.KY>O9 M=4J(-F;)@5TH)%,V*) "K!7H=ABFS48"AOLZN;OU$%,QO<3ITZY,!S^KUC_^ M7BY7D]F7ZQ'25HRNIU]3.&I-Y. #RMP$224"N4%2<*B3G<+\6%J&(;7.COB_ M7DSG5V5Y\X3K\R-^,U^GRBZOQ[7\.%^-IH^-R#?SU7^7J_?E>/YEML?8:NT[ M"Y4$U5I'DAQ)-C+T\V"#L96J5M@>^3$U!BC#%S]/KM5#FB]N/LKE=JTDW7:D MH%8;(""-\#J%Y)$F9",-D*16)J0?QXLO1K#=Q3K.Q[^]+R\N%^-S'/N[Q?S+ M8O3USC>S7^>7L]5.2ZM:"X5VT82H@+*D#/4HJW@3JQ"92*S64O'C3+-]B?3+ MR/=E#M1"Z^YN&'=ECB5IE48+KZA.T9J@M8R$V\#D9MXR'F6M:,H?YZ*]"&D( MT4CYM.[=:')L--*F>N&E%[BH&,-)$HY)*O1F[XQ%06N]C MNQEVO,+AK:Y^I.G8DC&!2*,(!4'R(8X(/G&K'6%!,ZF8K!39T-+2^:+2= 3O M@J+!!>MXLBZ(H,0-CLYI.+$K?UV1KK4T'8>):]BWJ)5%_>RHE81'4)9H[>/- M6+R0ZL1RT_7 @9VWJ ]#?S '$R_@%K6PR43E(P$NO3.6)_3H;I!ED9]8YH@C M6=7%+>K#!/&R;E%SPP)0+EWRCCJB"+C;L3G&3^S"6+_TJ'2+^C"!##J!5HH\ M",==X)9*'8 DMAE)3*;.'>DA;A'VOB[7 '_H";3 ,$VTBU:YF**(+M_SSD4V>*(_"KC]-II, M,\)IOEB'"G80GOWX*PM%N*%&&DJY\9P*B-)M$.8*ZEP+&Z!J[I*2+45IUY3@ MX.?(WJC:VPB0]_/I%%'(E7H)V7ZN(P4!:[5*5GI!@2G'J VW2W-D=4ZGA^@Q MO<#YU(5<3VB67:N??B?8=1\*RHDA3 ::9+3"6V?UK26=I*]UM#[4!]B'2O/N M9^-1)'CY$W%X=Y,").U<4M)K\ [M#N\V&_O!)])I+I1!WTTZE2E82_XO?P;^ M?2VB7F?@PRX4/I($C =K\@6!Z*0(L)& H*[.[<#J.QGF>@;.RB\Y7N+C<&W- M4YF&M4CP\JE[)C[I11&8=5X290FA@M(H$O.WZM#7\OBJQWO^F(P= M3\:Z/'CY\W&('J)D00$)GC%NO36),;+9"PO:DCKGU0?G&[KV$./L[,=$'"X% M3F@:_J.\#5((TFB[^/II?E8/9+#^EIX?([X]I2$[F3 MU"EIU:VW09.'$SNU.^D-U18%_T>:R .?O04E1J>@@W=6$,+7 @7TLHB'*)@G<&RJB5BPJ=NN-!54G\O-@Z_V' M%AB"%FB702]?"]QL+%XBZ8>I @[I8)&2\91(K357(GH&E,F-],"H.F?%IY0, MX0\S^ULDS\N?^J>S R M<3%X+2"E #1%!F0C.2=3G3.Q/^X^_ N?^JW1I]-$ M6*^7R\OR+%PN;A.;7D/_*&5+1N0OB_ER]_.T1[17:*F##T9)+8,W6@5E^08; M+FB=5X%.:45M8#^\ _$,?LWJ,.1FZ9XY" MX:% ;^Y-W1?K1Q2DPU[\M@.G8YHK0"0:%0B/:P XK7)@K,$9:6R,3*=.3[X& MGT*K,I7FG4NF%\UT^6E9_O,2VXK?RKO+H)UKGD?]J*)3ME4IG!<@@,FH6 1% MB262&*]D@'6,7*5 Y6Y&644E;*V#WA;Q1C'&K = C\LYH05-#(248&L]U3G M>5]?W(]MD(: '<"T?3-"RRFG;.@[6V>CTY@ZS8@Q.@H IIT#2ZB5(EK#781* MIG@GH]R;+/.9X@7#T6FN$TG: 4O>,2N4CCSA H&\.['L)/6%O'OR'H-I9V[P MHZ[N3U.YI49!HU7 (FHV&0&XL"!RM K3,88$J=.KJ)USYD 1[^'+<9#V2)G] MJ22WU2D22PB3=38*BI,L.)F? P.B0H@<;=_3ILW!DM[/G*-P[8D[>],[/EN^ MT,!!2S2@0!)@PEM#B0M$,:X]U_6>='H1G#E4QKM9QSUILJA?! M&()0*HW>&#@EG0B:\.AUX(2)4TOA5Y\ ![Q5<23&1R=XO->7#Q?E>#*:'L*: M0YO(9P*!>6$MCP:DXCIX!3P2QHSGWM1)_#E\/70\($ 0#/0PP % &YH=&,R,#$W,#@P M,E\Q,'$N:'1M[+UI=]O(M2[\^=Y?@5'>WONGBO6! R)BZ';[-3-WI?)*=7&OXX*8954P0 >^>N3AOZ"X-TUO9JN_KB MM.FXW/T2QQ>SMJ=Q>5*UG5QP]T"V"^ NAM-;LCCMEU/66_K@HW%)>+K]K>G7)NWR[],9!XW=I5H[BK)],VY=I?_D[W(4E_?I1#I9- MO7LT?/<_OW\\ZI\EY_%L$/DX&Q4WC:&^N&0(Z8_1KFMUY3W3N])LF&:)I^9W MHR+.RM.\.(]'COS]<^@N$,V^NJ9?;R84?W6V0F>CJ^_+XM&XB(=G23PCRXODG6NT MZUHE1=J?D:/KW)<;UUN^<]=G_5H^6K4UWR_\-7%&"3I\COD/SHGRWOD+^RC"'Z,=WSXO__G%P>-@?OW__QRGHSBP-^[F_Q[G'[[=W"8G\?9S]6U,OU/\AZ"B]'/KG^_#-)OTSL' M:7DQC"\]Q%S7?TE_O/?/3XKZ8SH8)%GUT5W?KZ>][O2/T:&7'Y'U@/\#_?/8 M[@19?.Z?F*3OE>OTP'<\&L9?=H+4\<4H[H]V#9,R4E:&TG"*%5,68A@J*"'C M0B.T^_WK[KT:[@0UO_AUQS&8]R>Y6[HX.XV'CE _5/_\\NY*IQ\Q!E/)D5&4 MEOUX^,\D+L)L8)UL;@R':6$XUU"%**0X0E)( R(",(L,C!R_G0[GKH8['W9W M(7(T]_1N3TFF[O8,QS92 $I0DH1)@KP4$F(%664Z$:'[VJX\\'WX.E=#C,' MR$OC.NT$X5XV2'[\+;EL=AABH;6Q3(68&M>?D&!!M>N%FT\MPGF'[VBX\P&X M_R1$@+5 ')-NUY1]F%SDQ-.?:*BJ-X\:"*4:Y99H+B8@1*I1 *C8G MCKL:[GQ0_7[B7E)IX-7K;NA[5+CG.5TE&"3]]-SQFU]W]O:CG6"_H+"ZF7'XZPCTO8/X@T^%-%./W)C\_S[.C4=[_^BDN#@J_)LG@[_%PG,P? MU "P=M.+A+# A%+6H-!0"96&FA%N(Q,9$[H_LW'>U?"IXRQ]Q\H'+V4UGE*-1V=YX23P MH$FUUKC.4JLL$A0;IK!@3%BLN2:2,S:GVCL:[GR@H/ZO_='=OH"WC(Y1I)CD M-.+&TM!@(:$5VHU!,TPXI7,.]H^)Q<].HH;V$U M,L*.[$*+& XID]JIUDX#<;B35%$G$F:CNZOAC-4\"Q[O/3X1.LD&A(VT="HM MLSH,11B%PO%-*Q'FL_'=U7"%X[OG^BVP' B-9H8H!2-"0RT]AR21:W4P M'GF'AG>77S'$B 4F#+D&@A*(-.(A4H9JCB!E(6T88KXK4C[2<_7J8E"/WD-%D3+\GYR=)<7W)A&"XEFH^O9!:8@A=$H:ID[0(:4%1EJZ+\9:*6##:KJKH1\4 M=IK $CWNW57W8(6R).LGY8=?O,OX?5EY1=T@@FHOX?U9M=WDMQ)VIUL$;W^4 MCFO6E[U?UTU!>GXQ3';>U8]O/K/Z6N;CHOI6[>.\GTQ4/>Z&XZ#RG]9-DLIQ MX'^8_I(._&^G:5($51>3I3LI9N]O5QTOUV^NWO'N^DLF[[BH8--\JV,WQ<@[ M#ROWDW)V2,G5QXY_!F76.]!LZDWN+U!>RZRWH.^1NA/'?1$ MKKX&CL >QA%8JQQA.E%_O(Z)(B\[4?QU3!1_V$2U*V,F3';=^0UKE]_X0=.U MERRT?::R@?\G]!O>\=!UK[QBOER[-C%?GFO69FA)OGB3I_JI M_FW@WOSC8ICVTU'=IV"0NB9U^-C,BWKC^'8^--LL#/"7=TO?47?IW4*?UD9M M>,3B;N:*ONYE=&*K6\9G7L:6]=E'+F/':E_CXNY5(8>^BS/WG_>=_._OX\R- MZ"(>ZCP;E&YZ]O-1\LH6=G%L.Q_\X-[?-K@-7=094O/B(O=Q)S8Y&1TE_7&1 MCM)-6-CY]O,M WRMB]M4CCK$O@1B5ZPJW;2H49K%63_UH7^EZ^[8^\3]QZ** M8]R4U;W7*#<4NQUC?LT8O@]C[C#\JIT3M3,6OA)G[ ,W_'!CHMIPQKJ)6L=9 MNLKA<7O4L3>/J> S1O!I&&?[\7F#!7C3<72YE_5]7[\E_B;?J*;^V7U5<)VG M_;JYCZ?(LT5;>QY?^;I81W-:)DSCUGFYC5D\X+6WSFI3/%V;UF?B57[[A+=$ MC2U%^+P2>KHRI/E"+AW3ZA9SR;:AN"\#OM:\A8@+^@?^ZRN(M:#MQUHTK:F. MV%^=I30/J^I6\5E9UHL&B4UTZW_%&2*[U=]U9%R+\^4#%>\]7\WF+;!X]@?\ M:YS!5Q#T )TAMBICNV,.SZ&R$VGGUL&_1J5FS8XRL'H+"E\LR(Y\Q/\+7&R.#]/ M-IT4;A_WUO"0)VDJ'>T\+^VLL=+:B9,7$"=KJ*!V=/!<=+!F@N1)RF@G2%Y, MD*PXSK6S<%^5A;M:6X6]CLC8AR>^:#$RULYV[5TGW%\,9RCYF([2+Y64,7'9 M\$;/X^/-,"Y+525#>EU 61S:Q#U\R]B>2;0^G!I@BW'2\WPQ\^V((A^,^Z.# MXB@IOJ7])B'DN1,HUW8O#I.*L7QRW;ZL%)4Z65:I+YM7Y@_111X/+G^KRF@< M]=,JU=7K(J9E$S0EI\8,M;2G6XI>0;Z:^U'T87(TRHN.I&\A MZ2M3M+4T_;(&T(.X=$?3'4V_$CY=)V#K:+JCZ19I^H5SY=V;ICMMNM.FUYVB M/4'C/V"4G,!=]P>)CE=WO+HMRL:^WN7]*;MJCMHZH-C(:]K1=$?3+=J)+YB" M]D$TW>D?G?ZQ[A1MJV/DU3DMV9%T1]+MD#2MSL;)^Y+TM>;/ZJ#N*+JCZ'5W M3]<$[:NK8+A;_9V'9XQ/RN3?8Q^A\"U9DFCNVO77190W#&X>=[%T=,]'$;RQ M3WP/BN!/VU;V)9TJF7^5/^8A4=.JD3=^,CZ M^@,?.BX'RYZ8ECE!D+__?&0?_L!9'\="_OSSJ2/WW3+]3_(>@HO1 MS^[F\B+.ILVKJZ?Q>3J\?)]F9PXKHR5WG!2^RI>_;_K:QLOKBW?VPV-N-QZF M7[+W_DQC4C3?@Q[CT'P^W#O>"X\"M6^# M\'_,;VK_+V%@#G[_?>_H:.]@OZ4./G89_Z&.?MO;_\OQP7XOL&_-VP !2N2+ M=JKZ^KU^QTD^'+A'_/>?( ,_O^A:+NE5='#X>S#M5/WW:I%(C]P!) "*AE) M,,;SLNY&8FJ%4)H;&BJE!?>E>CD"PB(;1=-Z@8,D?6_S?I7KTPOE:]4%FT7S M%D=T:^\AV/VCV?D;[ER8_&L%'V]ZPH-G,WC4\@Z3TV7,Z<$X>/-[7'P-#K+D MIP=V(\V\&O8>7/Q8THW&W1?QP)3;KBI^?G*U/K^-^>M^?TD'XWR\RL_ M%=5\H_J=C>5Z/(G]PSW6/[I__X0HN<;&KLW"V@_O1@3]\5D='H>''_\9 M'(:?#@Z/@T^?#X\^J_WCX/@@<'+PV F[ .+@X#" ],W@I^ @"HY_"X.&B)R) M1V6._64H,5DR6Q55O*N L*!ZK%+E>8(4:FN2H[P(1F=)\.^Q,X&28G@9U*9, MX(R<9! \@ALW>G+UON]GZ2C9]4PEQ%?[-PEWYAL5 \&0&"!K:0AY5QI M"4)&.)9<6.NDWC+Y5A,\LFG_[U_9U]V?MIC MWCY%>EIZAVP0I8Y+[E=>Q_*[I(UH"O];93MQYN)4ME,A M16B5D9(#ZLQ7!1 )-501K:0\:\KVL'+U'B9?TM*O_\AGM'J$#2N6VXS[ZOCS MH?H8_!:JC\>_!<>'X;X]"LS!X:>W[=FK-[S[T3S)OSA%J.:ZB _#8K9 M% =Q&9072=]O#0R"- O241GTSRJ%<;NM6PC]]_;P[=';6AT(SR^&^:7?WMSLI4ZS_J1V6+6V;L6+ M+W&6_J?Z_M.&KO3>9-N\7X]Z/W^[;*2/TM>?Q=)G0 8V22Z"O\?#87(9V"+] MEKRP+G(T3AW+P)*^<#\.G2QW"Q#\ECJ%(0A+S\G*7F#<>T[S(DOC() <=). M-Q_+:M1@4"1EZ;6VB\)AT)??#)(?27_LL[JZGQUQ^FZ[2\.Q)ZC@/^F%4T(& M#]F<> @M/G(@ >>I34 AQBS^=K9X:C M/__@>=J((/SA[(3L2Q(H9UFXR]Z9$0S<5;=\ONE%D?23:C$A"BJW:QF\<<]S MX K*WRUE[Z+]S%YCG<>EU4GJD[&YLGFX MFW@_?\K;\Q&BXI<'*6N86S^QL8K+L9% M.?9]WQO;#T<5G6O9EV:P28I?YIHN1TRM@<9 M:1G$P3 N'&N/^WV'#$_V@XH>"L]NE_X:9'FVN_1">>YUSV+"L3W-^JBW"CB. M6MWC'$LNOOC?OQ3Y]]'9]/);)VR2JF^#Y#3-*F=PI0=Y!0*!GV_J8749_CQM M=F>#F_LW;>AQ,6E\0U^G+=.L!C!$)[MH*C.;@O)M\,94"^#4GI_>/XHT.C?; M)KO9VH+\Q^7H:)&-OKB1W]94J38GZ<:PG8VBKOUES+[F9O7?9Z.S>AY6,F]M M^#IJV5+/R8* :7N2[B:Q%LW4$"Y7'E9"!@]U M1VZHXGMZBX+I_4U+]>+T=)FQ6)F(CM=E>66HC&<69_TT'GIIG8^SBD/XG+"#N!B4SM3+_5F3 MJU;BW$/S)OYIN9[Y:NVE)8=%UM]<*L^K*[ M*7\I>WJ9CK.^H3>MJ8FCX*_CX66 1!TLVJM6LG9=^W6M#Y0%^7A4@=>C.+_. M2&:^;TN1$5]8O=Z1 X59!:10S@G"#!FB0%4LU!B MPC154(8A%AJ1Q8@<4W6VJEI7'?(K#^9CO!J?LS<[$8O$;O5W)_ 'V*J+D\., M#AG]U.E%I6N^'SG+T8GOI+(AF[&Z;EX'^6C2=.<#A#U,8$](, W2F0[UZ=&Y M=;_>+A#7E9-I9\7/@]OBR]%7E67#V(IS"V'!+& M)2>4!"OM6-<]PG76I.N_C$+L#^L5'SO,XX<+0?-8U/K MTED?\%YSTWG4^[,Q\B7]68.@RB6]VMNWX?\\Q3T'E_OG5B[X.I?@KSOX3I>@ MN-DC*-C-U]B&.@L?;FAO_. F]#?I.KSX$93Y,!T$?P+5?ZL>?-6DC=%_?'^3_U^DIR>OA 9Q ^9A>"L\ KHGTK-K8" M.P5,.MV70,5#'!FC&8R$Q<@\:H;5X7&P%^P&T=Z^VC=[3F=Q>NW!X>_JN'ED M/WX [:W75+>'N)=CFFT1$ X)D08RPY"A(95:0XLYUA'CE "P]%3"G>Z&4>)4 MQ;>/H937A+U53%TT\YW-*D*5:SB/-W'S54TDO#[X^P'O6?E.6[,A:"0PUX8* MIJF11$LLE5*&(A$"8L"C$8D>A<@UX]WK,Z>_QYE313Q"9TXPFY;]<7V4S8=8 MJ"P>7I9I%>,Q![;)LT'M5?=M#I-R/!Q530XNDCH8_5&(?ZEU:I<5W+U0$#V. M%ZPSY+%06@,J.%. AC;4!@M$(XVX"55D'Z7%59#'FR^$5S!U?_A=J=3)7Q_Y MZ$'J?AA.OWN,#W.?TZP,U$D^'@4^>4XR"@[3\NL:SG;+HOK.Z89BBV0U-4Q* MQYJP,9:*D"D661)I%CK%17/)'@UA5SZF3NJ,B'987F3T7>3P;C*EGB MZYGC=G%\]R1#N3YR=FV<:-W@UGAPV^H"Q$Y7MH8YT2PH$%0 @'2DN0U#18"$ MCWA_@P?%OX6'G_]M8_Y^C&Z1PZ$@&:ZJMT,S1$%-AB*RD1CU>@]E\_]\J MINYC\B4>UAI*=1QJ\YU_=\\B EMD43!).0QUB*&"E&$B(F:T8!$.-8?4B,?C M46VO2;&*2?7F?N#CS_)BB^V(NV?VL>A=9Y "(BTDW$01"JD@H3.EK QM1,+0 M*B30,[OH7Q,45S%UG[,Z(#7QIW^/XF%2N=/#?X_3T67S@+\W_C^75<*PB83= M?/%*(D.\7$4$4 H1DXH"CI%& EI+2;AEXI5H!B)!J8D8H"C20KG_.V[E")(I M*ODS>]HW0KJN8DYM5*?\ M]K+Z.%*:9Z]I=MM%\-W3NXGBDR@:&NBL*RPY5MO'B M%':'O_T=U=>%:IG_4(=V]^/!P=_V]O]2UV?]/=P_?ER-U@JH MZW Z][8^8=).GX[/TC*X]4BZ3WP37,0>\.-A7$QS&TZV5((51NKWYHD2?:;G MI)R^V]E:W^-BL#O,\Z]IG?]FH=/G^.Z[?-IG"=QEM;I-::)-_Z&21>:C2EM\(^S)/.Y?JI$+B,_M74:KSK[Q_?=3'YWR 2"\X'7N)Z-,O)7XZ@R2N&KLKD_10/E7+ M*/F2^K3J/E>3FZ_!N#^J-\2J1*15:/O\4?F,OJLFDZ]5RND* W6.ZDGCDW'I MN$)9-SVO8^'S"T]2/E%*NBP1R8NRDW5D<=&--'8-I;ZV4>R3K?J4_U.7>$/'N,8RI)X-1S MIW'%7Y,@RX/\Q,U7G>C9(>IB[+[VW9/&%X-)=94Z5UB5/>S&OO9F":H\@YO0 MGG^]I^%T[LV:D:T'P*B<%6_Y[M[@T/"CGUQ49:%F":+=0(?Q]ZK7_7@\8_#Q MH.I3496A+V=YIJ]"UG.+D[BL\VCW_8C=A,9E.3Z_J %3W78>7U9IU4ZJQPW= M2@\F8/N6#[^Y']/R:PV8<39Y2,7?JYO[^7@X\#WS$]0?C>/A%'=^,@?IJ5NC MP//!(JUR>U>%Y.K,;0T&XA_>X"#^%:X3GDC2K$/D?1#ILZ"-SQU'N_1$-UWK M>NF*9%AAQBV(9]U3'M@+RB2YHGY ]39HA@HU$BO[&\]]=G*?^]S) )5E?JT7 M]9N_>22D_;.YDN%7^S0?#O/O#C'OK\[<@W*9-"T@.)VY&W*;!(O3NBP5"1<7 MS4JA#W'K[-S;9"#N_5?,.[HZBU&-7DD17IN57$& MQU0,&_0GW/I_IN4&M=I23A.1.HSU)ASX:QM%K/!KY3&,5@RB2 MBJ:_)LV;>X['.)+TU%HUC&F1F='?)M)?#JIY9'G6;]Y%?1O ME1[:T!/K5)]5BE#/-T]\/KV1MZ*J',%5];3J;I]6U]=LF;/,2C&?W^")VEV? M-)^_;*9GICX7I:_[-)B+OC(>)G5)H8EJZPC]//&9#"N-QSA5.>Y5ZL94<$XQ M-('*E"'/WE)Q>*^/N"U(]T]I)'Y,0P.HO]>='%-Z3G%QYP>;9T M CI,;2FF#CPQS!$T)=-*Q6R4_*D2[J:Q5\KKC+O!^:4CKX$G]_C"7>I7].$T MVG+"TZ=%5B;8\E0_T2,].(?#Y(N#SKMA@/IW$Z]*:<9]_> M**JL*T9:[8^H0_.](\2R^F5'A=+;I"=!U=;2E=.<79L]3^N"@< M1W/$<9)4?H;QU =:)#7K&_NZ6!5_O-'75AGHWQ-'G(/DB@T>#\LZ5\1Y6@Z3 M>'#-Z^*81)]K>Q-EZ&4S\ MSA,/V&G<3WI.'1U-O6_]89R>U_)V+M2]4CX_83AQ3'G?V#47U%ESA@">;IP,DHND&XV%==3/;(BKUKWG.N; M#96U([V.]*Z>!*G,C5VGU55%3Y>9.14C=.161=5Y>BI] *8&VX M5*Z",DA.3ZN2L96#:^;:F.RAU84CB_PT'34<9X.D[P?<:[[>^\BFNF=^,:JV M)IH]J\B](^:.F*>A#$EPYM[@-,!O2>7C\D9O,JJC#"8N*,=3QXYL+SNCIJ.D MFS-:G7E#I?+QGUQZ\Z08U!$P2>7[O*^5T4G;CJRN*'J>"_6+)"Z3J6GAS&#O MV)_RJJRL+8N+.!TTO>RU)[Q(!N-^^.EP M[+W1308TS+_[FE/7-+ L&541*N=)1T+;2D*3?6S/B^(?7K,%!U?;I#7_J<+>;E&E.BK;>BH[]I4N?535A3,6ZSC'N0FW1.N>6("S>."Y M0M61T):2D-^\NA)7.XT0\XZO;Y/\,UX M2^_:/:]='!>5H!Q="7XH'0^;*ONSOCC.6?U>1^9V!+JM!!I-=E8G\;/-0)DO M?I=UZJ>=!W'[>N@7HRKPH#,3.V)J3O;^-3=GS<"FVYLU_?AO56C7A#MEXU%1 M^;GBH>."%Q?#R=9H1UL=;34G^_!&NIKPK&F\_IS,IC+/*?<5>?6]I)UQN([ M.@*[DKGBU$=P>!(Y]8?*JX,:3@J>5!ZOZ]%V7_+<4UHV/O4A=(6GMHNJ4'._ M*HU=+#I3W7,\K26#.PGL::=RU^5P;0>3S81)- _%JT!Q60-BX(R)TO5N>L[, M=2);OBL[9]X35MR,1JE<,:.T])<[!MU1WI5-B$GP<'UNT.]@Q669]]/*GJZ( ML&GA^L/?7XIDD$X/_V7)Z'M>?&WH!Z[IER(^[_FK=:2SMY8G9X'KL..&EW!& MB*>SD^#]*R?!%\[#=I2ZI90ZB=%K.'4:QP,GAT=FS,\?X_814C,Z&L;]KYX2 MIWL>KO..[M-3-RS?IJ.J[:6J*GK)DTGM\7-\+QM7_AE'+LV8NX6-_[FJFDP. M5EUXT=UDF!U=;2E=_:5.!^&CY4ZJHSG)H#XX6AG7N=\KZ_NS._Z\A>-6^;G3 M\FI^YJBNRHTS]>G,)>!4 ^S=#Z;.<58M<:V7C:J- MW2*8AO_Z-$##85*?E:SCUYWQ4>5UZVAGBVEGD%=.PLDA5V\P%LG99.]VJMY/ MPTW\D9QR7%0>Q(G=.0TGO]9NX@V9,+-QT47V=O0VB23PC*C(:H$V+UP[R;'@ M!=IY,CK+!_7)ATE>H^ \'W2VX[933[VYX8]15[E>^F<^!=YDNVQVGMJ??O%Y M!MV5\K+T:8HJL_(ZS5TY6]BKC[W.\EI-Q:@CRK$/ZZQ.V]29BZZH9+,PJ7G, MRFD1CP=OZZQ/:I[:RSOROB5E=:;&OVCH'76N,Z<^(U]_EJ&C^>@JMTCVI:/V M+:7VIJ?$,\AEOKAEOF-W4[W'-[ZHSMW,CN/^UBRGH:.5:!'%2%+GC-Z,IA?2"_N5)4NS.OL;].E;X>UST M@N3"R;3SM#]/5NFMBO-Q-DGF,TC+I$J_6^5ONYPTJ5*?.[GGKL:^VF$M)DO7 MHWQ<5OFG.G+LR/%ZNK:)&.L%97XZ^AY/]@4&\:C2NQP=>NE9[2/L^GV$BJ"^ M5L9HT?18?I^/5UTN?)R7K=R&)W>DS0\U)=FH,?W-*8D5+WA*IX^8K^]BQQUJ(CWQBJ8G- MZWHWN\$9O?-T.Q7Y^_P CIL.G-99]7A.^MX8/\N'==8>OR7WPRD<:95H*N]_ M]5<<5CJ:WU*:MTXKO+C(T]I!^.]9O8QI=$E>+&Z(7)%4)!4^V=;;JB=R\B>GYQ%-!Z4QK]^COOG:.(^-+9\5G MHXE#:/*R^G>G) RF&=:=\*ZJSG1DO9UD'=4Y&>M\8R>7/EER7DPJ_2Q1W&8' M?:O21(V#=#<+Y;=WD=8C1]SBF9&']& 5=3S47)\_K7,3/J'(2K7]='-IG6K[ M(:FXRNALH;Q67;S#WU*5RJFU^3I3[*S,UK)*(9[+3"X_1R&S.AOHM9VVYB G MJ;NGY]N=!;2LQ-/3RPUJ;@4$7%HC =4$*A[BR!C-8"0L1L;?TY4;O)A\O5IN M\),Z/ [V@MT@VMM7^V9/?0SV]J.#P]_5\=[!_@,1^CPE!F?KCD-"I(',,&1H M2*76T&*.=<0X)0#8Z^O^? QNR437-7[>-N9YO2L[WC7Y4C/)*><4*$IMJ%5( M!5)&8XJ <@OSF,E?(9WOJ^//AV[2?PO5Q^/?@N/#<-\>!>;@\-/C2ERML*OF M8/_HX..>==1A ZT^.G()@Z/?PO"1A++"KK[9\Z(K'Y>.UY>S"FJ5#ESM&_ST ME ZO0]72Q5%J4#L/5.MO4^.O];96VB%P MXSC)"Z=)^*K8P_BB3-Y//RPPE+GF/ZLS+79N5O3K5S#ZYX99J_5<]%6]QK MY\-?QUE2SP@&O0 !R!]B&4YF8Q6C]:>?_4;#^[-TX'A'M_)MK[Q-^M6QD,GJ MPVKUV4TF<8?^9QIH>PO\YG,6.XO969D_=9C>@/6\<:CW ^A)W/_ZI? I6[S& MDQ?O_]3O)\GIZ>N9 '5TM*#N/VRM7_\5M<$W>.CW/9Z)MF^< MP)6/_+]6(9)O&>F- ZI6NY7]FGH\Z8_W69Y%15V!K')S#R !$ @J2$(1WOW^ M==?ON>UBI002E$2$$6JATB*,4(0,8Q%F/%([01:?N[>/R]TO<7SQWA.+R@;^ MGW!.*6IDXJ*X=,/]NZ]NNU-%,[CA'2:GO^Y$>]Y#\0?:"<996O\T+@<[OK94 M>AX/RU]W=CT;<3.=5 RE/ICTZT[Z8_0^&Y\/\M&DY<*R>^95MKVZX3=KSEU?,6@F:\12''7"(=*BE""HG02",;":8-(9RCL"W> MPOX@;? 61'L2;39O>8S)L;Z*RU[FCU;GOH3K'6HJNL,__!C6LBZ HWP&.(.% M1 9;#*FAV#"-:"0)LB%B0*K07@?<= (O]Y/1RF2V[ E 6D35V@KF#9"_6P$8 MSN: 401801AGD9-0ADD=.K77D;Y3@*G0Y(& :4D0P1ZB?!,0LR4&]$%]F/F* M!^R)^+IKP[)5(V!=@"GGP(0J0HHQX^!I*99," I"BA0G,I0A7U =JR50UXQ[!H4TM\[%*OK2#<9 NU0_ M"&:0SA CO.1S^#5IOA]S1C$_ I[9&_VF:2;G*+/_O<7KACY+U?*&6 MIRJ6FZ@X\CD A< 82*&-M(0RII352DEAK)#"R:\%)^9TIC\-XVRDLD$XG>Q5 M.C4=&B7:Z*V"SLC;5BS*1G1 ""PA$%BF,.58:8XC92TE@MM01.:)6&Q)-O:P M:-4ALW98W"AS[2]Y/OB>#H?;JVYR.$<8C+25AE*K0DN=[28CPTF$J *68QHM MN$FFL[="R<;91NB9G6VV&6#!\X 2)'&(H=4TLH@"IQ$ZW' 1:H40(Y;B!X"E M+=&S(6#9#J/L,"E'1=KW*3Q\K&NG_"VBC3;0A@4(21A"2S@5PHC(&6%.!510 M",T!N(ZV^>PN#^3:S[/^RO?F )8;K0IV9MFV(I/#>=A*J*W $$02:XJ<"JDL M-L@2!KG41"_LCC\)F>U(2M23K$V7__HA-6"<'-Q9V 1BKH!"',D30J054.45=2LX0"5$8.>V= MW1" LSK?+F4]NL+0MX-/@LX#!'FH(91 $Q[WCO? H4/LV M.#H^,'_[[>"C#0^/)AF]@_"/SWO'_USC5"-KD IJ Z3/MBSE=EA#TXQ/PS0^ M\75OTN1I:9]>^WQT2=ZZI6]#EJ_O.5?5[[LU&OD:6)<^T?C[XO M&PDBH)&8442E,8)*1J7 (H+$ $N T$OT_66V @#3 F"$IC(4 $% MM8HIH)^"Q)9B!+K N-=E!'OZJ&J2IE41RBU.-@$!GB,-<<(PQ)0+8*C20%*- M#2%&2J$IY@OQXI.9_#CW'ZX\\P3JL5:WO]=6MFV3"'O5^"%RCI\H EQBHY#B M5',EN3#8S0^Q3F&4BZFX'X*?EO9G<8_!C7#0;(GE-@GCGH@L7U4^*Y^<+'7<4*Z9(-J&"DQ,N*W% MHQ#S*$HC.02*E)L]NG#S3+E;'*: M.)(8!$7R+:^L^$V!#MHOL&N+ IYJ!"Q3%,"0Z%#*Y0"W(&(&BD>C9VV M,M]*TN9!P#471*_>?E/G=<#-63(_X[\VUKPG=J_F90BCDH)3,H L8B9]Y1+HW@'"J!D0946&V7IZMX3N=FCZ&M.#K?68'; M 3X$YL$*TJHP50A;FRH4*09)I'BC\)@.V*2\AZD;6Y%K!\& MUR(90>O[?:/XQTP,7F[QS@5BKLO@W!D)B7+J*A-B&WB'ID6:\N F$C!B)*<23#!;ON M$1AJZ01>J^E UUPZO7;S[6/NNY04YT&:^>PEZ;([LOCW(6PT\>W4%;3M;L8/]#;!'\V)+E I.*.0:$H1)"JR M&&#!I:7*4OM\L&]'BHL>E&"K8;]1YFGMIFW//?NJ44OFJ)4F9%+)2.A04NW0 MBI1@G"BK(DHD7(BI:ZC2*Y.X#/4@XYN@0W=VZ(8@ALUK44 (*0A9%$%*J8R@ M5)JC2$34,.08^6T^T]6=/*NVFJF'MR<)U(^>N!2HD9<)4J=K4@: ^Z"0IA'@5F$..< 16\@*TU@# M7[2IN0+WDVP_RO1]E@[=\(MQ,@,JN ;4O'J44U0_W C/SNSJB/P6(G>?YH60 M")(8:Z5#82BV1@GB\Q]9J#2C6B\D'WL8D2\11JLF\HTR,HY&>?_K63YTAEXY M3;^=_'OL3-]]):/OLF]O^D)NR<&@3\5T+[OT@.X%_P7>.J4BN(B+X%L\ M'"<_![3G5'W__Z \BPNGL\7CT5E>N(<,?@ZR?/IK6I8^-X17\?+QJ!RY#VXL M753*$B'7L+"X02:,+.&* ZHX449 Q(0TT%(8FH6=OMEZ5?SW[WZ%VO--_"X#E[)6!M MTD_.3Y(BP+#ZE6VQOY(V3$:I3:@$8%)C2H$Q&L(H9!&B3!D>D@4/?[UFJQ"E M"PG/-L%AN4W&S49#!LV3;1*G9!HCD?8)I@FCDD= 2F M9Q&)[&,@TU:.P$V MS):8D_%-U9KJS27 M4DN.".)TP0"6622[ >V_ #[9TAN+5 I/-DG0SYLB:1L39D MU$@CI(J,0D0K32*B%L[HW1^(+05IL1[EW2&AUV,0'B:C.,U\NMRXR-R[MSD, MBW+9""JA4@!.+&*&"DP=P)@!%CEK+>($+'A64AI8#K2B-0B&\QU)K2"%'3"V8;H\" M4CO""XL>[1(&OB:#;DX;05ZG2,K/+XKD+,G*]%L2#/-R*[,^O+D+H S. 8J! MQE)AP0AB%#*K 4!2^4 6'"(BEQ4RF4YZE:G%-*>\+B3TT%'R/AW8#Q##]P&VZ("]R:;G<9'$Y;BXG.Y&QB-'4>7HY\ G MY.(]BDBUC>B^2=1#4,QV).^UV=@+7-N+I.\/$ ^?FO;B-:=JNYMGL+FC%TL: M(D6LQL#X;/@:,R"%T]P1P!&T"\5@IFOX#+N3!/0H?\X#@*^'+W1V\[9 5*..P2WDVJA,YH>*YP>L,'8K/,C')\-D-7IW6Q/S7ZLH&W6>U]?ME)I M-^]&L>O,[/?J;Z,[PS1+=L^2BDE !/[\VC+BOVL)[D%> M3^Y9]?5[_8X3Q]K<(_;5\>=#]3'X+50?CW\+C@_#?7L4F(/#3V^?CH=5=-@< M[!\=?-RSZCBTP=&Q^^?W?]]5GN^?:_+1N WBS MEP6CLWQ<.DNH[ 7)CWYR,0HNDJ+>90P./B*QNMKVA.OH/-'OOO MS<=E7FX.K^@@U:#<(RLI$O23X7!RM'.;G M\8*>^3T=C,[<1S>.B2#MY\-A?%$F[ZZ_U]N'[]DQZ*UCQQ8F8O*42Y_>O4]@>@7B? MX);COJ."#S?G!NFH8*NHX.5XP0,&WY'(NC&*[8BIVD]&01D/;RJ4T#I(;IRO MQU'!B^ZMW+7TMTW#HT;[7!LN$#!$$HKG8250AM9BP1 #@!(<*<5Y%$H<,1LR M$2V<^CCR)'68?$NR19K)%8353/N($TL%T(+S,.*.;TGCV)M\2@!>EBVNA.\ MGG3:\:B.1W4\JL&CV/ST+ 0<8(RAEHQ3QK$2 %*!'5\@T/U_(>79_?6H?[;" MHR"$/=QND.YZ$FK'I#HFU3&I!I,2C*IC=K5,GDY"O+3V[Q06W%,]PZ ,C"OYAG"2$?6 M LXEI( @K7$D)>&8688Q6XZW*T4=Z11VH(AJ@RQ&FA*!=("V8@8C0QB6$9B2XB[=E11!'L MYG< ML<-=A[L7Q1V;XTZ(,!(A9])=I5AC813AT&F;0 C+R4(^B'O)NY9P)]MV4ZTK M[K8C#.$O15Z6P461GZ:C;4S!>!);:C@U\'OV>&'Y[#+[*88 @B)BVGP&*I0H(80!0#I2U; MB .]4_JUM".(G/AKM5K-^N%OHS;]#BZ2(AZYEP;)CXLD*Y/R_5,.*KR243]K M\,6ZLM!N(;N%[!:R6\AG6L@M*5KE:U.G9>F4GG(J4CM5=D&5%8U=1001TU92 MC5!($:)2,(I,A"S23L$E;&F46V.:53:(DJ1I)]BRGQ5Z5VW5]S<2C9#ATK^P% M7Y(L*>)A5;(A'IRG65J.O$?V6S+SR#X1GJ\8A;*QX:@%$2 ,-0Z-H!8*::4O MN,)YB+&D0B^@L)[AO]3SZS"HKLQN6$_N*JU&UJ.R3?&XME)PFX3=:T93HWIP M&$IHM$22AX@:Q*5&6$ =(2%,)/BBI?=8-+5WLL)7+6IS9[^#4P>G)\&)\GFU M+ZFUC:@@7$94.@E%B+/:E-*&1HB!117Q"<*II9UZUH.HS2H['9PZ.#T)3GP. M)QY:SIR:%X7*&5@FU%1:$6$;:0VU)HL'WY\@G5HZ!X%[&+>Y0[#F=M:KWZ>S MR47A%B^N2+$ROLYS-\K_5#]TQ2\?#E_9A"\'BF)H,5749ZY 6A*D$<1(.9MM M(;E.+^>JJ879>S@[42T'M2[C-=R2D/UJA0B,) MIP9KB55$ -(,"!E*O""4'XGJU@S&=E/\=:#N0+TIH,;SLK",AQKB,))6,:=D M1Y):"[#@DD/H?FD+U.V=\^>KJPS;H;I#]2M&-9VCFK(0<2$PHT+3$$9"BHB$ M(= ZPI%6+8KJEIQ18KL5\(TZ4E*7H\\7#I9TN3YNQBZGC;0"H;!$0&T%I)9 M1:BEUBG=5G%CQ8+Q/#O!,_%RK3805O0$:#40=EW3?71>Y2V!GIP7,P=<:$@A MY<2!#@@DF54.>)%Q'TG$%U(*W =ZK9FS%/1(![T.>IL#/0CGF52MB2#"F@A) M($5:20N!\"="H*7<::^/E'KMJ*>,] AI-:='![T.>B\*/3R''@FYUEQ0 P6C M6!L%*%9&04H,I:%<"*R[I]1K*9\'ZQ%!M@%ZVY%?;B_KY^=)<%KDYU,3,<^> M;!INHC\'TCE$L8*2:AYQS0$UR,-5THAHI*T-D:8W0K2>[H]YN5*K$**>8,]2 M!F!M!6/G=]U8''+4"&R0D(9,FLAHRB 6#I;N?UAKHS5 "W[5^^&PO1!9TI.H MPV&'PXW$H9RG#,!"P!!0)#5AE! H 7;BC%H G4P4%#]:'K:T24E[HMTB !T. M.QRN"0X1G..0*0V1B* U!CO[D2IL*;<2A!&"(2,W>VWNDH%P[ M'&[4SN'!R%T(TMI$?#/9-_RI%V3)DW.1;[ O!^&Y@DHPB4)B5*2AHC1$$E@= M18P006&$S"(@_8SOYUE^%9C/<#CR67?\UU9,;I4TW&0,TKE0C R),(.42L,I MU=3IJ"S$P'"!,+7VZ1ALSUY\SEBZ#H,=!E>+03Y/9*4--=398-39AI02K;UE M*!#AUJ<,8(N.FD?(P;8.CG4@[$#X:D#XYDX4RCD*+0<:<:P5)"&5!$B ,1<, M:(JT(;052?@ %)9N/MQOMZNESPC&1?I]RD*WA>"?MGUO\B1Q])%,S=!1_./I MH:N;Z ?"#3^0AB84 AE((DI1Q 76 E+.D8 A960A_<'<_1,5^;EQ'4BSL1OG MP6Q'6%>+4+<[]DL0_A@5L0-4FL7%Y=XH.2\=H_ ,H)I#:<1%8 1HT5B@&DC$)"8&D(7J@N\KQX;G6_E'2Y M9#L\;R2>22-W'A"":2.A@(@2KA3!6@*ED1%.;#/XXO*Y)5N:]8#LTK1W>-Y( M/+-&1EI$1!A2!!@4%$=6$@)UJ WRVZ_@I?'PK M2']+R]6G4GK5B!9S1%LK%8PBCB3$%'.AN01 [Q81BHP,&>2,4AM)Z4!E#$0P,B*D>J%<[?WQ MU9HUBGJ\U4-F'7[6 #^;++\(XHU#9%$41(N;YS1R=O\K2] )O^UBOFYDWIN MFZ='3<=S,[?&L3O+W 44,NQ,86H8U%@0J64$K(EDA!:4=T>:SW3P%?0P:'4# MZ='K_K(TWKFK.P;8,XC@%V#+!C@!T#;)1ZL+&NX88,< .P:XK0RP$9')(A9R)JUQ5C!5PBBMA%* 0"LI M,WS!OWX/#;"UPE=$=!K@ED1XS)U^P452.+(Z/W>$6Y[%1?+^#D\]7L%.\VOB M]QLPOFXM-V=\W5INSOBV9BVWI#:ECLNTO_8FQ?99#>MB&+!&QI](*Z.=:6"@ M#"DT1DJKB40BE)*J""_LC85QD;EAE9^2XLBK;16MW7./;'I/TU! ,SL!W&HG M@+=R=1G4'[+.G2=DW21PQ[:VA&TUDB0I9;$P0*#00DHTUURR, *, X,8CA[- MMI;M;#V%;<&W8#V\NQW;ZMA6Q[9>A&TU\DIA00BVG(;26DIP)&4HD,1("N ^ M10MNV =H6PONV*>QK146S>C85L>V.K:U]FRKD8B+&T:9B#C !E +N8H@%9'E MV'V.H%S(E_X ;:M5MH7>KDDTY:O:+5I?1Y9-A^-1,E@7+O4ZF=$KXCF\$;(C M&!.6&1M1@&@48JVX$A$53H.RBD%V%\^9T,[SN*:>=0-[;76B3O7IF,H:,A4T M3Y-@D!(24HX LU2'0#H%1KK?B!91A"EX/%-9@>-H=8=-.Z;2,96.J3R)J9!Y M;@BBPE ;RH&@(0442(*=YB*MKXF*(0N?I*F\:K=.QU0ZIM(QE?LS%39G*C 2 M,C(1$KY$G:5(^LSG5 )LN+8A6#BR]2!-Y54[7=;5$EX>S#6K>X?7UDK9XY(PP!YJMXS!VJKP6^ 7Z+!9 M85.0&3:E14A3QK3%B$K-M!30.K-:8(XC%2Z8TD_%YL)6P-.PB7&'S0Z;&X1- M"? \(!)*SK'%B@-*E<3"&HX51C94G'.X"KGYSS;EY@JK;W;8[+#Y_-A$&@O8'G@WLO:/ M)'-4:\*5,%S"D%F*)951*)RPA5H2S82P]T3U9#D6P/T,MBKOCB9T'L8.Z$N! MSN8GNYDETO@"VE)QB@#542BQ9(:%.!)4+*1T?SK0VS9\J>R W@&] _HRH(OY M66@.@>$.UP(R11D/I9&6APPSJP2/T$)0:RL2O54KFG42O0-Z!_0E0$< S(&. M.9+:4BJHPM0R)\X9 (3@T "B%%XXAM>*1&_5).=;+M$W*IFCB<)9O;S^Z]VD^LKHJ4^OD-]P"GW['8S:/QY!YT(VA M$$?$F3_$Z4,X4A*02$JA=.@^H<6BK(_D,?<]VO<0'M-N6?*.QVP3CVGD*7^) MM7XI#O3(83\W?V+SP",3*42%L#Z_$^5AI)P"% *(#(BT)&K! _MX'>A>!WH> MPI_$\QIJ+TO1'??JN%?'O2KNU0R;%"H*#:1:X)!&*%*"$A$9I@PU2)"%7'6/ MUZY:YU[P>0N*K"?WJGQ-[T:QZ\SL]^IOHSO#-$MVSRHWX7N(P)]_;O2OG[B5 M*NI?TLPMY\B_\<>J.-++]^HH28*XW\_/W8V7#KY!EH^2,ACEGFBK:C#Q*!D$ MIVD69_TT'KJ'NQ_.71?*M^LVEAMF>$HLUWNYV*F=VT?10A?1-9JM_IX5TV=< MQ%^2W9,BB;_NQJ>N1^_CX??XLG1O>G=63 835PRLI)1'SOY#P(2:XE *+$+@ M.(L "C(IB;\GOC(+*Q[:,DC>M03W()0G]ZSZ^KU^QTD^'+A'[*OCSX?J8_!; MJ#X>_Q8<'X;[]B@P!X>?GD33J^BJ.=@_.OBX9]5Q:(.C8_?/[^'^\5%P$+G^ M_O[I,/PMW#_:^WL8[.V[[V'PYO.^^FSW7.N?UFTH;_:R8'26C\O8"'X+\W'Y=Y,3^\HF!5HW2/K"1;T$^&P\G52B_P MWUTW^]/O2\9]G)X[MKZ?? \.\_-X0<7^G@Y&9^ZC&\=$LO?SX3"^*)/WTP\_ M7Q?C.[-=G=EV)F0[-V_ZU.\@\L\_[RQH(9/WWW()/.ZV[F6/>=E&;=G=:R.> MWWIX]XHVO%@GKU6G>5L<>.?#\5GAM+O?W<]G91 Z7C,(_CK.D@"#WG8:_AN] MVD?ICWNO]?;A^_;#^2M8\<6)>%RIS?8(Q'M-7PSW#QC\>N9OV!8285LN&CHJ MZ!A%1R*/9!3;D2UN7M#YF5"RIM6['[6MM+$%Z(&@ B84ST.7+7._HY!AP30U M#&HLB-0R M9$,D(+H3IWU9]?%O?WN*ADT,/MYJ]<3P+MCAYTS*EC3@WF1.>E M1FS$$9501QI)BGFDK:81PYI8;919C%6^BSDM"QA\''-"/?>XCCEUS*EC3EO% MG-B\9$EDM0RMHA(K18&& FAJ,55$"T5Y%#U"$+,8+WT)Q:8DZX1\06 M:TX;M:MU,#JKCY1>%,E9DI7IMV3B= K>#!TA_=0+LF3D*Q2,XA^/KD6P.0[\ M31]?MY:;,[YN+3=G?%NSEEN2X M'/GH]Z?F==FHM"VUCLS$/!,"52JT)!322$DI)8(0R)AK"0%&@(CK.G*E[9BF MLE.KS)/5,)/%./9K4;]=98/C^"*6Q&*J(0*YI:("PAN'(4D!5 M)$&HU@/3#]N'*%U'W&^W@ANC9T'W(MT_A4[:8@D_=>Q@B]C!7=P -?*08 $( MD@8B0RDT5ED-#%,T9$)#"Q=<]"\FX=OQK4'V+/$2G8CO,/W<(KZ17"AR:":2 M6:>R1Q212'$LE& 1-H)8P!>J>K^8B'\ J.\CXA%O-?W9ZQ?QFU75[S 9)G&9 M5.5\Q^=C3WO?DA49]L]Y>.B9I3^;V_=1! VC'!,B%44*:2XX0PQKC2/@+MV7 M47CPWY=9'/I\&F69GKI9KZ[.UBPJ\G-U8/8.$S>0$C$$0_KRP'QQKMLVV35W>;\2[FB@' OHP@P1&V MDFJ"=&10!"W&/#2.16P&B[B+0S1<@58# MI_V'*"+NFJ\US$-)')-@ EM-Z4)UM?7F$.U[%[9$.=B2 %_^K-_%F=??#R> M7_8N7.!Q'*3A=W1, A)+L?L-44Z(QL3Q$2AQ:)B%ZM[A @_A('..T44(=-L' MW?;!8TV%1NYO8K064E&*I:&,*$55A 64&D% )%Z)J7 O&*_ X)?=CD'' 3H. MX#E (W\V A)BHI%TZC^%6$CHSQ8#GU9;"B!>5)"WK-5W#*!C !T#\ Q -H($ M%0N1DB8$4$9^HT (:C%&6M@PU":E)W7\$9.T2B6*&48 MD9 !#12AAD1:,J<\$,90B*U$"PE(;N(4\W7Z+1_Z<4^#B@ZRH]F2O-"Y@*WP M^W4>_\W [IUBON&P8U A8D(K+0@IX59 "VBH(;**LU#>._YG!>!=@:W?;?1U ML-]>V+,Y[+7AS IB& \A=<);DU#[ 5JG\!LN7EAFMZS?KZXB<@?[#O8O#?N[ M4-\XS L(=,*=AU0XFUX2(RP!A$.#.036DGN?"EB-L&\GG*?5[;EUU=2W(SVS M69(S9VT*@;[8SNU*:H ^)>W7FC Z". \8S,41!G$+8524B.,XD!+ PBC$=.A M6/!>+F%RS^%6\/F;Y>I\"P]9Z+7U.FSR=D/'MSJ^!0&>)W/6*I1"H\@8"ZC5 M1E"#F63$_4,< UO(-/\POM5F:F< 5F=6=7RKXUL=WUI[OD4:J50A!Y*JR H* M*85(1#@2,"2,4T9,A)^L;[66]9FUF_6YXUL=W^KXUNOB6XW\],1*%"(%&4>< MAAHK*A%RO(L!"91E"QZQ!^M;K26$QF3+]:W*Y_6NJIL]^WVP#B7''UYA_'EZ M=90D0=SWB:?C[-)A,%=-G7,1?DMV3(HF_[L:GKD?OX^'W M^+)T;WIW5DP&$U>\JF2 A4PS#(W55"$BA"%&"_<-0(%TY.^)K\S"BH>V#))W M+<$]".7)/:N^?J_?<9(/!^X1^^KX\Z'Z&/P6JH_'OP7'A^&^/0K,P>&G)]'T M*KIJ#O:/#C[N674[A_?!0<1(%11[\%T<>#?QP%;S[OJ\]VS[7Y M:=T&\&8O"T9G^;B,LT'YI-ZM U->?&6C]175SW>PV6/_O?FXS ORX165J!J4 M>V0EOH)^,AQ.KOZZ W:J[ZZ;_>GW)<,\3L\=[]Y/O@>'^7F\H"A_3P>C,_?1 MC6,BVIW4'L879?)^^N'GZ[)Z9[:%--LG%3LW;S#5KV#TSS_O+"@9D]??)>V^#\N>O=WCCL]@K8'J4_@M_=CV=E$#HX#H*_CK,DP*"WZ75% MN@K'71'LCD2Z(MA/CK*8ZYK1X<'OP<&G\% =[^W_)5#F>._O>\=[X=&CRQ)M MP@0]WJ&XP9[4+5_ZC=(D?"*41T=7M:H6OJ3O^S5XL"'"D"5$P"TLL+JV&V8; MP,T[A*\7PBD 6UBEM NG7NGHYZ?KJTV@(G&DT4^'255^=%*1U/WNO_7C\BRX M*/)OJ?>HG%P&^452Q"._B>17^5L5X/_46J6;K!YO[<"[U=^LY DVN7",(IVD M0N\'\I_KAB:>N7N6IJHF IJQ10,EH(HD 40@IM$9R98B-=&2YP%KS MZP*Z.:4KU< YVP3AO 7J]U8@AC=*CD&N(*48(ZBI<#JL1EHA'6$32:@7DXO= M@9C6-%IG/6\"8K8D?^_1*.]_W3V)R\0CZ/PBR]G,$_MZRM<] MNU6R0]R!V7-2!8!@=O+L>"9C;W*>OU*T1(^9E26'E&;&^?1O ]2%MGR1;&FAXQ+T3 N$Z8)2@F*2:H9QJF.'4M%$OOZ2IJJ ME9++CV6G]K8_>I*W>[)C$O)YSBH<3F8J;^>G765>UMBJ3%)+E&)$ M:A]]0*Z'97.]MQ> M[GN ^21:,I^T<:I2H]-$(X9=K$VLD,!.&$ZE2)/VF*_]G91N'^7M&):ZWX?> M3ZKH,KOR&6[V46U]B"W)DBU3+)E",<3 M_KF>[XT&&. VP\@[0_)-RL.=Y,B&FP>,1@L2D9E$228=-CB52B$0F\X(Q5;J M13R%(]LS(EOUTFX?1^Z63?AA=K(R^Y&W)1_?,M,UCH& J'/2.)V86#*!8BEI MPI%U*+5$DM4B+;1+QAZXNBJJ"Q=K+ M7<2'O*"J<=Q#@:,0"S2?]M&9SX(MN("KV( MKKD[7M+.7-Q9?F[$]"B=$JYC1H5,&$@O+247"7-*2Z<2LE*GZXG\W+Y75;U, M6,#;X>?=,C9G&Y S 9W_\"<%=SJL]4&F;3AY6.H2H\',M"1A) 76Q3J1+'94 MI +S-93C,+VO)(E)#^,V>??ML&AGI[X-7GR(%1NN'ZQQK+40 @G''(X5=?"O MBSE.F;7Q&OKP^JS87L*['E.=G?IV[-0D/\O+$N1@F7_+1].]W)5\4#XV,H.@ M)):,QX*JQ#(NF%$_[R6F:DOZG"? M\WP8$HKD_\B&P_V.>44Q:9P:(=09)I'&@C)I4F4)T=IRL#2! >T:)RCMM((1 M@H8[^):-^GFE1X,DOQQ7Q0L='R&X34UW=X3G/LG(;6;'![FQX??1DA(&;$>% M21AQRF A4TJX5-P)P5:*_#Z7&UL\D"E8F\KMEDN_-V]P7C]?V<@CLH_*ZL," M4S1=LT8D<VC6+7R15WNX(T'OAF!^]O8 M=RDO+WPZ2R"2XMNSG;PO607WI24N:OB'0"%.4$IBQAEFV%G)!<8Q3W%B$-6* MKN\?:C4M]'K9?F+:JL]WS35_^X)WK^3K3G-RP]GD$!&.F80BIIB15E*D&:&4 MD#3%:;*&G%V3D]N/1F)QJU[?G>'C_4B_>;1NI;$-(\%.:N*(-<^;IB(ESBG! M$\:--5Q1R4BL$^R(B%>RI,#"6%B7S[-E,5>_5_Y$P*?YTNC%RECH7#&:PK79 MC^/1IJN*\E:CH)Y,&UM[:J6Y9LEEJBSEG(K4I0R+*F4'$FPR*E.M$Y? M@.5;L\A)W*.D50?;FV/YG:HV;O7QKU'ZVZ=_'$?IET\?HP]'?W?')Q^._A)I M>_+A[Q]./KCCY^;=W@&HV_7Q[U^=IV3\':[**QF=>H0?9,+D*^?3S M?T^+2U^3H9/I3[#T,1&-Q-Q2<$-D@A5ATC%MG,6:89LPH9Q=*=WV.;L*Y9Y/ MQKH/BU#FGV?K\GF8C29Z-'#SI=EL.;Y" [9$ Z.U MC;6.68(%0R@VBBGFA+*"!"._531H39UG[6Z6[SX:[)3ROW#Y3:NZ%%TQ^I97 M+^ON>]L (&0CQ)M0DQ(7FU0S)%,I%5>:$X6E4G&RKHW_8;X$&W;KK;6U]Z*Z MPML!@7TR"/>;O]62OW5"?!H?*[G1C"BJ18JX$&D,7&\M6=FB;YV_-[#A]Z+2 M_^WP]WYL^-UT_:4?CO21;=?UM\O&T=X.O%O]W8K;^Y)?SMR%WEOH\XB-?0/C M_A][?&2%\'AY%%M;0XU-6)P*1K$SB=8)Q402XVS"5S)$SVW[=%PNY_;3F0TS M>^PGME4/WW_R3&*F]Z'/2$ZWFEMU3#7A[)5]2>-ML-/"IH(M!YP-_ M GO3>"DG*5-$I@K$HB\6GSJ%5,H)XS'33F%^IP_\T]EB(3:Z]17W8M%F-:$] M\'=W=D['^7=Q/EYROI5$ 6]AX[>[K#3:[X8#\V*0ZC[=]=,XO\6CVYBW6NIO M]QE_MS>ZSHI1-NIW&UUK\SI%R[@7K8PSF#'%)!.&2X,-9[% EE@KZ0JOW^$( M3^=+L T;72^M&;P='.CL\'UA<;YD<9=*8&^-K;*,&46-21,B->CZ7*>$K"0$ M;9W%-U# D/84[\ZW[>]VESL[R_L3[^'.?_3/L]'7/ +Z\Q&RHUHW\-&QX8,/ MD?T&M#5Z=@JU/34,)&ZI4^G;G9 M&GV!)?HT\N"B1P/_CULNSHNH!A1U=D/G,.@Y%I_G78C3R?G1_SC004J<:/X&I M^9*I-=9:IL9I)1T#6]I@@Y-4BHV@5W>!C81WL-\ MNZM;K%#J@0';;L'K;@1NDSS7F,;S&>]3=BR']Z+X]\_?_[-?0151_\6)1^.[6^?CG__XHZC3VGTZ>17 M]R5:'(2-/AREG[Y\U"3K+LQ9=^RU6_HVK*'M/?GSH:JFOGB8-WPF MWN$]+:^B<.;52X2^WT?":RLE;TCWD,BD7 MPW"16":M98PAHXTQ#,<$.:Z%P2O11^%(H2>-?( VNJW8(ZK-RC:=>?)*\JYC M\)=G<-%P7,04.ZP$_$)C%ANA56J88RPA!@GE5@*5'V#P-FM%MAHX^+HVPI\F M&1@LB^OA;Z,[PV*4'YSG@5T1CO_KET;_?!VHO*RO%"-@UXE_XX]-,>WK]^K8 M*PW]_O@"'O3F:C0:^R#CR=A36_!X9Y-\,#^ E VA<;@0#L,=KHQEOBPWQ[8Z ME'?WC[V%@=$;U!'^GI?S-BZSK_G!*6A2?QQD9]"C]]GP>W95P9O^=%[.!I,% M7JYX2AC5U"!D$L:941Q3!2SK*-:Q25/_3'9M%C8\M-N(_Z$E6(.\GMVS\/5[ M_8[3\7#@ \_TR>]?P)#]U>G?3GZ-3KZXH^0XLI^^?%ZEGM?NZJ<3L+)//D'O MCHX__?8AT29@B$867<$&YCP02)M3]13)%EV&K MD+06X,4(A+F>//H](/]A(-FEA]-RFL]8RP6WT&?W)3B!CGN1T<?,UK\@("X27XOQTHOS!'A M]O?%!!KN>Y#*)M,R> &6Y]'F77Q)C61CD]YFGPAMIT]ATD'U^37/AI/SZ*0, M*5CLN+P\C'Z:G.>1SV.%XU]LK46%;^B7GWM1%B7YT+MDOO;!@4]NEI=]_WAH.CK/L\&_IUD)3]8G MP[^,Z_M_+8;#*G)!.ZMZD84I 7U_5&2'T?'TM"H&1586H-AYIBSAF;I>FN_\ MK->1?[/?5*]"=_K0Z5[T':YY#.V%_LR&">\?%I,K3X3PDGPV7%^V83#M3RJP M1@9Y&37FY>C7D^@OP_%I-IS?>UI">T_3 #:VRMM(>2?+]0FYTL0O5?3]');O MZF#\?01K6#77]CS[EGO""CD"\NCR_*KRIAFLC!=V_1#Y[Y?E#!H8?_=4(WL.1L1MC?\ZAJ[\-_SI12=9\=V/ M !X.M_\2'8^G\/*LFD2Z*FY]_!A&D@%S ;U^S(:@Q!=9:.#O13X!E6#6!+P M^O%+]-<,9O.7<(.;^ASVAU%CEB.PF\>S,H(PHY[!IM6\P?_._I/]<0XLYJ>Q M'$^_^C,440YO_QHLHNA[ >_)(M EO*&4E]\*F/19?<+R&>2^H\(LZ&)^!9O: M6"?-7@!3IJ-L.@C<'(10CSR>7&8S^>-]!^4@;$W4U _?IZ.0 MD_^R+*"1RR'PT==\!!P%L.5_SR_K%Z^"BJ>%&0J%;8UYYY;]*4:U%\MKI9XE MPSM].\6H K4X:)?!>Y'";1&*#_X6;OLR'>;^6XS\*[[D7Z?#NHWC@_]W", " M3 LD.!U.>E$_+R=9J"UP_4UGX_'$^T9 4%?]X;@"-:R*1OX6/RP8Z7 ZN):L MY?KLO/@6D<7Q03>. P^E _/[XL1GY8\"0@]PR\>N&G:ZZ@ MIU")UR_\]$''HVSPKVDU"==[<\2>Q=[7$P>3WI^69=!W5NX=!!5GE/=!_\C* MJT 00!9942[?-Q=--V7D[03C6ZAII1Y-'4%8S>1CF"'/'#4EA(D=+Y1L_\W+ MA^O/1EZU ZI8=+,(M#" Q0@B>-:]VUL$*CW-H_S')>A]?CIGO3LKO,LVNLJS M,O2GRM>8]NI\/!T.?'L@Y *AP#/_FHYJE_2"2QYNR)-Z"4JKOZ%V!39)^[:Y M]G[H2(_ 5AP"9X$=)%09K4B2Q*EC+-42TS31 M(E5",FZ2^%ZWP8/O67&2?%[B*3#?M7$]UP6R3F>>,Y9'N$#F)/12*LR?;LS. M;5>>T?6V-)TV_%AXK6;66I1D4(AKC]L=\O/; NGM/'OR\>.QH?AM[#&PP+_3ZHZ'=F!@$Q ^( #+8Q+%QP.?N%7!RH/AB?'.O*6TP-:ZEJ'.\.>_I1 E99H#S$:J.A-QNMO^6F%>B''TR<<77-")LY MO^&3-\4'X\L:0"K_X-RP]IU=_!2D-?S^=5K41GY1!1MQ8>F!X5>[:L'\]GWP M9BI(Y/YD/BDW3:R'0S&B[>+Z9WH;-P1$M0'90"$ E@6@'/^^!(E8M0H2?CES M4*X"=1Q$(:@K:EY\'WVX\&[BF0X(].'F ;W'YUF9'YC,NW)F6:@;X/=<5*F M[H:@' *N5/DWCR> (9Y*%SIGPS?EV:T*W3D-W;F<=:>I.389K':U@+()VFSV M(Q QX(G?B/ NGF$&YOU9<)34/%.'+GL,RX$3@6D]^/AMIC(:%MDI8(YW$]3, M>//I1V.)?\O3<82OC2-9[1>Y&T=\3VX R4+-]_=XN+@&)MEB:6;[@!YKX:Z: MN F:>4<>@*1!$=P[*SB4S[).=CBT01Q*\]-RZEV:ZT 1;A6*?O.Y,7!3 M&1F77[-1\9^Y0]/_-@PYQH ]<^_)+?.SO"QKF0>4.]/,ACG\G%[W9XE M0P=K-IUU%FC_(G#5Q;CTEC=,"L+P930Y]S8T+,=L*6H=)&P1SJ;@VFZ E^OY M\')6EGA^O-71X.RYL3M2; M[TN$B\#T_Q&^ [#/+LS&,^/B32A?\OF@ M>0G":@;YJ_K7'#;A%[^I /QCP#-5-5"&M5:5J#3@(?7QQ? T+<]60?JM@M6 MUG/3;5F,+GM^C.ZVA-JVX&# SW,PD&>$S&W(VF?W"C=VX VR%H6;F8F,XR R M[(J&F.9F 6-HX7BJ\7:$T!Z2&PJ=^M*K@S4/4OO F^:ZB[05K>4%T; M^.OF8_^>P^ 7/P2I[V^_H7W.%'PP>8*Q 5T<7M6>BDGSTG5<#YQ0M]GHR(V6 MKS=YEZZ\&.!,7>:'4:>XKL';?YT.K];B:]1KD:UKT>8+D8] J;IZ'QW75NO5 M7*Q_#.=A%Y;?XL[#)[/X[1Q>S!L.IM-%_590RX)^,:-IWY^ACU8K1CW0&T"C MB\;32?33;Q_23S]'X+6AXT'LK=0HN> MB4>YU\-ABO[C#SM%WWR:B5F\?'1TRV]>+_(M^6KN%T&KF8>:7I;%,C9P7()^ MYFT3,/O+NL+NZ2R0OA=YO=TW[$-$3X$4 -D&13^7 MXRH;]I8[3#X^H-X]FO7U]6SSZSZ^!Q"N,\SW -\^9@'>Z)WP5M.LO\7["*_K MW"T@W9<< %8-?5FG"\]XT]B5M$_/&G:*9B4%V B/M=X!SCR\^MCWCQP#>O@ M\C(_ST>5Y[B+\2 ?UED%YE(=,&E:)PZ_X0XL9QV^9G_V%QVO=Q3F'0\@4$U] MB'D^@%8O/&+,M9MY2S,_0&".)O(N.7H [957!U[,>^UN<=?"4O=KX]&N]E+. M.&816%=/0HC;G7CWXBQR:NE_F/<$!CW(+XM^#< !O,YJ#/XZ]ECBO:%UB&]] M7'(Q3#]-HYD!/_>7G V#4W4>@^6#VVJU%)ZL(YH#-M==JC<*%@%B_N*PWG]? ME(*IG1X>Q58Z,P?6#Y-KG@J8_L&@6!PVF'LMHNS4RR?_]E$X6]*[X7JXS?.P M6/;Y/M$M7HCY?"S)H;F,S:"$?TT'7Y?!9_4 PRQ>_V&F,2\6:C"GMJH.FYC. M_4QGT^%9\-,L7CV?DH6:&M"U#H6^_(37NL-!;QG(:@6'0QFUQH2^I:W=DZ=V[P/3PVT MVEPG6W!]D'=__A08#[B[7N.9W+T6&MT,95DH2IX!9D&XI_FPR+_5OMYE8//C MMUOG!KM7/:?AO-T=M-)>L-/+Z5B+Z"=AG$(Z29!@B!EM91*G*%%.J9@(P?&K M1C^1IT8_ 51YX\!7"0A;I_?'K5*K<2H11E2S)*7&2L=-@@T5VJC4-<*<4L68 MX4E*$HN82X1AV! IB:*::R/N/]S[X'M6#_>ZD^C#D?WTT46??K[SY$02T?W P M+>?/UU*_-SL'TC@.,?"=\NI$OBB(.&\PQ%$T0I1JE>&6!V!A#OR67%#;%L%0 M]?-%-5?/:\'1W&2:Z5PW$J[5SIJE%_B.&WJ-?;RY8V01!1*\)6=+ 3,_+#C3 M8I:*SWE6!P]=!9?.0O6]ODT8.IK] $XRL^*F2[T?7DBQ!\WFAT]6MH EUDQ M. BUH"Z] 5K'=X4V?2 &/.@)P*^V/]5;>!>/7W_0O8#$!S/;)-2G#KNWE],2 M-/K'$YG2QH$PQ<@)JP MA; &Y\X9:FX=S(XIP5,_U2ZQ:54?X 4C,[^M)3]_V$6V_Q)7N_WS.U4Z4?UJO?@N[-:ON2 ME<_;RDGE94"9Y]''$'@4N;![\-?I*(](W+ME.O9OT5&\@XONC8/]3%6Z\^O* M.ZZ]+__XFI66-CP7[:WXAZ!YWZDA;^2=/P4#*YN,RZ=4-]\E$'EN1;/8Y+^OS1Y$.;J9NW?=CW3LYULFQ3H[M/*'M#9ZM M(#O[=+O)]?O MU,[,T5+)S[YEQ3#$R82J7LO8N?/Q<- X4-35$=S2.H)4$9%+LBPCF#!%%:+. M$ITP[(QRR-I$,)1JA%"B5U-"3FJ?WF_CJM)S6/:#"> M>I&]D2"7UY2X:X_T#< (5TL8,=H:)[A%RC&0QDHEABHLG5),IP0_=/+C,8)W M_DP3,_ ",N)[(2,^5+A%P'AP-3M$V07QW*GH:^&!7.(!M8A9:Z40%#.5$$FI M2'62,J5P J#0OHK.6U/1<0^:Z[2*#@->D9=43!:\I!*,#>/<) 1XR7"C) +I MRB41)-6.M:VBKW#2\U1T0CH5?0>8J5/1WZ"*KC!>P(C6((9M++%+$*/&ESWG M+HVYB"WF)'VRBGZ;X'V.BHX.8[D7*OI^!-VXQ3'TQ:>$[ 1[=DI(MTO:]NC7R#W>[95V_M/.==XM?I@.5#E0Z4'D6J,"A(;!@F1G')&!*22TTHLCK&L2$XWH1!L;V)&CJD MZ9#F-1B2+/.F\(0J&QLLE!8,C'J3.D44M]R15#)IVSE_,V+D$V'9R6 M>?;'078&/7J?#;]G5Q6\Z4_GY6PP&^[A;7,^?^^UF;PQU8&'3F!*C_-A'DCO M@%*K<2H11E2S)*7&2L=-@KTWT*C4'>":*: )D,R31S].-K]>M\W&;31V9Q_6 MJ534PDS>F(IK0L6?A0S=*$8@#>OOS7Z./*(,K\$SBFLP#BP6]?/A%!=Y%1WEWZ,OXXML101?9.778E1W+YM.QO,+M40/5V9US=4A MCP&2V7_-X:@_'@ZSRRI_/__PRTW@>;?8 5W& >!W=V^0UF_"K"L;_\;>M7TS MM5/;[^M%V* =K,E]7/R(/L+%\RIR@)F#Z*_341Z1N+?K$1=[789=[*?YNO/K M>E/GWD^NW9LRGEU9XM<$D:XL\2;)K"M+O']XMD99XF[==W#=.SG6R;%.CNT\ MH>T-GJTAQ_;C#'M($-^=8.].M74'&KNE[PXT=DO?+7VW]!W@=TO?\W0T>?T^X4C0R47B\A0Y#22L6 NT;%Q*8D5$JE,C**:JI0]XYCY M/65^_Z>5,R$X[@G<9OFP+L#\E41AJR#PTLPDEWE,"5)"D(1H$3.F%9&)%403 MG#@MA$ KS/3. M)BH6+F:8VUC56CJS3*.T?2V=MZ:EDQZ5;9[<[D!@%T#@I9F)T 4SQ=*Z%/OT M!T:Q& O#&;+24FK3&!/=NI:^PDK/T](9:S.Q6L=-G9;>:>GKXP@C"QP1EC,N M4Q$3&[,$"9TB)M-$$/B< N(\54N_3?0^1TO'AWN2BG$_0F_GT3CLVC@ M3^47W_*HROM3N+?(JR[LIMN*ZW9ANZ7ON+Y;^F[I]WOI.\#?VZ7?3ZY_2MA- MO+7#/!J/#K[EE:\45\(_9='W'T.XS1:>^]F\@=[5MWV+D+2#A+B6IPC'JI'I MTQ")&=5&I((C9ZB-=;U]8RW27+](?=LV@T5:#;OJV',+-(:NOFU'4"]#4&\: M^SLEY"T2Y0X2XGI*"&++@F*IYJF46%/)%*,6(<9<4$*8=HE5YD64D#;WPG&; MT:H=>VZSS.B4D&Z7]'&CGV4L[U(4=/[3SG7>+7WG.N^6OEOZ;ND[P.^6ON/Z M/4Y1$%T.IU645=7T(O=$,()15\5X])3_ ?;&]F]!TZP+4*:EV9(M$Q'(E!L!;=<(JX9 M%TY9E0C'"4^T%.EJD=KGU\1L.X<"[TY$=QS9R?XMA1K"%U!#M7/&,A%+YEC, M8D6)3#C C626(.Z>7A.S2[/0@4H'*OL#*FP)*MI*IK'D+!7"H<18D]:)&DAJ MJ!8KH-*&0;&]J1HZI.F0YC484C12*0FL3,(8L"5A"7>*\#BFE#@;4ZW)RB'M MYQL4;:=[$*KCR(XC.]F_G5 CEU'^*)4JM2F6AG*6, PW@"*@8F*%25S,GFY0 M=!DAGA/K]*<0J[BXOE+ZO(VW-8;W0B7:)CJE *>B=SUBHK8P/F MK-(HCA72T,"?LA?I:OCZO6[Q%!17:((>1D;_IH^LBXY_=>XDLI\^?OYTY(Y. MCK=@#N]\XTTJ;5:?)Q0@J(TNU2P8"I85_;L="35NC,XG_??'_?-\,!WFXS,- MH.@).!N:;)B-^OGQ>9Y/P'"X'(]\].U)L"2@/3,$*^)=H!3_]3@?YH'C#ZC2 MU !,&9T81BA65%H<:Y[B!!'-V<%2C9(N-5(CPE(EF!6)LI:K1%-*8\'AIQJT M@*= 0-09I7T4]PX^1\/*U 2:M^?C^'NMD\/XMU;Z#'4V8578?# M:W+='T=M4IK_WNS5R(/Z\)J$1'$M#P/*P3P-A[-?@Q3PWV&T_?GW6\CSI+C( MJ^@H_QY]&5]D*UK0K$!\#-,Q _H^3'-V6>7OYQ]6F.7=8F]YLU? M;.E16/J=K\INL^H\ B$:]?V'_-_3XAN8%R!QGQP[WRH#S*@K2,$'3NQLDZF_ M%]R_#PN]'T=I/ B\$)7?.57;Z45#/?OV1!LN>M6[8?:JOWGK(U_ MWM'&CZ*Z=LO'('M;V.+BI!>W6N7D]2CVJ8[T70[J[@#IS0,26P8#4L21E0Z1 M%"NFN=568V$I=B01";.T+4#B?Z.O!D@,]VBK"=VW#Y!VSR)J&$)[F05E/4X6 MR]P3+!6*84JQC!$STACC&5L8+!BA-EW9A7]!U:+Q6VM,+4@/8]9EI]@M4W>? M>5DMBQQ2*83D6!(5:X9C(5.K";,HX1@G1JS4(GI!J;PA7J9\+]+=K;UIL;<6 MQ$9B=-Z8B?'0%.R #<+0,J"7:"VQ9#2EG+($:2-=BE-L.4\)%^G*"<%G:"XM M@!4BO(?YBX;P;I^]T<%7!U][#5^$+7VZ&/ K-4XKZ1BBTF"#DU1R8RD5 J^< M1WB&LM8&?&'64WC/X6NGW"6?)O!#E/7[Y30?1/F/RWQ4/:-*U>Y8E;L^OKU9 MR_W8 SX&]*ZB,I],RR>E2MD#S6('% >UM'NXHT)*FBK&!:-4:IXHC%FL#24. M:7HM*%G7^!Z(Y$M-(QLS<7"/Q*UJ"%NG '3V2P[B,OBL32)XFCBE"$E-LE+'?L9@\\DT^2@_*R:5G98E M&/D;$]B\%TO15:Q_$^)W+UB(+H_L^A1C1CI,,+6,,ZI5FM@8NY0IA%3\?!9J M25S%/4;;5'JW7"R]=6OY'UF9^^.'\-I>5(R^ 6V,RZNY] H'*L;>,?;<@(,V MIVE;N),ON=,JS;# UIDD9BPUAA!)8^$2:2VERZBAIOK8F'H]&GR8S_V7>NI= M[8#MN MV^5^5?+=8X.Z0ZH.J19(198'(J15 L5:".D44RI67!.&#.'8:,KPBN/AT4C5 MDN.!]I1\T?R#VXE4>Y)'S"E.TC1&$C/$"#,:[.V4)TDJ72R0>]T\8NPP>ER^ MK#GOI%E1AKBUI*CZPW$U+?/JWKQ85DNIA&)@T*0,*:I-2H4SC JNI+-Q(R^6 M_TE9PV,4PZVI!'W#<*ZPD3%1UF^3WY,7Z\'WK.3%2O6'+]'?]6^_N^BCT\>_ M?W$?ZSQJ]R6X>CAEU3H=>:* M6B$3AEFLD!2"$JZ!#%-A<8-J%4\GU[DMSXXO:S6<#O((Y'_D<_ME MHZM0@U[\4@7/X1!>@"O2+RVP8C<:3 MO KO.AV/!O6G_KB\')?9) ]M]**+\2B_BBZR\H]\$IU-Y[=-B@M_Q^6X*B;5 M872R[)*?_JH(];6RX3 Z!T8;7D7# @8RN-;-[\7D/!J#WE6,H"^@=LPZZPED MLBBY/E=1?YA5%;3F7U&MKH+/+UCZ"R7<4+>< M]?L^]R!\!_W)3[^_4 Y"3(J'$3!K->V?]YH4!XL.\WL!( JK.7F(\*+S? C3.'GJ MP._-L=:"UM4"X !B1-7Y> KC]$1VC7@6%>@.@# .*J"@L$:>A/I968:[@*M M*8F^>:VDII;IJ,QAD?\#OW[-@+C#,Z"L5"'L$KC34UI-9=.+:;V/%/:0:B[/ M@4VJ(O!%*(-77*]Z-X.,0-.3JYIU^V/@%V"[FZM7P+L'_YI6<]+.+N#EQ7_J MN8+[X647Q?2B[N$ 5*HZ!2=PQ8R=0_N^E>:#Q0+*PC#JKM>=/8R^W#7TGI_0 M[SE 2E8MF;Q^K%=G_1Q6XWM:]@-=3G6 F<90?0.G 5>@A_^>COV09Z@'P-G/ MJ\-;"&Z[=(Q=47L62OJGLQ1DPZA?9,,/HPH4B(NE_G.KVL.T8"Z)4P68X5NST,X.OBQ2S09! MM2J+S^:=]I)IWNO>C#+]\W>*^-YMHUH(#=(:\'-;O T;VDG^.EDUFO7-2KFD7__L.B1RZ M,UAR\##_E@\C! U?3OT;SXO^>:V9U$@WX_":M6LPG7C,K%E^QNQ/RA-\'U^A MN!V^NLW-^-J\KFO*]Y%4%.0SG6[IEX*6F,4H*+6VT#Y M;5)R_@,HPW<^AVDJ/.>%9@^W:Y)O/XXR,Z@1^^SX??LJO+^I?-R-IB7=Q@T'&*-F6S!?8*?YSXA M#ZS7]DKU146K=%SZP.ZEA7*O*X,H):SEECGG9;M3*4N-+\M>O,2G[F+\>TW=W1UK4[\#J23GEG_;4TW[JWK6+[]JI MPQYK1> A]-)9Y^\<=U=:H%OEQXQ\/RL)M)(K8&>J2>BY@]6.J\F>,_G>+/I? MRG%51;\O'?U_\=[N.Y7YC?3AI]^"7_WGCN;V@^:\6ST*?O5NQ?=CQ3O1LH>+ MOB)::ICOEG\_EO]>E-^/([ MTIC[HY+_7!"Q\32L1X,C3\&MI3)'J"=5JV4)MI/HN[/+'>!U@-< /$$7@!<[ ME"#+3"*Q\TF#)).$(94K[>I4SC6##LD%H?";<3WH*V MUV;BM2VE\P[C.HSK,&Z)< M-JMUO1+@4=*C*NX KP.\#O#V"O :>36HI5:[%"72Q(P9IR5#"*E4L215"#\& M\)YEWKX&'/XG+\>#K#KWG"(QPK]T4-A!80>%>P6%; F%BJ4LD11S2@W#EBNM MJ562@(DK.'O,UL:6X%NG[NUN>*B]EH&B<49[+_.4U[S,Q3+AJB IX9Q;1X%U MI=!6EVX-J]7-MF MIL!5&G\.L;3%Y?L>./V6.?P!!I?QDL&5QL+%%FL1(R;B1 I@;ZX4E8YK;>-- M[@V]I(B-22=B.P;<%@;$2P9DVG%)-0A7EC!BJ-%"I 9+B:7FRN 7V[AX,6[L M<=$Q8\>,6Z/O2KJ,DL6IPBG&B::8,RY]N#PUX[5\*I9ON'#LLI*EU*:)#1A3% MF$HD(XK(%/[/ M7O;DR[62T=8JZ+N\-]ZAPSWHH.*E0F"1746(XI41P].:/B6P,.S8:4-/A1H<;.X(;>'F\3,34."PI M(DJSV,2@2U@K4J2,<$;)U8+:;1^JZ!2)#A Z0'AE0*!+0. J21GBG)$$,6>) MCA.%B!%)&CNN[$I)SLV>0'@I=,"R1^)6SUYUZ-"APXZ@ U^>3T+$F81JG!), M&-/(D#B1V"HF " T?\PVW\;#]3LSH\.-#C=>$3?D,K:=4SF8]L[16++MCO>R*[&R7B2#6\K$=>H(K$ME<2W\P1/"\7"MP30 M4!S+95Z>E",B)-&6,\8P5PJG"E'"I)-$F$=$'*ZQ'=,", G2PZ35##H/+>S6 M:B0[H'ATX/+FP.6A^"T4X^7Y(44I9@P)IQQA%O0EDF!! &42Q&)+7BR ZQ'8 MLT[\U>84HWO6O@O0Z@"K ZP-:$-TB5 .@6HPY,.3YZ%)XWSTY@8+(E21#C-4BN4TQPA9Z2U2:();747 MJAUPH:+5W 8=N'3@TH%+B]95(Y16.X4$2IRASC"A8I5:[+AD!A,I8B)?)R M+Q2@L+_UIU#]>G']1I7N=M[6&-ZC2L@C7Z![4XBS,M*G]K+-0OI*OAZ_>ZQ=/Q M< !-\!G$'L%:E47_.O(EM5_I?TY63*I\%+BJH_ M'%=34.6@#3.$>][=0FG$$JV36'%#$B OH0W1#&GG,$N83?A!O$P1%@(A4ITH M91A*P:H5%,=@[3**!7.BAFI8]GR@)X]^#WH7Y0#S93-Q;\8?Y:IS?/&0Q^MYU@^)@^M4/A MX?;WQ00:[D,;2?&M@%$.[BY*^PIS=5M'GSM[FQ('Q90G>7^8E?G@Q"L" M]X("1HZ0Q!"$:&)1BF/F% @@CA."G2.L 0I.T<1PII(4"Y=0 %*OY0F>&&4U MJ'WW\M&#[UD!A9/S')2Z(1@JH 5'0:4!,74!L@GFJ8HF\+,=7\#$7LT HXKZ M674>#6:3$'DU[QM I%<-P^UW0/P4&JF*'UY>3\ZK"(:;#^;# M>71#T9.?_.MTE,]*S\>A]+QX>B=^*D:P2N-I!8I&U8OR'_W\7OYQ]60/7=(DQO$<>* M_,S>%<57OP/+__KEW8H1-WO_TWXBK;?XHB]3SW[LX9#)-:-!WTA492T[:_1( MLDE7ZWRK5[V]NL>?0=(<>TG3+?A^++B^&$]'>UK5?C]6^$O>AZ'L,8KOQS)_ MSJZ\Q_.N=5Y?@7GC6:[T95D,(TQK2RSZJ;K,O:?W*?N.NWPPKG6FW]):'UU- MFVM;ET+%**=L>5Y8&"RL2T6,G,3*)=@D BQY0X10+)6+\\+^C-Y[.[ZX&(^" M__VX9JN%LPT4QZ WSIUNU_;.YMXL;$9W[NQ&1^2 M5H-&MY..N\.]KXEA.P=3VX)$8GD".7$F180ECBLMN1 HQC$@41*;!"&B[O;S M-U#)^D/_CT*>)\52D)[B]"4PIX.5;8.5UU*/VS,4/F97]>C5]M F6*-.N[^&J$Q((I#2W#C%O5VC#5QTPN_3 M7]L*L I7];D7]9;1SU$.D*_SS-GCG-=6+K5*IN[7/,T8)R1.>)O[">A?V0CT MAO#W[>TG;*U:T?'IKO*I6IY8-#@EBF+!$YQ*JPQBR@4E/A6$RWC%/GZ,M_UN MOGRRM[W5D],=1VX11V[/P#>B3J;Y:>E5J'H*,.I\[EL]\ V9%&7_?'9"9&^< M[C=-ARVQ&;=5WWC#:@6G2[=[DJ8D51H;%2M9*$**42+52".Q!MWO+ M:CKJQ:CCG;?!.[OAJFU-M^Y6=$M6M%U-N3.9]F[@F\BDMJ41X1O)O[;K1Q]$ M(T1(.+CJE*%,P2 M3A3=D8@.';>4.#IT? HZ-J*\C)!IDEB+6:I31@Q&+/'F)G&*,,96"IS<8V[> M"8-/LS/C7BQ>-)'EEI)XAW_=P+N![^? ;TMQ.]B*G'VW@-);S$B[3H:S>?H4TPPJ=1--^G13@XW'@OT-\JO479='(^]FDG!T#M/M=RF<.4 M1I/QK01;TWFYF/KHLAQ_+;.+Z*PHJTF47<+W;SXQ,_1@.KR*L RO9]%9.;YX M>B[&6LW]7P_IN6)9:B(A-HXQI@XQRZ1C)M%&.RZ8CK%#\O;LPTN2^EP/2R\F MITZHA*YKP#Z-._L;@9%B>8\*S!8J,+]?!6:'JX>#(IB9(7RXH0@_>@K]BFYZ M_N4RH2I*F ,#P2"9(N:,5&D:,V/35 +6LD2U-O_\;PAH'=U7J6S=^1?Q!N?_ ML E8D4_ZF?^X!!X$9H&5.?5?\_YT]M6S'@S22Z')^4R:W&3%/"M'H+?4R-1'I*^CV'^+H?9J*KG MQT\G2&(81P93%D8V[Q\[0+?U;_G<(/1S M]MX)?X,Q3-EH/('?_CT%;+TV!F@XZ]>7LRA$VI\5_0B([Q2&!7VKM8EZP?QX M3WTR8+C/)[ZM@3/DIO=TX?^%\7O-8CQ+XWH8Z:");$.BV][F(689DTZHMD82 M$@M&F<#*%ST$$6",XAHINU+[\':(^9)?9(5GI"76+.^Y%75FM1%1"XA#\"81 M?T;VFUX2A3O4OW,-[D2,NU4E#P-S/:S^^88N!\UYFO4:V[S@3,@#/K-4%I@U M@^NJ^)9[6BCS4"\KRBN D? )?AY[8,E^'&Z7 KN-5L<7F+>R" ([D.U.S=@F MNA1FZ> T4+$7SOFHJLURK_B,@HT!=88S%,;$),QHK95(3 M(RTI)MBJU0ITH$KU/:^$?3WCQV(;0W'U2&[WB__M7K_XNN>69(_'#Z8,>#PN M>9#9]+RCN)&W(4TLQ493IIA*$YTFAAHMC-;$):M1;D^>=_[0O),UY]WO1VQB MXN<%&R;G99Y?JW&P%1K<\PC#+\ SE$?0@KU)!/)J>-5[$1+%C41E0)?O[L+-9WD6M./@U8^R[]X1"HKX:.9QR<"FKEVBT??S<2"*0?V+ MM^JKB1^\7YXR/YAO)D1W.&:"BIZ-0&'+ MV]E1EZ7WN?@=%7.UO&6VR:+]<'6_#W-:>I9N/GE+X?!9A'L[$IYOB(N+V7;0 M?:KO/5I 3=6D#GOFVV^8W;H/.+_Q9J=7PXO?W3^H%OHL;_0W_#TOYVU<9E_S M@U.PMO\XR,Z@1^^SX??LJH(W_>F\G UFPSV\;5;G[[TVDRV4!+R_ M2#CS^B M M3&B%#?CKOW0VYTG@^#-Z5.&RAZJX+C^B[7_+F%H\;?>>2%"+SDUSP;3LZC MDS+L"-MQ>7E8XWY=N3+Z,/+D[1TOGXR)3Y MY3#KYY$O1HKC6-S>3BTV%@W4COYJ 29!G/EQ?\O*8CP%0*D;"3*E:OCNBT6K MM7MJ?#ES[P,.'H"LFTQ!#EXM+X>[9O\$W)U?"Y/C,WP$:@P1%/6FP1CZ QQ6 MP$)FY:P?,SR<]>:.#<;\XG(XOLJ]\VI\!L(15J#NUOR'A9R&ZYZ0/6S/OWBA MF8UF7<@&WXK*[W!>WWL_C'Z_;&$O["$Y2I=^:DJ$Y3BEUJJ4::,T5BA%AB7* MQ@F/VY.C1V%'X=-9^+5:>E%O\Q4T\,(P&X;M/]G[^P\Q#!LZ:0C M$C&I2OM?_/3?NNV#[Z7=>&W*)8KTI'@P MH>&3*?>./0)/<6'[MR;/25.>'$9;KVR^=I<:D37S# C7;<^Y2;EA;N&L4<]: M)0G!*0*EC1F1:A?CV+NOM.+8XI6S^4_FEKE$6%1A_^2%_,EY-OI4*PJ!::H/ MH\\PLO$MY_MG4D<>A+\+Z1 :/[FZS*_)C.5V2_MR@_$>YAL5&N5RL^B:K+B% MZSSHSZ7$0OM9Z'0@&B['57!;G$W+H%4%$O=J''PK0EQ$[E]7ASV S*_O]IKD M=3T6=*(JGTR&P1M2^(FJ.W&9EV&N/"HL-,.JWIWQ]V[:Y<"7+@>7 ,XCE5@M M"*.62(8=9=PQCG5"5[=G FE\"$*T]@G5I/?W;#C-;Q!0H+*_E..J>L:A^;4C MN0Y7ZTBT%T@4(E%J4O/>+6_49-&_ 92 $(:@5V15 43X#4CER2\)?HFG,\)5 MGLTHSD?8-/0CF+.SO B.N% 2.8_R;[-8V_!E1O\+10M&=%&,%AZR*B^_@4UP MPWB8<=4LLL:S7%/9.HS:$FM\9\7:&HX%F1BCN4X8#US)%0.)(YRF2"OLL#B( M[W4L//@X>E)5] ;.S@S2>6'T6Y#V?4NQU7<>C&]A%M%U_\JU PU[72%;O+L[ M3T#]"L[N*?K,7[+4]7T=>4SQ:5C!MY(7K)WLG+M2M;,V*+5:O<+R869N/RG?B6?_MYYJ_&@\\CJJ]T/ K.3]8,8M M=K=>^^S?6SB]K1IY^, 4,H120U3*&654^?\9E7 DG.4V?CE;?[&NM0_M%E<9 M_QM]BHG_5)=T2ZX!(GN8\:[PZ-X=O>V*)S]OW=\ZRC92,J:8)I9+ECADF7%6 M\I0Y&6NG-%6Q7?5";1YE_Q$L/#"L876RKWGPM'H=(\V*,GB[M@J GUFJ@=!# MU&:EIRUEP[L@^"EVH=Q:!? O]8;("R'NMJ")6(:W6BJ)==9IS!.6$JQB8U.: M)"25C@B^DH_L=?9G&I');U!K6V]#I\M2NQ5JUCYD>%8*+3=H"96:686TM(P1 MIXT3B40TI5HJ@=L+9W@D #Q6IWAUA'BF6H'9(6VSO/N6*PAK6FK;JSG\/6B^ MKVVCOA2@_/0 HB#XL#S&F+A48)$BZ@2STFA EQ0GFA)?^RG&+P MPT $*9OXJ&"KL*,B21!6UDK*VCM M2YD3($M]T[9D(>LS0+:6ZY3[%384'W_MUIY*ZS](+Q M;K#([(C[['34B5] ?S+)#.&W=[<<5%)*QDXK%&N9,.2PT18#MB".J7)4R8-& M;D>E!5$*,6=3QFRJ8P+:D;8TY4+&3-U[+NS!]X!UEP/S77HZ+P$NGG)*K,Y& MZ0 M=?ZB-R. NF->SUCW-P^6:GF:EE-_*D.E-E&6Q18;0CA+*06;+$D5?\$HRMVPOA0]3FUN"6\M-^!"GMY7DMA.-EOE:-J<+8.BZM94QR+0WG!",A)?5E M8W?BP-;3M*C_Y.5XX O!_SGXUO ONQ 0L$\V]RZ'#.%&,1=!%*%.TS@Q@C&F M-!$"4RJM(58AG^-O'\YG=G"#_,'H8TR7N! [+7Q=)Y,0P4R" M9"(=\H&\R6"1V,I88Q MZZS5B(%5H)&6(HV-DDHZ2U\P'/DUCS^]0??!ENL=;T6]V-MC3+B1U04C10G& M%DDM&4J93&..F356&$JI?L&8W\T>8VI%EZ"H.XS4>1:VE_,?9/Q&B7LI48P% MY8I*QT2<*HNU$DHES%&-W0ONL+[:8:1613]N$QJV7,+O5+!&=ZBH=9PA:(DS M-.;$%T,F2EE&8FY48N%6Y5(;:X>V*I+CB0'[K?DI6DW]UAT-ZIP6N^&T((V< M+<1R@A/!!;>8"1QK!J8*P NFEACRDO;*:QP-ZIP5;_R(SR8.V-P&'*_=)QVJ MQVU'P<]0 X8I\S[XZ\C^&EV;N:^NN9E/O1EW'V!+E^T=Z8MKIR\^9Y5FRXK MAPA;'E$2$I'86FU)+)G%@'A.R)00;(S0"5M).N-F=BB/R.(4T\> M"U(*]>FRZ/M,"!QDM13PU0B+\>!97'!-.L[/SZV2QS)JVAF<&I[&26(- ]FH MA. :+@D;&S#^5X3CQLBC=N"!83^[Y.]#+=ON#7HXJ/+^^\&T].7ZWOTY/F0W M#\+5A?R>7;%PNS#VM4^;UE_][>\+7V*S[W&_WY]>3&OL# I3.,-8YN= +;Y. M^V_CJMJN6=Q&Z?FT([/'_?-\,!WFG\X:JQ 6X=H:?!B!Q,O]0CQ\>M9B$#(X MQHDEBK%8&8H3(A!RS@<@$-0X/4N42*W4B=2I8XE.M6%4*ID0[0B7RMY[%O3! M]]QZ>K9_[I7XRE?@S!IT5Y^2[5^CNR$,-SJ]"E=#8?=%8=JSHJQ\:?+;3\X^ M? IVG:X_9^3X*014%3^>7O3T JZ0B25:)['BAB2,"J'!#F1(.X=9PFS"#\A:S:RU$OMW M'AGA!P\DLR<>.L8O>59Y"U^V?P>C]^:H+*B^P/BCR$[+,A_UKZ*3,AM5PQI[ M].!?TVKBG4I[OM>Z-^3P^ZC,H4UO+WK%"V#;D\&WK!AZ\#\ :CDX!CLW^A!, MK>!N[$AC/T@CV--[NQ-KLJ%/&]!KYL&.6I2 G6 MCH&BKX@5(L%I0ARF)EE)WK^F37R43SZ=G60_'CB?>CR!ACQ.U]M$=FY65M<\ M5XUW-N3_4OP_Y $]( L'J/\$4P[7[O6$ROA%-G6>%+KVNAS5Q<%W2-HAZ0)) M&^D#7(H<3H6&WS CFJA8PMH M':)VB-HAZKV(RM 246GP0QL=4\V9L,XX;1!.36J85MJL9%YX942]ZYV;4$]% M!Z9K@^E.^8<_W;(K5P0RBW[RNW-W2).].)?!2",+L6::(Y-R[F*&=6(02:FF M*8]CZXA=V?5=!S ^C\M@>$XF97$Z#1M.)^//60F@\'!0QFN8NO?%^G"R"P8LJL2%(J6**DP3'A0E++C.!:KM0MV#[>?7'CJDUW M57>@LN/^%Q;7T#?)Y6/=1YF556<%3ZV;CKQ@6'KA-MM.$?^FSSI]+ VH>)& M?A9BB4BU%DHS2KEV*A4X9EHGJ1)X):WKE\5"]8/RG9;C"SWN%W4,RJ2.R9XC MR]NQ!=9RT;9;/_JYI/?V%9!=]M/N-P0]A$ <+1$HD8BD!F&J4L52B15G!$R: MF M#*$U7=H:V$8%:M6A>*K/DDREO:_T9':#L*J \J--PK!H'&!.'C,62",2H MQEKRV#@+NDT:,\7$6T"4E]LNZ=2:?=XQ6<1&;CQ#3:OP\JK;S.N.]$W@)ENF MO8AYZDMP8TRI8YP:);7!!&$G4RX2MX$8G>9Q[FTU^]3+UM)^.SBX!_[E#O%V M$/%$(]&/C"FB3-B4.4:5DU()J@4G*-::V'C+$._%-\Y:#:3ID*]#O@[Y7A/Y M5 /Y"$76Q8[BU#*GC%8TQ .I.,4V57K+D._ES&'5;O3@[H#>6JG.7C_YV6;< MC^%/??EFCU8/;+Z[O\O<^&W[.K MRJ<$."]G@\D"/%0\%5PY)I!%FEE$P?SC1&(G2&I5DCK_3'9M%C8\M-M\OP\M M0?O]"%_K=%O RL,!-"$.HZ>ES*F1*@1:#(O^U;VY<)!,.">:$)1H%E.GK4N% M1%@8*ZA2I)$+)\5$(>>(3!QEDF"9$"PH2:CEAG)G[LT(\^![5G+A?#BRGSZZ MZ$3_/W=\5R*;>F$>SH*RSMN?TWF\>0[WB4C0;P?Y!XQ64(T#B;^MSJ=[^T%]KR$CP;78& AK8N8)(&<#F; M0+\OZR DWWXQJ:)^[7H'N3XHJMKA[E\R2WB19^4(N@.QM%P//H*?1OD MH%/X!(K%//.VG^&S G2#?'CE1^N;]JD6?S\\/HRJZ6E5#(JLA.X=1M%)HW]E M#J,JBS"R3:9>E#@'QET>DG-&4*$%&*6"8HM3SIPT*+6224GCE=#.!;+X#'BC M?C$L L=]F?<>/G\ZFV4)<;,YNV6O@O\-_'#YOD\GU0."SZ(/F9E_WQQR+\770+M>LJJ,RWZ M?)KCL[,JGWB2",V-X//X,B]ARJ#58 20!"BCH;W!I>%73+U!3#H0)5)O] MB&"V3V'*)U<1:*7?BO&T B(#N@,-J:C.:W)]B("GEWY8GBQST'S#V^_L4.@X MO'S:SPLU_]/,*V"!$45VCVL8$^;2$LXE928 0VOR:C_R;?/_*\<6"]VYV M]@:/?(=E7:"T'T6=C-+KP$//09GO,Z8M6Y.2L_SD5>SN8[9J=,/%UX<"VJT,E): /P%@1_R, 5%A>( M"N#.C]7?[C\<1EN5R[8Q[G.8Z*S?!Q7@.M'[1?/TO9C3,.G-)R^'V6@V7W.R MO"VR;]% ,9H+D9J0@-[T<'B#@9IWSX@?VF/Q?P6)-R/+B^RK5F2[<\)^K@$?"^5WO*Y:BBN4T#.*=J#E$>G:\AU M5@QG?!Q4GD"904QY*AI$P=,!VH^%X0*_C(HL- ,=R6K4^P;-@.A8@-2_ +@K M0-&0_OTP ND=G>4#P.?K&#,%"*E\PV>%%\UU[EF@LEAX@3B>?CWW),>@5Q<9 M] ADR:CFUQ\P;Z-Z1KSZ!VUET\GYN)RIAM=UR%4Q!!I>65YY9V152PLPCD"> MU*\_S?UMTZIFK9F,G?4:.@' &> 9WAGN/[PF3XJJHG,G#^#"&\G Z-^.Z&=R];GR\CC+Z)9M#T MS:4_O,W_L2Z?;M!-,;/LD=_ 4$(EB:;,*BR=AC^82V[ SA?XIF7_HL:T?*HQ M#>MQ4=3)R_1H8,/D@_[2A_5(@!. 1$&"W&MB2V1Y8C5V3FNFD="<*&&Q4Z!\ MQSS%#1/;"$)<#!JY=HK%L37<&FT2DR"5\I3=;Z4^^)X5$QL,[(\?3CZZHY/C M2!\ED?UT=/+AZ"_NR'YXOLV]3G>>,YKML[G;H=MP^S+W]'$.&%)CI?5!8V C M3)K&S;8*Z-?NTH=1]-<,J+.\FMED[22LO\6JEK%D.2'+A/7 PBA5Q&E"*2-8 M2R3_C^79!2HJ":BEI6! RU(-)_AV, MUBH?O?OSY/NX]7H%H'J 0/;G;ZHE*X3XR6BV%(M>5W5:9Z\A#:+L*URJKIL( MAKKW;Y M+1^%J?D"*N@H^BW['J5%>1%N^"W_5D3_7W9Q^4OTW^.R@B7_XRKZ[;?/7K/L MCP_"RV#R1U4^7*QA4&9+WVB@H\-&;^;$+3 ^8=#V!5?YU3?8>:?'XJ&D/%\4_9 M^D-M#.+6%]V[\+"B^5=O+7G:A1D9%EEOU6-QD0UR^ -W%,&'=09XFX=^7Q35 M$"C7FPO5?.O:^^*^9L$]&%J!-V3!&SCS^&B2_M$+E-!U[M>K2< ?<9 M P7< K4L[?"K(#M,K?S@D2,AOJ*%23X-]K:C'25=A;!'QU[:!).5ET0,& $ MQN/.@BC>L,Z6%# NG'<"*#!?KW[B9*RB16:UXT!1B&->0*$-073:<[G1;I> M@.WF(O)E7!GT#JP"=7(X9'9_ACT0WFB;@-]2EV;Z,F#YYV(:DJYA=MGUDG=J M2::"V!W=B5!YEG/I&._R%\$&H?\$LDPR%S$$EXX!D:W6BJ A,A):HG00C0!$Q9@>&* M>(O?G@OL!TXV]R"Y2>!6\7$ZR&\)8)?9>. <@.'N*I%=Q!4G(S9MAQS)60%Z MK )&6KC1[&"X'Z"/M2() @&?U@V!,AQ[S;P7ASSH:^(?A7^#(XU@SPA!3P(- MSIU$$?M"TNWG+E4M$0H;9Y/0M=Z$@K\/J\'-@7FX\LA'S4NS5Y:XD+9J;]>J M_T)QYZ4HDP,.'A=X+CIB''GY=R[(\12H-:)"@D; SFF6FP@C@@M%XKZYR'/@ M'1'H<#N M"3<6J'D0LUP3?/"Q T0 [F0,00"Y$T>"]NX R8*[]%AF$&#-RQ6 MZ K!G]EWA7&-8$;S!_EXOB%CHJX1.A^'?" MOE4&4""A;;45M,5\C@(!D0DX1$B%W@0@^0Y"(N!90']78A4SL:NOU]G#:ES, MTZBFO#]U+QH@*&(Q%<2' /X)^8!E#%2R!LEJD!^B(R&,U LR09.+>4R%YP)W M3F4);%5J% ACQ 9T>:/%SM!GUS-^\]:]"4*.&3>T74"N03^(W46ERF]QFPH>8C%_8B,\-H[-R"G=5C M^-(MV[!LV9>>8EY[2Q>:2L5&M*U9;9$&6R>#;:808I"9!:@T[:\2BO&%4F H M&X \_3D#OD;&(BO5'X/(&(!=X(GH0Y'6^/\#'HW6.)M!^P?IP"Y1OH8"0%2 M]Z-0*/WN"1<42\^)"X"5\1ZG0R$#N47%1S,B==I,_4C*B&0E8^IVPOM'96;JBT4S*,X56H(]]2N)%]&: N2O='IDA& MRFK)#%; AZ54^3:]>[C5^)'#X3)':IV?W6>>L\N#SI&APZY[QQ)I)^]!"I@) M<,X"(9$;:1M08(!7.!B*%935MDJF'@YO]=DG3-;-_4!'T^00_T -77IW@%#X M7Q7%%IC/3YDN(:;64&9=SAY76C\@5938/N-RWJH"*-SD#4[\1>/^F^)#-UTS MNZ%@";$_KY-N\17H^.07R%GW;"-Q*HR*\^>\Z06*@P(A8CRG"YMPK,#-?G0? MWND!(G\ QK(=(DM ?0MSWU)<%NP+(YK.(Y?W!319VH%&I](1L)/Q) M6S?Z3F,W>MS:/5*3M>SY34^QS+8]R!KSJ1W@AE#2[Q[Q4TMC*6F,!Z4;R7 7 M3FZ'Y/B$YV9!XCDJ)PD(",2#B!%+U0+(68&D78692WNMZPDV^9=VJV%I:A,O M'TFOF&_[,^E*Y03/':D^QOXX^_RY/[UNISL8=2<#T^JUXZXTECV.LUS&:[BTV66P!-J]'IF5VST1\_Z!!Y]#U; MB3^7DX^#Z\G8^#*XO/X?X_IR\.EJ,+J^^/SIX*R?I^SED*,\EO7S8JB_'R_N M%,.+/V]$H=L;N>.I]"=E]S)8 [M:&X.<7_XC& 9^Q&)4Q5FEJG(UKAKU?*?-XPB<"439#')C(:$.%P M4 HB #L'LQ+,%N3)3KY,O A?7(!\>V]]!8[3ZED_@W:R&9A&P"BK:C.!$T\X M%;X PQ9>W#G\;[1^4<0AJ#*AN2EW/S+(:RK_TFP#9^H:"=(-' MD38VF6P*DE+QFZ-D7&P44UE9U @K$=Q(V0;T M#\529*:G_GT8O^3#&%%4@^ M^!*F\$H<.R2!_=%$*[/9$LUF-I&F/[):D_-V8WC>;;6;YCGR3VPEVQKU6XU! MUU3\'#.@/D@JN 2.OIU-U?Z[!01E]=,\JB\,Q\_AE0AO@5*T3"I")DZ=2A^_ M3U(,U_HGV2*,/DQNBMJVLK%\F?JU.Q4+O>0/=5FK;S>A_^'@7"RX7J1:=';< M"@Q)498UE=XIFY *RQ$Y=')_#Q\N[-L<#W!^K$DG!J#Y$OU,-:QZ07\3<0>T M]',X?1>$GG,'A@\@*=\FAV%E=8R3;F%'A589JBH.,3/A0K7QL=__:DJ,>[[* M0B;-5CMK[77>F Q'P\G8'%KM27,TZ)_W1F:OU3EO-?N]YG9+1*;.R;<5"J7= M_0W_KO4W+ -];E8M6O>D26Y-AWB\P=<+X]83[[>=*:P3T'5ZH*>U03EKCSJ@ MI W'[7&_:?5;S<:PU?GN^^V&5K_9'7>L M;K,!EITY;)Z;S49S,IGTK6;7VII+_!1R_I]R7W?CB;=MUJRCI>>L$KS?.1\- MN\VNV1E;;:MG]D>C1FL\;%I@Q@,3WS:-GT#/);_@)].S56L\QPTK;67O%2+W M6T[)V7\K;UP[RC/7#2^T]$!B7ADE7\=9?C:5\BGM--EE-BF79)82A\["*6?0 M40#,P:)M7"=VE^04+\9\4IZN39+O9BJ:V3FW)JW!V#0;W3:84+U&KS?HCD=] M:V!9[:SY UE/7(;R>3ZVU]&UW#M0P:<@!F(NMSVU6;#B)*%CKX%Q6XU-;Q?E M0AY*V"I[V"?8 #9]5AG\M0U<2)$@RG60L!H%Q2>LHXA/[/:)%>!J?#B-[-&O M-PM(7&H>[)C[]:HL7K1+<14'H7*&'4 >E-]:@W D-[ ,AM@RC:' M8/9T0#7JC@<#^+W7'3_=R]3\NPG(89[!/U;O":R1(5[YFE[3UU1C.E0)-?1& MU7A ?*/$BEOJ,X()3]N9$UHQQVY?/;Z>D'LI6X10F=M#? &.*^N5" 3R66(H M\)X9.77I8C$+*\;Z-W3[UMG;G(,HR*:K!,1.UD"&<@&@USL'DGT^ M-],+TN;]+48?\4-TGL=P>0G35.L<.^J.V^,AL%S3:K;-4:/?F Q&5A.LU_-> MJ]%O/9^KZ0CNV&R9SVN=5K[T$KCB ,TSSWIWV.V.S5'WO#^9],>3<:,Q1C_< MV!HWQ]9@:R)K<:ZX8R"';O=H>5[+S"*; [/?F8Q&X\GHO-NT1MT6:)UPR8/6 MH-,93CJCYW/''<$E6[U&Y9%[2SSVE#URK6865 /./C8[YZ/!9-!L-ZSSX03; M:#5:YZUQK]=O- [QR)7/]GQ=OYP1A#6)([??.[UJAC3#%4<[CH>F8-Q-4/5;.R;HGJ53".L>/?CR2U6(3V8D-H:M:SQ:-0=-,> (N>]_K#1Z35; M$P"(U6E80RTA=3)LC%IM4#N:P(K:W>ZP ?@U ;NZ.QCT.IW&@Z[51]^SE9!Z M]>?P:O+W/R>?KHW)/^#?0]-0G[*#0P[PO6FHSX'P.Z?IO+Y;_@FP.PCT>[GE M/Q\@Q;%]A-2HS$):'>]J?X\38;FD3.9J>FLLDUD8U'D(ZU<.]WD_:(#T6KD> M=N:P,VZ-&H.AV1VWNQ,@>@! IV&.^]WS\?ED9YO,P+_"I-6QW''T1814!3^6 MA]M62KI_;_XK\9KF&?V;3>O),[7K]4KDYO1L?+[+L%#O?EHCNTT+HU$WS>>Q M(6T#U5JJ]7CQV]5"&JU6MPT7W&A,SML]&%XL7'6W=M&K[(^O)L:54*-2PD5UE8=L"X6BU[1+UU#$/[ZFCJMO: MY[UF=SAJ]SK#]JC?&O:;_<%@,&I;O4D#I.1QSJS*S4QLX9@W'5'.Z"_/8>Q< MQ&)I6'7CC\&GP2\3[#XM">'*&%]N9R5 5K$502MP@.>!P"[-_>4;%N7W M-%3]*3[?HBM(W)TX#)^#*?Y3&-SICKM7L$,.5#TN$3O3FZ&(,Q09(IP)54&' M2H$VYD%V@O&XRCF).$>!N\22]AAB:@+\+>O\(0OPP(!0C4<\=RYD,9[RBNJ= MAN47/OUZ;?SB!5/;4\].0UBO;GQ.0NQ'ZWGK,RQ"<_*#*"C'PI8SMT!_6:PC MZD>P IFHND%R#1HV%L2#R80 MR_#2B\B#+6+S8/'-G7'K8- (DY^-7X"E8ZV;[*RRO?BOV.[C]X :T-KNG>W+ MYK3P^,_&%:AI"V%'L3&(W)U?OX*3V*L P?^'[8'$D!,V_N&*&+1FN00V(Q:P MWF\VW.W/], D"8.5J!N()=AU0L";7Q\>^"VM4XP$ZIN/.J75K;. \MV#IS@",8<)Y M5%2CBCV$$M7W0-)O77VGO H;%=7T/W$3[,CE#C=A,"/N1XD*8$.R+@[F14!P3I>A%V+/HSC@AY5FO5,A M"1.'X^$%T/S&#*F89M*34_I;BLKU,O*@,NZI3$/A[@1G$V)/E&26:W26,M"] MES<;W9K5;QS@RV.EAX4(-8U9KFP9C-Y_5V:SUC4/V%4N6@9ZPRHLZ8D2O4&'@ X@P<\ MU$74R\@%(%5NG&^ TYQ\]0T1DFYM!L8*K# 4E@3I2I^06)&8,IC0I:SJ;HI.S7U8B.+9WS!P,).R%-"CWKP MJ+0;M,W)-U\K1U'F3C2?KT3+FEVK(3D 9NMGT6PPA\XM9J\_FUT=XP%ACYO>] MIR9;O&H3AMH&CLYVU?PQY0\BO@2<8NG&3D7]_RK-]'MFP#ABQ-;@%T0SOD.7X4:+ MU 6$PZ=!52"Q0/D*,D=<^4$Y_ S*"(8XJ$,_-DB/:EJQ*#G)[)D<.E^C]& 2 MHLKG>!/:2Y8I[.'DWNSR5>3A9(@CKB2^PA; /QP-C28A?0N_#S_[Y.B0&0.@ M/2("SQ.Z[B< /<[""!FV$9VDV)JM6=MZ'[7_BZ6:IY2;C5?I\D"$4>0LF 5EK(P;K=&K?/VN=4R.VUSU!PT6N/)J-4TS(E ^ 6/9K]2@QV,+VSSVL6-77YK07%DRM2(/>2J1OYM1R!DPY(J"B+$2>ODEQ 80&ZAR -C*KC<=KKUCJ!ZT+E\(9(]$][U>*D&8'1D:R"MBZDRK?.AT":8>A2X89 MVM)HU A4:SP_$'CF<.*-T-@L!FC:Z+4#(\?S#S [&?@G:@!;V>%(3 M!?0ZX!A[6F4!.D,0D@\"-8202G7JQL3'' 36W>W95YR7**]/UY-1K/N!'PH< M<4?R#D3Y6;(RYH)FH$;4@S\,)0BUCIUH(*83!97]#0#!]@9],'[ M3V'S=%+6;-!"5]\-9J "1Y61^00C$ZW'M#]%FF\!)+NT0Y?TPXPFL_G(TL3* MXMU:SP\D1'7;J$*R\P2+UE3L4+<,=;=@SG-*WG>%5SML2=50))WOA(3"@0/6 M?O%/BAQ5HXR:5&KY5#QG%N?[J*^H:'7>$4;(A?,_Z-LU-0^4>W=("L 9GDOX M$V(?6'136$B0=HC(&80T("UKSG;Y:%TVA)*CS?%O MTM[R;+^6D0 ERKN ;D)\]=8ZG)3;6(M7 &]G24SQ1/RN\#FGKI9WTL+G;F@L M4._CV-TZ==S7X\\\0?38SBNP9S7!#!>9&H-&X@KUH.31I MPI"V8S)?<4[-(\X<&N<5""Z$QOY8*((U8*#KR$W]NRJ;2?E>MP ,<$&Q'661 M614O0C/4SZ!"@]L0A"HC2-Z+_CA]L!D"5:Z3)%X $_I/WN+4?>G G937B%)U M0OXBIIC,I!H0&&CU9+>K\TB,V0"#Q,0E5.,_Y F>$VUF8-E*\J9"$?P=GIJI MWW>0P+6[A*-\$G?&9;#$A+YM4H_! HL=]>4[UXD7'[H]X IH:L4.?BA_^(D> MS3U^BSX&.)]D+W&P>KJUV8+WYW*YJ73O^YA/*ZV0MCJ;)86\]_MW^AV&<6M/ MKJCR/71R)S; #ID-TJ3!???29T2QAQUGI&OYB5"DPI1CQQ3),)';)BLNUMFT M-#4U$I!%4[(V+4;CO?3++NU_<0Z)-$C3U)#,DB1AD29I4\;GBB-B: &S!YO\ M"^@ 1>8]%<2OR(.]M?6SW-YI%S1O"E_[8_TQ'-Y7Y6KW3M?.F,BQK'HJ#9MV MJ+]P]P\5-L60/S79P"], S^)C-O 2^#R5H%+7MZ1QH^DE&(S.PYB6\O6QWN_ M@=M=[5J&^O5)?88OFC,DZ\9PQ\.DQ4212/TC^#1Z*-$VU]N IM5E&^A,V9:9 M1R%]+ W8@4:&J?4JB41YC[VU%/UD6N2D/V6TPJ'1J\#?EKP76&^Z+NM,RJNL MN#::./I:-6UKTO+ 4@,.!^CLGW:WS?-MM0-*G4U9O]3)*&U"A?IS%,QQ3 '( MYTI_O7RY_M):IA_)^(7>@P;SI8UO255E M07)T1C',/(IE*Y-T98I0 :A(N5&RU\FEP?B.9%2"XDIHXFI8DBY0,HNSA&/5 M-1N+E>Q=MM8LCX79I:&A@?EC"OG5,#!J/;K $M:9O0+,\#"72,[U5;S-X%01 MF8^RP;,DM]3=LAFEIB2J4[_<@)-I(Z&/%@08(U9\\!,I*S M-4QS>#BTA3J#Y.0I$X1CIQQ+&TNL+:UO5TKXO=]1-_[0[!LZD&;D )6&2")9 M1'*%)A8I#"G$L9G5F;JQU.<4I>D< ATY "V,U$NW&K:_PLW"?]4&/S;&:3*/(\3J,A^;T$&:UB_4PE!\0G&<<@FN,IH25ZS*IJY$]G8ZJ$5Q MZBG#,VELGXV2^#\L[7R\6>R9!:$JX#SRW:?;2,7 MF=JHHS?P)B 7K(PK1 I:C*[THXQ?L"C*8*6=FY-N9:1$:;4JND;QME2"X2]( M03_6_M=-N9)W^QZGU[5)+T"$[ X[5*PMZUG!;, MIQ5E_2,U465I0&O*[Q#?V1'J1*_FHF+U:54U;,O42-&AS)%>4EDK1,CC$6+K"D%KKD8AQ% MQG_(\+V>$Z5Y@!Y,B<@VGQY9W[IZQ0B$&O=?(\49G5'LXJ82[YBL3]@M+V?3 MP!"V;_F$9'JF7# ]=\BM/+1J,^*+:BT])$LN'82'K.VX ]P7)/6U[7(85&P^ M"QJ*\&\ <)O/R/*'<1KWX7.+D2,%GHN"C+SK?7;)4RE+V1UKOFNU1:VSV MNT-KTFQ;XV:OWSIO3IJ31GO2:O0;[2>WWGV)],]+6?P']/4YS6X^<-A5F;)& MRVE+7>?Z!,4JAY",W9@C_#O:6D1;T0^M!':CVP1LV*4_03K8/ICV="Z0V M-KJGX>_ZMJ ML^ T/()0^ML[TWKW7_<&H_D=K?X/6N@Z_YEI/O#9?A^=SHI/"N_G(_;8E$_' M(OUWF:JF_XG&E=%?WMVGY!;#2>]I1RT!D&)3^]T#!Y5H*H]AKKYA%J3K&']I MT/_V L2]QY:Z?2&\"YWY?["3>4(UN=@(Q6@V:M^3'\&;?I;;QBSK.?#6#PO7 M ?94W?8AYH7[[J MBWX;%UU1]!NYZ%T4_30Q/K5G7V^H30\:6D'XX2^SF1#S^;'(]T_*=-X#U0L] M^WX"G"!5B"^^T:@WG@,&V5T^&Q"*PH4?7AL'2L8'*^2OD+]"_@KY*^2OD+]" M_C>%_"?EP\L5_N]SV2_ILRT.M?O[8?8CAWWVV]J5I H+ M*RPL%@O[%1966%A)Y"*Q\&UXB'^A?C;6:P]5%H669GO1X.0 MFV4"%4)6"/FJ"+DY8[E"R HA*Y']0OKDD:B-GS=[/48?=E_2X]DF;\2H.X'S M57=Y.N>K[O)TSO=F[K)0ETRCM,)5[T HQ>OIZWDM:S\G=NGTO,KP.!&$[%:6 M<(6094+(9GUSEE2%D!5"5ASR55PSY54?OZ>'W0L93"\0?;;JO3T.4UH>>.JL MKJ18U*ZW*RRJL.A +&I56%1A40&\:!_MJN1*U-$[Y\;8>QMG5JO6OO82)P_^ M9\ MK;#PM;$0>.%S.*Y*KB\>>_7J!<_=IO$HP=9DA]/-O+#:)U(44YGIIX&09J^^ M3]_D"B$KA'PF#EDE2U8(62:$W+=55.D0\J0\D9_E+#92(]]+/^2/-9PY]69, MG^=QH9>689X\7SQ*),01B:;U'.>M$+%"Q%/#=->'NG""9>N)8*\2L/6<@'@R&[QJ2^.PX40T! M?<,T8+8+B&I6-%#1P#'3P)[1@(H&*AHX&1JHY,!]-$"6P4^Q#<=*_T[_:EOQ M7%^<+02=Q;0:/SR3I?+0&PN'!O^*CW]P8UAXQO:#VM%WG\?8\YN[]G&U/=+Z M>V!#O[L^,)'X0[,%B/5,K.2U]W2]$,8\\(!G B$9A,)&).((_AC&"R,4M\)/ MA#%=&TL[_ JV(?S=B.%+*U@O<"*P%1T@^E@XQGO7AT^")+)])_KQP]//N7T, M[>D<,\36;CH4\'=].3\(E[:7XQ-F@[D"'VTF/$]^^K=WC7?T.VQSIG[? ;IK M=RDBXY.X,RZ#I;TE4^Y<)U[ CW .R>J BWGV*A(?U ];%_DN]2-DXS=Z[^YW M,_ [+/.'G]]M<5WY_OL_ZN[UK0<^ZA6]8+7Y:O,/8/_Q!F.?-'C';-XW>8?< MB2_I^9T!3Q5A,6(E%,+X _Z\B(P),&O'^"WQA=%LU-ZF>_^TK_O*_?;DRWY[ M%-XYP1NW&N8^V3^G1,DG>JW[.+JJ:RW]M5;4>I+7NHM:WT:@>K"$O\_LEQI# M\WIYJW]]#J_[Z[J2:YU65>YS[*SUY0XNV3.Y\YZ>#U1@'E.A[6#VBFOL!X(J M\/<*J%])E]>6+OW^7HF'E70Y%A([)>EB[93 M)K'3DBY[%0)5TN5MHGXE75Y;NC3:A1)L)5W*1F*G)5T*;25_(M+EI#(1^)IU7WSM ,GR_ C<:M:]NGB]VI8]#92?D<+U[&D5;5A_SH\?%4N:4%VE\UW/C8L?.4,+)9S;4Y>GP\56[9 MK#6J5,:CQ\Y3PDCK1$:*O&5\/%5NV:[US*JLZ-BQ\Y0PLEEL;G?)G9='XJ.\ MMMT[^YZ12\<>7:EUK?XQ><6KV$H9T6B_ 4D5$I5 92LG0IFU7K_B2^5"J2-$ MH_T"&Q4257SIWFA$KU=E\)8+I8X1C?::/5(A4<67[F]A8%6BKEPH=81HM%_Q M9\F]3,>>(G<5)/'"^#T(Q5M+E-O+-54^9VCEG#\-?&P4VS2RPL/CJ?)*JUWQRF/'S5/"QXI7'C\^GBJO;/8KW#QVW#PE M?&S4FR>!CR>5(/>;O3K1_+CF/MA66B9WZKRLG#C4V*M>K$*B$BAKY42HO>8Y M5OA4,:7<<7J6:>USG@J1*L9TS]$Z1Y4]\ ;PZ0AQJ-*6RH9$1\Z4FI6V5"Y\ M.D(<.D)MZ8WDQL'[[%40BK?FE3\))VCEE#\-=-Q/9ZOPL4SX>*JLTWJJG#[B'#[+>'SGHU,*GP^(GQ^ MJ[S:K%GM2A,Y=>Q^4QB]7QYBA<]'A,]OE5LWFWM-:*YP^XAP^RWA\Y[M5(\. MGT\J2?(ZB&WOX&MKPK4Y03+U1'IOA>)H4:?]ZW.>]'5'JINU5N=P3\V.XY56 M;KPM\?#<)%:ZN#"SEAPIS*^%0R(R[D0H#+6Y[V?N;;/>-N 9SPW\O5#1S#-M;"#@W[)JC!SXZ8A<*.A!',#]BSU:OW#]YSS8 ][_WM9N>' MO;];9\HS?@W\&^-W_,=7:%\SHF2*/4]BU_:\M0'_(*CN%NYLP201+=S5"JX] M#HRE6$Y%&!FAB%QD=8;K&Z.%Z]NU%,[.(5#NUKNO#>7>_E"&-X-L>10KZ\8U M/,$\)\7..SLR5J&[M$,7+R&.0W>:$ M'N..2$>@%3G#GPZ48"_M6&%,A?$-\ MP_6%/Y.W$22A,8A$; M*+AB 'I-PY!T9>$414:66>LU&OO3O#V+73BXQ,+#+MKL'W+1\S!8$E]EPI+, MM8-WM?77;DU2TPS6H6ME8L(K2<$*5[<* R>9*6ET&WC)4M3W%Y;/HQK3/_SG MS1UI&YB!A!;AAO:SM>,BM+W-1%;Z=Q&J15;VC3B; HB_GMESV-('V[NSUQ&\ MZJ=%*$_SS%O<95\\!LI7T80^)S%P=:)PY"(9)Y@FP$-$! 272HU"V+U9;[XR MMS<+Y_::^K5+'W%"8&"^,046O_^NVXW]=YWC.'C-)+X-<09G6(H0)(6Z;6J) M=L N#X%M;I<(X0'L#6PVY/GS>018>!@$K?8!RA3L*=L<%^ZR2']=2MA!G(_? M<5[M0$B#:I=X,3*!C,1Y5^RRTHKP@KQ#];-US88 M#[ ;=K.H0RYJ_]MX7@.U593I]Z#Q4I0MV+4*L@4S*BS,,+3JO;=J&!9CAY5, MONSVJ+[JE@;102K/MC9P (-TQ%R$:.>$ KA0PF&1 W3:>J, ><&Z348,H.5$ M;H0ZSD%FC5F$)08& M[=S:H'^SK_& >VXU:HU#].Y-,-K+((SA 0=TH##PO"40G+&R9U_M&Z%PLR#. M ELHA>9Z\!9V\?%?P@!DR9Z-@&HNT&+714 OT8N=P]F0E.0@D)7G ' MI@PRPECQ0UT=YX^]X ;DI#N+X(ZB.*I4L1=E &;1V/R*ENJ),IS">?1)7=$S M,[C4N'N% +EV3/$;\H"UH])?3.XB]5X$&\ MV;K@*Q;>C-*(/X4%),K$3C3-@!W@L"^*C4KY#]K!TL8_DH) X S\LYL 74DS M.UH09 * <(@*!]P QG=!)[D)[679+*)2NI"NA 7\2E BEK>N&4X24E@HU=ZEJK.AL2QMU\^\!PJ E D@EBLO6 MQ M%@I/4Q5P'78?2-^"C>CM>:ROZ9%Z^,EQX3$[!-U#R&B9'<'R$0:FHKS/0LLN MU/(C_%RF CI%!%F6@ F\9)2AM2HXTUB)Y"Z@# &V(5:5L3#I=165"W^&Z>S7 M]K=R*2*[]EI&U61 *(H@C.UOB*&W+B+H@76[1>@@AP6GK2+B_.BC#,4LN/$I M*KW%E$IK/B'LT#>QR58/@VF["(UI-TR%/5L@SKVR.[W,=UDW!BBBLH2PF;U" MU@)_B9/0YRQF-W91K*R0D%F10(@. Q1B\)6Q"Z"/@S#2<7GNAE&\6:#,T@X, MYYF[(O$Y3^ MXOZ7UK!"VA&P!&@W*,X6=HP>$$SI8'Z"V6J)[Z#F([.508D" M=@>RV@XQ"T0JFC[*5/\&]N((L:2T)->_%93[@]QO#MI3#.B,I\,U?3#]_ZQ? MU2FMWW5<.W2Q$.B?F#,">P]=VO]?S7Z6U:>$+7UM-UDK'/C##@$UFV9-$A0( MZU@K%[ C3=[3=HRZPK9+R>:T]= MSXW7P(+%K1LD$9P/C@R*I1LM&%2/ 2]9X;'$-XR=P)OOW8PD02>9"0UZ,1GK';Y@&G@-+?'3_G0#=QFLBVI%D[9PL&*5JJ,0Z2.*QI0+-3@-<$N3MBV/T[5>;R83Z0OYJ-0GP\&''8 M^^MCD&E84";OV#PP6HB"JPRX1HH5)6,[H*%A[>0": [$K4?,Q,A$?,2>NB!T M;UR4L$L;5$964$G3UU0M4&X\JBVY6PC?6 'W62 2U/#04[&%)J0*ER9]GCH# M'4)T :JXET8,TZB4' MF4? 3@KI1K80'CG)IK;_%4R169#@_K#>*Q)VI&H("MAO(0YL?;<1Z.(SLDN0 M1E1-,2K2_Y)*JM)T9PD8"?YLS66>@5>V\&4)$SK+Q!RHA@NLKX L=KI+MGU( M+*=_4?:?*\VSO=]HU;NM@V2,66\TB.X/9FO]=@&%0&1J!^%7CNR3@@H2*/\' MPR[-A6L*S$':2P'5/WI@ =7#NV*!5K!Z4Z-PBE;[&&Q&3T@.D4HF'1J8H*?Y M;LH68RT9GRZC^33"*R5OB\,:OW:SA]4@6HTBTR#80_JJ:=X']<^Y&N_4X-QQ,SN:]>A:DCU:GMRVI+/U/5) ML_?C(/6YJM_7:<3;$:L@S;R[KQUPKI#P%UCC3LO(:!5.*T9VZLY$]KH5L$I8:GG*/++S M;#QR[OHV-\'6T+]TN/=JBI/"]"CP!*,Y 27P (@((KA1T'P!6U?VFEUT[TF_ M"9(([DA'10 @B6YK_I,>)[\]&_O&N_H=SC(3/V^ \37[A+0ZI.X,RZ# MI;TUGX6+#'E[V.1"_8%'AM!?[EPG7L#3 PY<60&EV"O(O%!_;!%0N_20>+P M"(+Z;^_,YKO_NG?..+^C:?WPLWIH\S-SOX^*7_%%7]8[^&N/#W5_XKSZ(YG[ M/A8SSV8[V!B#)K\12GXC8Y)2JFN^*_6M2Y9: #1 XS2ND,U7%_XV+GQ TOQM MWO;;N.%+@5E_;YB+OXUK_L+Z^WWW_'0%!DS4FQ"8@H,*:A!^^,ML)L1\?BR: MRP!L>L^P6APZ,=YC[KEK>S_N@QLO"8HR$<4^Y[L76)+"R S;(J]RCEY][-X? M L->IRUL"&:CWMS,:CWHQ*][>?M.:*T(MPC"/3G:?'[R:];ZG=JB*Q MLI'8:^E'Q6F*?]AK/GT_GUY25B!4M_\LMV_>?_U/-A:.TB9XFU9PZMJR'G%M ME7.Z>Z-N[C/@\]1)T;V]E$S]@=)E3E9\8:2(D?%&S9LD$:MT>U5W*'B#M7!JX.?^,') M/OJ)&B&D?W?*T-NCR"Z>!6WILV_\EGAK-7JA6[MWE 65RV-36S7$ KY%G;<< MU5\#GO]KHVZ:/-7"D(D3.Q^RVD;@\SP2;KF!?3N#Y3+ W0?802:)HQC6 9RJ M&U?)+%N!IQ&L[#4UNH O#)*;)(K3$V!30UIC$7C8W N7#KE -'M8^4KJAJ&J M"N$QVU^K"1S9VW!+N,5H:X\TT&$JU/P"QXUFH=#G<&R#L:@&.*>+D$?;_X9Z M+QW>E,HJHI]K[:$F4 ?LK5G$O"=7T4\H5 _RJ+Y?HYV2S%Q[CMY4_Q3 6CQ7 MW H>S\*]T^34&1?]C=CMW5.S)6I&E*QP#!"W^"2>"XQHP0.&'+U'XF9WUV@1 M))Y#C,P1P-MC&DXS![W X#Y#QC2) 11I'^+9RPZ(?T9I]0PD2*_Q]'NLAEZ MVMLS@ >%();-'/:46X$5AP).0'-W%O:M(.D4P0O=.>AR(+ 2GQBD'"."E"V' M W#CZ[IQ,<]&_E #_:6]!F$5B^6*FI_SN,P8YP.$@BX<<2OMEZE:& /G^"IP MB.,4F_EQ*VW@)'?I[G)XJH1B-FRH7$ M(:E_!O*AZ9,X(\:-N"_]+&&Z"D5Z MP7HC1&R "I\N Y!\[A()'U$BO2HY-TN;(<$S'GX)A8WSQ[@1/@N)Q(^IO>G= M N>"Y?C,DII/1X0XA(/<%=;WQ8RY ,]Y"A,WQI:J- 2/60-.OJ6U9*?5"!D4 M;,F.C"O0[1;"AHT/(M>N[QR-Q0=5I_P#!Y#2\!S:-DX:!T@A;Z$U08JL@H@' M?:;3O'#[]/C9E!J%+VT_F8/^P&H#X';:"KZF&F#C!ZL$OCTS;&Q;R"Q/MC4, M%2?=.!1>#H$*:0A?"'SN;(D-$K.'J!4FZ2\&B#N7],-(A+?4(S%FAEI#YNK3 M0TXZ+NM787OQ8FU\=.>",,H84:B)9GG@EFB>'_9:Q!FK9('1R ,/EX6_XVKI MC/80QTN$(F/,MH2G0]JI&E8,7&2&HW+5/"[<"EV2[44!8T$Z*"["85X9AL+) M_@#8AV97I]<;M/K#?J\S:;2MP61@=BUK M,&YU1LWSCMEKX'>JF5W\:WYFUP@>0X\)#11,?&*&7P(@!]4'>@(,<@FL--I; M#RY2XS!/>?H7,/GE$O/J)"O6=2 [NYZ5NAZ0H&FW>^!(GX)8SITP56]0_!/) MKA$P7O1+4R/O\U2#O0*>+/DD+/!__M*SK,;/%_ GHU??_1BBQ!4HX![]CIL= MV[%-WS1_5AL?^'Y"D]]07*,X/P?UVC ;9[^#]NRIWN\T,1,G.3K\ A"88J9& M.A'J?0,AXM^ +$!%FR9=&^^O)J,?<4D>I&DVE'OCFB9;BY7J= A;R33U*'=. MFV9G8C]?WH@.6Q":,Q=.%ZD9ZZ PN=BQ>-"=VP:7C18PHW.;"5X4(WP@7F1 MMP6 O[2_"I373$=J\'<"RBFK%C24:Z M2+_$_?75?04SJ7JH4:_XO([W&=@ VU&M86_;'%47W ^ -N(&V_(6C06H=$%( M/ TW AH?7C1I@&I>CMSC#/.=Q.B+!Q7+@T MG*8$6YB*^$X(QH^-JP95C";<8L-^T%ZDWTW^3B2CC:E0GC9"!^&4S*8H(]M, M)=@N%DE7G5T'-02?TT!A4*&G 7$AT*@E#>J7*T?Z(M:&]AK^H(;4:N:_1!AZ MR^[[9%K77R)YA,8BD'F:W9\CMG'DS"X7M,]_)EVU?>2EYQ 23:\IK=>ZBK8Q#XR(YW1EP MG\TL=IP0/U>S)M2P7%%-EWB2$D>/?T"OA3O[&?M"\@5>9A)/UP8"]&#L 1!T/.BE;J"O1=U:B%H4"W'IR4(5 >USBF(B0%R??!I$S4"@""&I"B"QUXV!U [D2=3,<84@:C!-#J?L*)MC M+IE2W>"HF%(V"AB94H1O'Y'I@/A"$1,Z[7),"SX,%(7/?0,YO&+YZ:TU4@-+ M(KQ!/0V@SF2I\YETIB>0!,ZX)\*I@]U!,UZB* "!KZ9K$HN3&O'&5W' "+F\ M^.N36Z5M D=BU59)6E=#=-8>Y QYJ2Z $DE?9F[&WPUFH,"633Z6T,L\\O\%888'CD[OO$ M=V(:@1TJD;K"&RWNO$I %$W#X-L:A'KP?)TC&_,7_'<: [Y.!>S M)./(2\9@Q+WHQ;()[V9_R=!J'3C/ZS#!U&H>^/H[381O,N.!A[-H;A8\"Q;( MP@>=<+D$K0;]$*"^<)Q%,_\Q\X9=0(K>*""0F>I(?ML7@C$"7WTU4C:+-+QG M% 1FNK;]92E.@$:=6YL\"Q3 2! N('=2]>X"I(T(28?38F&@D2L-.;4J M9\DR 7L,E:R6VG;J:4T2JXP(NB!$-"KG2S M@:J(WE/')*0=KY2"XM2G]@/).S);A MV&L2)X$OC+6PPYKRL+NA[L262V/^2NIJ(%U3+O0#KM'](;,[%#O+'9[8F9D] ME7+*5\PFE*!7<[*/G\\<-OAW)ZIMH_&!DZP+$0H'R26SB%G:E5QZ5"Y)?/H4 M9$$-32/.0@*DBD\Q>*49N5L,$IFGB# WI I*[2/RLAAVYL+Y?G2[V':A@Z@) M_5Q(A6432B:T1U/_ >$JUL&LC&G@@RES&WC)$D-<+CJS<"JH5.>9X]J%ZY38B^EYA/1@Q"+N8!@TQ?FE8/>8 MLF?_G< VYS*]+TU)L'6T39>1=Z.P$U^F:5H18 N&.OBR8W2J<4@*E3=->D=" MWQ@N,A7LRP.M1U#.C$TIY_Y9^@?T.]N4+2[7.0>Y3SHD !4K=#"%(%V5ZR_VMG2U>A.C/P=GG MN'0.U&FB!Y)F*&[ F \IKG7KBCMZ4[+"9).:X>:RM_,)%"J"IY^'OU@F=FL%,8WZ,@XA@SFS:9%>V0P'V,B\LMHS!?LHKZFK* #\UB,L7*TZ[E& M:?*!9.]H;-^7U)?E?7$JHRHY@(5(^7@P33,&;= FJ8OYE$D53B%',&'@^%3*(6]M+E(H 8F'* M6UISF@9&%-/*4HZ-3$&KG;LRY=1/$Y'3* 4>5CNCK#:V#7X/I<*EG@O2O>^R MXCZ;*!QOJ#,L>4RD-XTRBJ;177P2S8S-:];__: M'=6-86HU$>QG"Y_<;YC:&Z?5,;C *HADBAS=O0*95/0T= +%YBY+E0/-@O9( M.HOG?A5H.V *#1XTK7Q4BZ>9H%$227T&Z\B_V6G2W73-QTGB11#*,UQ3(B_F M*WV3^J0T02)=J4K3E#F<98-6,7-7"D_DUK2B&%H#7N79K+A1/G.:G*A YE&" M19Q>!QUI@1$@,#JY&(N..W?G@('2T..WN8N 0V13P4D2,MA-M6)I4A;G8:E\ MR[E+D5:Y->4Y,Y1MCBH%/BBW2)%US$$E4VDG6 M$B]A,\E,4"8: 9Q2T>Q<_D&:H_H8XN?"J!J-9N]2/( U=K3#:?LRLGOO/GF3 MBKMEK#]+9CM Z2E9L*:@M@1?%&2(EG+2DLWQE. S4484R$GZLM>%='SDD2V5 M;D &G".-\7!_Y[T<6+]?B,5P8/2U ,,)??V[G;(8IA?E#J.@:9*W,&H'PK1= M;ST73'6LK4)B.^^RCJ(TIV')NGD9HH\CJRLR_8]U*56.@^7X41RZ MTR1F'9SD%#KXX&)8X*4I69T^9+X23*GYJ6_J"FA=+^F[43M+]+541%I\<4"]K M%["KRDA+1KH'$+$" 6P<9"VW*,C P:Y!L@_RJ4K:RCOYK13#4NW#?$@"("CX M:(3$(F7R];)I5*Q'28<;*3":Z34G/ZJ$(/=MX%0SA@YHO:'+]\>-D;2\H_1K MJ#VQ!I%JE0/ HCS>ZD^+;ZJLK=V@D+M"]?0A4F+A_ZA.$LQ'5R43QTSXRK#; MC>5V:2[@A-K9%*0__5/SS-^E_6RHG ]]MXJ*4MTV;1R3P.]S-T*;$YT!Y#3@ M &;Y>:VT%FK.0L\*Q569ZLLU@@[B7S.6_O"%7^G#N?=K'Q->ZB8J=IF>GR MF-MBIVH>-9*0&!!M5B-IFKN:-0!_V"K1%$/C?.#"1I@$R M_ZKIO$J:I\HM<4,9C^1T1P]\XJ?Q'ZX\SMO-N5HWNJ[TO%H!IP>FC,>.$:): M3#'$A7@WW#C"^5+[#L_-#L#8;#1KO7[0P:[U;[?&AU1Y/!^7BTV?GA59LM4&5]LV[\_<_!I^N+Z\'UQ3\FQN#3&/_P4?T^ MOK@:??Q\]>?EY,H8##__>6W\,;C\?7)M7%Y<_5Y%C1_>TW:KSSG]CQDS:0I: M=2Z%%G,1-X]CLT@NNXK]V8"Y$\H+&T2REHA2L*FZ,&5AP)=='[VW,Z#C2*3] M=21;K,M0L?H.I7UK!8"T+?2GA10D3;5!U1.!ZV;GS.=XE9(%< X4SL^'"[N# M#1+V1ZYC*:'8F(P60%ZW MMNNA1#\#A#^C-)\H;0I"PAPHA/I7D5 '0>:A382?30-JF4K9 4K!<,0TKE': MQ5K1*)9[R5X6Z+%T!'G<(]60PN4&+&D-?AJ63ZTY=+8^M$O9V(RRY4**UE-+ M$4P<6;@>:D_?W"5'7J22@-P&E:Y\X8O6JPNINVX,!1>A! ^"5'J5*<6)G"[8 M]C#$CFG8$0S[)W*8(8SG@><&_Q]VU7!#R59G&D93" M1I4H>>N(C+(M.SN-16V 4Z9,J]=20C0\H1S2Z4U4W.T [G8NI<>([% =]I: M![E;R5J7'1-[4TJ%$L\S!6 6ZUHG#&YQR/F&^28Y@@LN98,AN0(R$JW,GC01 M"@0%GF>'=8/J^[EAB-8M9TM+(!V%#"QV^X=_*S>^IL-%X#*SUK MA[*7H+%.;/CM,HDB%YX-X9:2B4AZ'_P1P$_H"&F7N[0]9& M[P=Z3_<'8U__S /8)H516J:XY;HN_I6OX0Q_ANT\L.0.OWMY]EV@L^YEH0I$ MZ/$N] _\+!\5R M =D&V2W.'=#9-^\^EQ6A,BZ($,.6.#.=[#/NO$+\-X# MT@2>07LCPU>E8+*+ '-C9/H3-C2CRN$<>'0I0(8UW!4&@7/5'R)M'AIMR(VT MGSE5*J>M)V4OSK0GI:IMPI(JRJH+,\"5$H8)4!-Q+-NGK$JOF^ M:B](65C<<#V[;?)+G%$3G?O/C!']A*[U?LQ& 1J"[*M1D'F?"WA,J)?*@C N MS4SE223=%1GS@T/,;=>3C #@!:*"^^PL;.RI]2@4[NVX6K8^_/?IHS)\V1YU M^GVK-VF.1N-V;](9=,['K?-A9])MMX;=?J=\X^T8/@*A%SSG7Z><1SY>2T-7SB:PH4*ILSS M8A4..2M792I^=-]>M(;M,QT35BDF&.^YDQHE4(*9<9D !S:;]IG9?B]^5.MJ M'?-3E_Y@1AX!L]]L46:+O>2UK",!ZY[" M9W53RN"T4%C6P*A,.[DRSQ33+BR?LB,S"-V8QAA0=SB0JTNL_@%50)8&Y^Y! ME@]C<]N::G>//_*DA[3=0*J1:XD'%)Y4;LFLKX+\] FC$L+$DY_BL2/57D@5 M;&R43>E4APRNLL7,A=*9XBOZ(E?45HF&1=4TT'@ -7# 3AP2X90 MW-BAP_5"\BXS_,B5(Z*>;/F*P*R5B&IJ^_(:4A93IE8R M,ZJ,DGR4I2M>J!&%4J1SDX!L>,JERO8KDVS?<:0R"GL0 NBKDFXG+4!"5D[>9M,H,"U-3@2I4?DL>7%L;.LS MA<]445VP_87:TT&UPW0JE=^\?[C?7%I=PV:O,QR/.LW>H-=N]-J]1L,:G@^[ MX\EDT&KTS:,?%R8OY3G8Q)?!Y;5Q<4&*I&G];'R^_G5R:5Q\.O]\^]80=0HC.83*QQOST:E- $-^O&Q\DO M@X]L>T_&%Y]^.<#X?GW_W', 2M./1YX-1MJ 8J-EDL'E%+D7OO&;[2?H#^0" M3NQOMDIBSL[3TAQG!%89L#V;G;'9[!H*LW3Z[_NW7L\'Y']^H1 8;[N&9X1H_"MLQOM ]N?-YA&E3 M"]\8VSS&]+<$WO]/4+%JJE.W^BJ YA*,8]_X:-^!9AMRZZF/XM8U_H^]7/V, MN5X1W/37M?'QXQLXY,?@T>ZJ10QC7H=VUB;PR &%;=ZLQ++W[H]HNA.6F8WWTZ@Q"[W&!#@<#1_6O29AXO, 9%_NSL'H MNT?+&4ML1\?%9MFPCUS5R'TGC:@QH>U3L:B:SR:TPCG'7O)TA)671%D^M^JH M)UN*!+?L\7'<"%U)LOG*?32)AD^*Y75C@*HW%S-.0U>DDYEM8R%LM+UTI@R" M"UU:3@YC,)H/N.A2_])T$_";:GYFI"\#CG\NIB$)*[/+9A?%KB0K012.[H36 M0F;7*6@=9BUF2RV2;9(T4UZ-AQ1@AR4>K1WI8_S@&+:#(CMKZH1/I*U.986/ MW ?\HMIJI;ETV65KLBOVQN;"1NY1Q4"#R+6ZV_:Z^?;4$SZK@:TVGO[E^-K.5 M@INTM)PAP8D*Z:J]7:O^"X4<4KZ4/CIPI)>,R[SX\M.0 P&U1C1'T BXCM]1 MK5%X%H6>5;PV(O?;+B M";?2O"(RY'UQ S20MO?DR2<@KXP[X)3P'AV&&31X MPS@$5Z@F27)(23!+J#TDG2OM04")Z=0O4R()[?>6IUW20=*W*(^\CDKL&?]W MPB7J:H0'0]MJ*VA+OR)U79UST@@#2$V>123"J94>2()5S#2NOJ[ZH5[,Y=[0 M R+;F?&]:(!(:ZHI2HV5/NS0Y\P;](#BZ)1,;N12+W/A>M80I<: T%0U.M0. M3!;?\74'QJU[$X1!$I%[&M?6)=82LZEL?9 MQ:H#;47@SP/-44KNN_>NDF#H"E/;/@F/G M(PK6VT8:PFH:JLJ6.2C\,YYI$Z?CS,/!JV.L> M!^*!!IDI:?GZ4+C ..NVI_+AI38OXWVL]7#N:A!&#QV'4EZWSY3;_EH=,6V= M(4T E% NZY>>I]1FU%A7;J@T#+)@:-JY:D;.5BB(?&FX9LI VF0_,S$PN0JG MUF3N&-5*\*$SX;>/RWHZN\]\TF+@V67ONF4#[ 0G;^G+KG?8GQMI&U!@ MJ.$(,8$%_]B$:I5,@1+U6/M#L$9E\A#[+=?(!#NR@%)"Q<$QY>^%V#>*&F'E M#">EI^7G+.?TX&6@9H$H$P%_T7C[IG#0C8U,TRN8_Q_0TFPFN[7[A%%Y>RS6 M)D3,A4-DEG-V%LCL"X2(\9RNQD,:]^W:[$?WX9T>(- '5+R!+ &U*>KAJW"9 M^R^O26XK#)67^2Q"=W]PDTT4Z J<-%[)1?-N>=T;#7.6].AEVS/>J5,$XWJ%/3'N-\,+K^?%FJ!-DC20#!M'%-'6"? M1I:YP G@B/1:?KL2?%R"3ST:?2GM67;IZ6M!1/F"L]"=,C/X A+.N*@9\@9K M2L>E1@GG-FD'4K5559D#[J/%B3Y$M2#L#;-Q]GNNO;M,,4G=F&I\@]+3. %> M:@]I L?CR?"UW9GP->X-,O>"NU3O$5C_22?G#'W5B5/3<^J&P5DWV5@P?\<$ M,=71 *$RMZ7.A"-*BH#(<0Q'2CE3ZWS4PM0!J]5HMTVKTQ^T&]VF-;1ZYGC< M;DW*QYFLNO'GI\O)+Q=7UY/+R=BX&GR<7!F?SXW)W_^\N/X?XVHR^O/RXOIB MPCG^?UY-\$.9;O =?.PT'2N? G]'CF29[ [ R;D_:D==X?-8:= MR7#8:S4[[<:H73[4;-<+RH0MRIHN)PX>/]=L#=J3D6GUK&:_VQY8X^&XT1J8 M5KO9,]OM0:N$Z<*=NC'Y[U\OAA?7I6*3!7@@MO>@/;W"B0?^S1EN_P/N6#\" M_JXOYZ-[WOM9?2<.5GQ*6))]YS/A>?+3O[UKO*/?89LS]?N.L6<#N@G\?H[\?7^W][UT2$ MBQW\)TP_E;N1KS!_^%D]M/E9Z_Z/>NWLLQUKW^)(BYGMR>U-@S@.ENHD_-L' M<_7-H(0KXR\-^M_/N4NQ , ZQ/7?Y0KZGT*Z*8MO1;OH AC3Y-O"G;KQO9A7 M!.^CV;P;!D\>[AL@!9 \"[Q>2-@\?+A7Q!?M_!A$=N?K%Y"WSU" S[(# M@)XID:M8N*26"]2EHX4%#AAU,=L._\;-#9R VJ+I2ZBBB&;#2K/J['"*+9+/ M/G_SQ%I50UB-AE5_ Q1DG2B2O54*RIHA5!3T$A1D53+H& ^7HZ#H,2'$C<.> M1F)FC]JSCNI9\6&SW7B4G/J-SILG)_XUG^%E-LSZQ:>K$T7#$Z:Q79=YX>-T MB9DPQK)&RC@CC'?5WU7M%/P@N'3'7JTP>T6F#E(#()O'!8WMV 9:]#!SAJ?U M8'.P_QY>?C1B6\YPQ5P7Q\DW^[KPT1O)#ZKWO4VZNAK]>I*H]^;HBG#YVOX6 M^,$2!P[%.$L*A,K5;"&6]MM$[M'@XTG>?X7<$KE'MC>351-O$\/'D_.31((* MPR6&CWD,^9M%\(^#X4GB0(7@$L$_VE/A16\3N;]<3D[R_BODELC]A><=/JB@ M_$09+T].RGZ5_/9-_^8>^>TJU7#<;K;/^[WN9#1IMSJC0;,Q[EB]1J_5&G4: M_=9F/M?1)<8_8R_0JXM?/@VN]\B_?0/YME\T?ZKJD^.&LA#^J=W[^8LW6#N, M2^'H& >;ZY!KR>$2=.[?*_O8R\;W6*0,KY%][F1+&6H1ISKC<\\X;+"%Z]E) MO BH'7TY$X.K#,"#,@!;_?O3_)KM^S\S.WND !Z%S#P@9>U(SD>,>?#1^'4R M^'C]JW%].?DTOC)&GR^_[ K8G,BA#\@Q.IN<[[O.=&J*.[5A\D$TJ^=!6 M?CS"\20+%P62GZ*?=K7;K9#]= ]Z(N>KL+;"VN,[WY7PL3'9/[#A"?J_J"^4 M[(+NBOEVZM3I@J+"Z1,YW_L',O]^/-UC/XR_Q^"XWDQMW]]QW3KO38;-?J_; M'%CM3K,W;(SZX\&Y-1STSQM6OU$YKN]W7,MZ:./BTWCRWY7'\_0\GE7-5'Y?E)JKRX^,\ M7%5^7,)KX5_Q\:K\^.@/M^LRJ_+CTEQ%57Y\I(?;=9E5^?$VQ"\*C\^O?NOD/O$RH^;.]*<_M?__6D: M..O_^M__]Z=%O/3^Z_\'4$L! A0#% @ O$D"2YB$+ TN"@ K%X !$ M ( ! &YH=&,M,C Q-S V,S N>'-D4$L! A0#% @ MO$D"2Z/'V&UL4$L! A0#% @ O$D"2VR/VT]!.0 ]\D" !4 M ( !2J( &YH=&,M,C Q-S V,S!?<')E+GAM;%!+ 0(4 Q0 ( +Q) M DLRD$P)X@0! ,]## 4 " ;[; !N:'1C,C Q-S X,#)? =,3!Q+FAT;5!+!08 !@ & (T! #2X $ ! end